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INTRODUCTION AND OUTLINE
1
Non-small cell lung cancer (NSCLC) is the fourth most common cancer type in the 
Netherlands for both men and women 1. The 5-year overall survival rates for patients with 
stage IIIA or IIIB NSCLC range between 10% and 20%  after (concurrent) chemoradiation 
1-3. Efforts have been undertaken to improve the outcome for patients with advanced 
stage disease, however, insufficient local tumor control and the frequently occurring 
distant relapses in these patients remain a challenge. Attempts to increase radiation dose 
to improve local control are often hampered due to dose limiting toxicities (particularly 
in patients receiving concurrent chemoradiation) for which accurate normal-tissue 
complication (NTCP) models are lacking 4,5. For years, treatment has mainly consisted of a 
‘one-size-fits-all’ approach: depending on tumor stage, a patient was offered standard 
treatment according to the guidelines. This approach neglects the heterogeneity that 
exists between (and within) tumors regarding their biological constitution and regarding 
patient characteristics and anatomical circumstances. Nowadays, tumor biology is better 
understood, paving the way for more individualized treatment as systemic treatment can 
be directed to specific pathways regulating tumor cell survival. Furthermore, functional 
imaging together with highly conformal radiotherapy techniques enable selective radio- 
therapy dose escalation that may improve local control while limiting adverse effects 6,7.  
Local tumor control
Stereotactic body radiation therapy for inoperable patients (or those refusing surgery) 
with stage I-II NSCLC has shown excellent local control rates of ≥90 % 8-10. These 
outstanding results are due to the high biologically effective tumor doses that can be 
delivered with stereotactic body radiation therapy because of the high dose-to-target 
conformality 11,12. As a consequence, toxicity of the lungs and esophagus is in general low 
13. For the more locoregionally advanced tumors, however, it is not possible to obtain 
similar biologically effective doses. The target volumes are large  and often in proximity of 
radiation sensitive organs (e.g. the esophagus). As a consequence, lower radiotherapy 
doses are prescribed in order to obtain a treatment plan that does not exceed the 
maximum tolerable radiation dose to the surrounding organs at risk. Despite this, dose 
escalation trials for patients with locoregionally advanced lung tumors have been 
performed in order to improve tumor control. For example, patients with locoregionally 
advanced stage NSCLC receiving concurrent chemoradiation were randomised to receive 
either 60 Gy or 74 Gy radiotherapy 5,14. The group of patients receiving 74 Gy had worse 
survival compared to the patients receiving 60 Gy. It has been hypothesized that one of 
the reasons for this decline in survival is the increase in toxicity for the patients receiving 
the higher radiotherapy dose. Concerning the heart for example, the positive effect of 
improved locoregional tumor control on overall survival after higher radiation doses 
may be counteracted by an increase in radiotherapy induced late cardiac sequelae 15,16. 
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CHAPTER 1
This illustrates the delicate balance between radiotherapy dose escalation and toxicity. 
Therefore, instead of increasing radiation dose to the whole target volume and thereby 
increasing the risk of (severe) toxicity, radiotherapy dose escalation should be more 
sophisticated. For instance:
· Escalate the dose solely for the more treatment resistant sub-volumes of the tumor as 
determined by functional imaging 
· Use highly conformal radiotherapy techniques that minimize dose to the organs at risk
· Use models for toxicity prediction that are based on modern radiotherapy techniques 
to titrate the maximum acceptable dose
The abovementioned examples will help to individualize treatment, which has the 
potential to improve treatment outcome without an unacceptable increase in toxicity.
Functional imaging
With the introduction of positron emission tomography (PET), new possibilities in tumor 
monitoring emerged 17. This functional imaging modality is complementary to the 
‘anatomical’ imaging modalities such as computed tomography. Whereas the latter only 
visualizes anatomical structures, PET visualizes functional information of the micro- 
environment of the tumor and its surrounding tissues 18. For instance, hypoxia and glucose 
metabolism can be visualized. Increased metabolic rate and tumor hypoxia are both 
associated with increased treatment resistance 19,20.  Therefore, this information can be used 
to select patients for treatment intensification and/or to evaluate tumor response 21,22. 
For example, the change in total lesion glycolysis found with fluorine-18 fluorode oxy-
glucose (18F-FDG) PET in the second week of concurrent chemoradiation for advanced 
stage NSCLC was predictive for treatment response 19. Those patients showing minimal 
or no decline in total lesion glycolysis can be selected for treatment intensification 23. 
This selection of patients eligible for intensified treatment is important in preventing a 
possible increase in side effects in patients that are not likely to benefit from treatment 
intensification. Moreover, radiotherapy dose escalation can be directed to specific 
sub-volumes within the tumor that harbor the more treatment resistant tumor cells (e.g. 
regions with increased hypoxia) 24. This approach prevents overtreatment of sub-volumes 
of the tumor that do respond well to treatment, thus avoiding an unnecessary increase in 
radiation burden for the organs at risk. 
 Although PET can guide in the treatment for NSCLC, there is a drawback that needs 
to be taken into account. Because of the relative long acquisition time of PET, motion 
artefacts due to breathing can be challenging in tumor delineation for radiotherapy 
purposes. To reduce the effect of this tumor motion on the PET image, optimally 
respiratory gated (ORG) PET has been developed. These gated PET images show a 
significant increase in mean tracer uptake, with a concordant significant decrease in lesion 
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volume, while maintaining good image quality 25,26. One of the chapters in this thesis 
describes the influence of gated PET imaging on the target volumes for radiotherapy 
planning with emphasis on the actual impact of this volume reduction on radiation doses 
to the organs at risk.
Modern radiotherapy techniques and toxicity prediction
Compared to 3-dimensional conformal radiotherapy (3D-CRT), intensity-modulated 
radiation therapy (IMRT) and volumetric-modulated arc therapy (VMAT) allow for the 
delivery of more conformal dose distributions resulting in lower radiation doses to the 
organs at risk in advanced stage NSCLC patients 27-29. Compared to IMRT, VMAT techniques 
deliver even more conformal radiation doses. Both IMRT and VMAT enable the treatment 
of larger target volumes and the delivery of increased prescription doses to the more 
radioresistant subvolumes identified by PET. However, these highly conformal techniques 
may increase target dose heterogeneity 29. Moreover, they may also result in larger 
proportions of healthy tissue receiving low doses (the so called ‘low-dose bath’) 27,30. 
The actual impact of these different dose deposition characteristics between IMRT and 
VMAT have not yet been assessed. It is likely that the abovementioned differences in dose 
deposition influence the risk of toxicity. For example, a significant increase of Grade ≥3 
acute esophageal toxicity has been reported after IMRT compared to 3D-CRT 31. Although 
many studies have reported on clinical and dosimetric predictors for acute esophageal 
toxicity and radiation pneumonitis, most of these predictors are based on cohorts of 
patients treated with 3D-CRT 32-37. It is possible that the 3D-CRT based predictors show 
impaired predictive value in patients treated with IMRT or VMAT due to the abovementioned 
differences in dose deposition. This is supported by a study in head and neck cancer 
patients that concluded that 3D-CRT based normal-tissue complication probability (NTCP) 
models performed markedly worse among patients treated with IMRT 38. Furthermore, it 
is likely that the high conformality of IMRT and VMAT allows for the treatment of patients 
with larger target volumes that could not have been safely treated with 3D-CRT. Hence, 
the patients considered eligible for treatment may differ between the time period that 
3D-CRT was standard practice compared to the time period that IMRT/VMAT was standard 
of care. For these reasons, new NTCP models for the prediction of dose limiting toxicities 
such as acute esophageal toxicity and radiation pneumonitis after IMRT or VMAT for 
NSCLC are warranted. Therefore, effort should be made to improve the performance of 
those new NTCP models. Dose-volume histogram parameters (e.g. the mean dose for a 
specific organ) are often used for NTCP modeling, however, one major drawback is that 
spatial information regarding the dose deposition within the patient is lost. This may result 
in the loss of valuable predictive information, particularly after IMRT or VMAT, since these 
techniques enable ‘sculpting’ of the radiation dose around the planning target volume. By 
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generating a so called ‘dose-map’, spatial dose information and dose-volume histogram 
data are combined 39. These dose maps may have added value over dose-volume 
histogram data alone in predictive modeling of, for instance, acute esophageal toxicity. 
Further improvement of the performance of NTCP models can be obtained by applying 
sophisticated statistical analysis using dedicated software designed for the development 
of robust NTCP models 40-42. Once such a well performing NTCP model has been 
developed, external validation of the NTCP model is mandatory to evaluate its clinical 
usefulness in independent separate patient cohorts 43.
 The comparison of toxicity between IMRT and VMAT techniques for the treatment of 
NSCLC as well as the development of predictive models for toxicity (including spatial dose 
information) are described in this thesis. 
Systemic treatment: another pathway to  
individualize treatment
Adding concurrent chemotherapy to radiotherapy for stage III NSCLC improves outcome 
by eliminating microscopic sub-clinical distant (and local) disease and inducing radio-
sensitization of the tumor that may lead to improved local control. Compared to sequential 
chemoradiation, concurrent chemoradiation has indeed shown a small but significant 
overall survival benefit and is therefore considered standard of care for patients in a good 
general condition 2. Further treatment intensification by adding more cytotoxic chemo - 
therapy (i.e. induction or consolidation chemotherapy) to concurrent chemoradiation has 
been explored in several studies, however, treatment related toxicity increased without a 
benefit in overall survival 44. The role of targeted therapies combined with radiotherapy 
for the treatment of stage III NSCLC is yet not clear due to contradictory results reported 
from various clinical trials 45. Treatment strategies aiming at the immunological phenomena 
of tumor progression, however, seem more promising 46,47.
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Outline of the thesis
In Chapter 2 the use of PET imaging in radiation oncology is discussed, with the focus on 
tumor cell metabolism and hypoxia.
 Chapter 3 describes the effect of gated PET on tumor delineation for radiotherapy 
planning. Furthermore, the actual impact of the smaller target volumes on the radiation 
dose delivered to the healthy tissues was evaluated. The planning study reported in 
Chapter 4 investigates a PET-based individualized radiotherapy boost for NSCLC. Patients 
were planned to receive a stereotactic boost directed towards the sub-volumes of the 
gross tumor volume that persisted during the radiotherapy course. The feasibility of this 
approach was evaluated.
 Chapter 5 describes the toxicity profiles and treatment outcomes for advanced 
stage NSCLC patients treated with either IMRT or VMAT. An increased incidence of radiation 
pneumonitis was observed in patients treated with VMAT. This finding, together with the 
knowledge that incidental radiation dose to both the heart and lungs may have a 
synergistic (deleterious) effect on developing radiation pneumonitis 16, led to the 
assessment of incidental radiation dose to the separate atria and ventricles of the heart 
and the risk of developing radiation pneumonitis (Chapter 6). 
 Accurate prediction of toxicity may guide in radiotherapy dose prescription and 
treatment planning and therefore allows for individualizing radiotherapy for advanced 
stage NSCLC patients. Chapter 7 deals with the incorporation of spatial dose information 
in predictive modeling of acute esophageal toxicity by generating dose-maps from 
radiotherapy plans generated with an IMRT or VMAT technique. The addition of spatio-do-
simetric information to the NTCP model, however, did not improve the prediction of acute 
esophageal toxicity based on the newly developed multivariable NTCP model described 
in Chapter 8. An important step in developing predictive models is the assessment of its 
generalizability to other cohorts different from the cohort the model was developed on 
(i.e. external validation). Chapter 9 assesses the external validation of the model described 
in Chapter 8 by using five independent cohorts of NSCLC patients from four different 
departments of radiation oncology.
 The general discussion (including future perspectives) and a summary of this thesis 
are provided in Chapter 10 and Chapter 11, respectively. 
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Hypoxia and tumor metabolism in 
radiation oncology: targets visualized 
by positron emission tomography
R. Wijsman, J.H.A.M. Kaanders, W.J.G. Oyen and J. Bussink. 
Adapted from
Quarterly Journal of Nuclear Medicine and Molecular Imaging 2013; 57: p244-256. 
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Abstract 
Due to the amazing leap of technology in radiation oncology in the past few years, cancer 
treatment will become more individualized. Molecular imaging with PET contributed to 
this with its many tracers available, each of them visualizing a specific feature of a tumor 
and its microenvironment revealing the biological characteristics of cancer. Hypoxia is of 
interest as hypoxic tumor cells are associated with lower disease control because of an 
increased resistance to cytotoxic treatment. This is especially the case for radiotherapy. 
Treatment adaptations overcoming the negative effect of hypoxia have shown promising 
results. Several hypoxia tracers are available of which [18F]FMISO is studied most extensively, 
however, other tracers are studied as well and the search for highly specific and reproducible 
PET tracers is still ongoing. Wide experience has been gained with the use of [18F]FDG PET 
as it is used on a routine basis for diagnosing and staging of cancer. Although not a specific 
marker for hypoxia, increased metabolic rate reflects increased proliferation and glycolysis 
indicating increased treatment resistance. Molecular imaging by means of PET creates an 
opportunity to provide personalized care, with optimal disease control, minimal toxicity 
and best cost-effectiveness. 
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Introduction
The challenge in radiation oncology is to achieve optimal locoregional tumor control with 
minimal toxicity. The treatment of patients with cancer is often multi-modal as surgery, 
systemic therapy and radiotherapy are frequently combined to accomplish the best 
chances for cure. 
 For the optimization of local tumor control, radiotherapy can be applied in a (neo-)
adjuvant setting to surgery. However, irradiation is also widely used in for example head 
and neck cancer patients providing organ preservation. In the past decades, technical 
improvements made it possible to treat patients more conformal; the irradiation dose can 
be delivered more confined to the tumor. This reduced toxicity as sparing of normal tissue 
improved substantially. Also, the higher conformality allowed dose escalation without 
increasing treatment related toxicity. 
 Failure to obtain local control after irradiation is due to several characteristics in the 
microenvironment of tumors and the tumor cells itself. Hypoxic cells are more resistant 
to radiation compared to well oxygenated cells 1. In addition, enhanced repopulation is 
one of the features of malignant cells that compromises tumor control. The third reason 
for failure is the intrinsic radioresistance of tumor cells, which is related to DNA repair 
mechanisms. In clinical practice several approaches have been used to adapt treatment 
and overcome these negative features of tumor cells. 
 To overcome (intrinsic) radioresistance, dose escalation by means of hyperfractio-
nated radiotherapy schedules 2,3 and the addition of chemotherapy 4 or a radiosensitizer 
have been used. Accelerated radiotherapy schedules have shown benefit as it thwarts 
accelerated tumor cell repopulation 2. For counteracting the adverse effect of hypoxia, 
efforts have been made to improve the oxygen status of the tumor microenvironment 
or specifically target hypoxic cells 5-7. However, all these adaptations have in common that 
only a minority of patients benefit whereas all patients experience an increase in treatment 
related toxicity. Therefore, it is necessary to improve patient selection for these intensified 
treatment approaches and/or depict the more radioresistant subvolumes within the 
tumor that need higher radiotherapy doses to improve treatment outcome. 
 With improved imaging techniques, e.g. Magnetic Resonance Imaging (MRI), it is possible 
to give a more precise representation of tumor spread. Except for functional MRI 8, these 
anatomical imaging modalities will not represent information on the functional status of 
a tumor. Complementary to anatomical imaging is positron emission tomography (PET) 
as this imaging modality is able to give functional information of the microenvironment 
of a tumor on the molecular level 9. Several tracers are available, all visualizing different 
aspects of the functional status of tumor cells, e.g. tracers for hypoxia, proliferation and 
metabolism 10,11. Combinations of these imaging modalities are potentially applicable 
for cancer staging, treatment selection and response monitoring. Especially treatment 
selection (e.g. hypoxia modification), radiotherapy planning (e.g. dose escalation) and 
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response monitoring (e.g. boosting of tumor areas with remaining viable tumor cells) 
make it possible to individualize treatment. In this review we will discuss the use of PET 
imaging in radiation oncology, with the focus on tumor cell metabolism and hypoxia.
Radioresistance and PET imaging 
Upfront selection of patients eligible for intensified treatment is important in preventing 
an increase in side effects for patients that will not gain from treatment intensification. 
As potential tools for treatment selection [18F]fluorodeoxyglucose ([18F]FDG) PET and [18F]
fluoromisonidazole ([18F]FMISO) PET (figure 1) will be discussed. 
Hypoxia and the microenvironment
Since the early fifties it is known that hypoxia limits radiation induced cell death 1. The enhancing 
effect of oxygen on damage due to ionizing radiation is known as the oxygen-fixation hypo - 
thesis; it is the presence of oxygen that anchors radiation inflicted damage to the DNA 12. 
 Hypoxia is heterogeneously distributed within a tumor and can change over time 13. 
The blood supply of a malignant tumor is often suboptimal as the vascular network is 
immature and chaotic. This chaotic vascular network results in tumor hypoxia, which can 
arbitrarily be divided in two categories: diffusion limited and perfusion limited hypoxia. 
The first, also known as chronic hypoxia, is the result of proliferating cells exceeding the 
oxygen capacity of the newly formed vascular network. This is due to the fact that the 
new microvasculature is often insufficient in providing normoxic circumstances in the 
distant tumor areas and will thereby contribute to diffusion limited hypoxia 14. Perfusion 
limited, or acute hypoxia, is the result of structural and functional abnormalities in the 
newly formed vasculature causing malfunctioning of the blood supply. This in turn results 
in an unstable blood flow causing intermittent hypoxia close to poorly organized vessels. 
This form of hypoxia is characterized by rapidly changing oxygen concentrations 15,16.
 Hypoxia can be quantified in several ways, for example direct measurement by 
means of oxygen electrodes 17, or by immunohistochemical staining with hypoxic markers 
such as  pimonidazole 18. These two methods are invasive and are only applicable in 
accessible tumor areas. Also, they are not suited for longitudinal monitoring as these 
measurements represent smaller subvolumes of a tumor. In contrast, PET imaging is non 
invasive and is suitable for repetitive visualization of the complete tumor which makes it 
possible to give a three dimensional representation of tumor oxygenation or tumor 
metabolism. A disadvantage of hypoxia PET imaging lays in the fact that the tracers diffuse 
relatively slow and show low tumor to back ground contrast which hampers interpretation. 
In addition, PET has a low spatial resolution and thus does not provide information at the 
microregional level. The potential of non invasive hypoxia assessment by PET imaging has 
clear clinical advantages albeit with the abovementioned limitations. 
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Hypoxia and PET imaging 
There are several radiolabeled tracers that can be used for hypoxia PET imaging (Table 1). 
Used most are derivates of 2-nitroimidazole such as  [18F]FMISO 19,20, which will therefore 
be discussed in more detail. [18F]FMISO is less than 5% protein bound and free diffusible 
which enables a good distribution in the human body. These characteristics are of great 
importance for all tracers as tumor blood flow might be inadequate and might hamper 
distribution of these molecules. As the tracer enters the cell it has affinity for electrons, but 
an even higher affinity for oxygen. In case an electron binds to the 2-nitroimidazole 
molecule a radical anion is formed. This action is reversed in the presence of oxygen. 
However, in the absence of oxygen, the 2-nitroimidazole molecule undergoes further 
reduction. This produces more reactive products, which are trapped intracellularly by 
binding to cell structures. These bound bioreduced radiolabeled tracers can be visualized 
with PET imaging and thus give information upon the hypoxic state of the tumor 20. 
Dubois et al. visualized hypoxic subvolumes by means of [18F]FMISO PET in a rat tumor 
model. These hypoxic subvolumes showed to be significantly correlated with immunohis-
tochemical staining with the exogenous nitroimidazole derivative pimonidazole and the 
endogenous hypoxia related marker CA IX 29. In head and neck xenograft tumors [18F]
FMISO also correlated with pimonidazole staining. This correlation depended strongly on 
the microregional pattern of hypoxia 30 as the distribution on the microscopic level hampers 
the detection of smaller potentially clinically relevant subvolumes of hypoxic cells 31. 
This indicates that caution must be taken when studying smaller tumor (sub)volumes. 
Several clinical studies have already demonstrated the prognostic value of [18F]FMISO 
uptake in for example head and neck cancer and lung cancer 32-34. This may indicate 
that treatment adaptations directed to hypoxia may be based on [18F]FMISO PET findings. 
Table 1 |   Some biokinetic features of [18F]FMISO compared to other tracers.
Tracer Solubility Uptake ratio Clearance
[18F]FMISO 21 Lipophilic Low Relatively slow
[18F]FAZA 21 More hydrophilic Higher Faster
[18F]FETNIM 22 More hydrophilic Higher Faster
[124I]IAZA 23 More lipophilic Lower Slower
[18F]HX4 24 More hydrophilic Similar Faster
[18F]EF5 25 More lipophilic No comparison No comparison
[18F]EF3 26 More lipophilic Similar Similar
[18F]EF1 27 More hydrophilic No comparison No comparison
[64Cu]ATSM 28 Lipophilic No comparison Faster
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The prognostic value of [18F]FMISO PET imaging in hypoxia was assessed in a cohort of 
20 patients with stage III-IV oropharyngeal carcinomas. Patients underwent two pre - 
treatment [18F]FMISO scans and one during the fourth week of platinum based intensity 
modulated chemoradiotherapy 35. Despite the evidence of detectable hypoxia in 18 out 
of 20 patients an excellent locoregional control was obtained. The presence or absence 
of hypoxia as defined by [18F]FMISO uptake did not correlate with patient outcome. 
There were even two patients who had residual detectable hypoxia on the mid treatment 
scan and they showed excellent tumor control as well. One may assume that high dose 
radiotherapy combined with Cisplatinum, a potent radiosensitizer, overcomes the 
negative effect of hypoxia in these cases. Contrary to this is the evaluation by Zips et al. 
They studied 25 patients with advanced stage head and neck cancer undergoing four 
repetitive [18F]FMISO PET scans during a course of chemoradiation. Scans were obtained 
before, at the end of the first two weeks and in the fifth week of treatment. Not baseline 
uptake, but the [18F]FMISO uptake in the first and second week showed to be of strong 
prognostic value 36. Eschmann et al. investigated hypoxia with [18F]FMISO PET scans in 
26 head and neck cancer patients and 14 non-small cell lung cancers before start of 
radiotherapy. Dynamic and static scans were acquired for which standardized uptake 
values (SUVs) and signal to background ratios were calculated. These data were correlated 
with follow-up data concerning local recurrence. They found that an accumulating type 
curve of [18F]FMISO, a high SUV and high tumor to background ratio at 4 hours after 
injection were highly suggestive of incomplete response. These results indicate that the 
outcome after radiotherapy can be predicted on the basis of kinetic behavior of [18F]
FMISO in tumor tissue 34. Rischin et al. evaluated the predictive value of [18F]FMISO in a 
hypoxic imaging side-study of a larger randomized trial comparing chemoradiotherapy 
and tirapazamine with chemoradiotherapy alone in 45 advanced stage head and neck 
cancer patients. [18F]FMISO PET imaging was performed at baseline and during treatment 
(week 4 to 5) identifying 32 hypoxic tumors. The risk of locoregional failure was significantly 
higher for hypoxic tumors not treated with the hypoxic cytotoxin tirapazamine. Patients 
without hypoxia and treated with chemoradiotherapy alone had a low risk of locoregional 
failure demonstrating the need for upfront patient selection in intensified treatment 
protocols 32. Furthermore, the study shows the potential to select a group of patients that 
would possibly be cured with less intensive treatment thereby avoiding an unnecessary 
increase in side effects and consequential costs. 
Other tracers for tumor characterization
Not only hypoxia related tracers are available for tumor characterization. Several other PET 
tracers that give insight into the tumor microenvironment and tumor characteristics are 
used clinically. Tumor cell proliferation can be quantified by [18F]-fluorothymidine ([18F]
FLT) PET and search has been undertaken to define its predictive role in evaluating 
treatment response at the start or early during treatment 37. Tumor growth comes with 
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protein synthesis which can be visualized with [11C]-methionine and [18F]-fluoroethyltyro-
sine ([18F]FET) PET tracers. Most experience with these tracers has been gained in the field 
of neuro-oncology 38. Pathways that are associated with inducing and maintaining 
cancers are influenced by the epidermal growth factor receptor (EGFR)-family receptors, 
which can be visualized by targeted radionuclide based imaging 39. Opposed to tumor 
cell maintenance is cell death. An important mechanism of cell death induced by 
radiotherapy is apoptosis. Apoptosis due to cytotoxic therapy can be evaluated by means 
of radiolabeled tracers such as technetium99m (99mTc) labeled annexin V 40. All these 
tracers have in common that they evaluate a specific property of the tumor itself or the 
tumor microenvironment. In contrast, [18F]FDG PET reveals glucose metabolism which 
reflects overall metabolic activity. This metabolic activity is indirect related to proliferative 
activity and tumor oxygenation as tumor cell proliferation and hypoxia increase glucose 
metabolism. [18F]FDG PET for treatment adaptation will be discussed in more detail.
[18F]FDG PET: a surrogate tracer for hypoxia?
Significant clinical experience has been gained and research has been done with the [18F]
FDG tracer. Nowadays, it is a widely used tracer for staging and therapy response evaluation 
in oncology 41. In contrast to hypoxia tracers, [18F]FDG PET visualizes glucose uptake and 
thus provides information on the metabolic state of the tumor. Under physiological 
Figure 1 |   [18F]FMISO PET image (3 hours post injection) displaying a hypoxic carcinoma 
of the oral cavity in a 68 year old male.
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circumstances non-tumor cells metabolize glucose to pyruvate, which in turn is oxidized 
in the mitochondria to form adenosine triphosphate (ATP). This so called oxidative phos-
phorylation is highly dependent on the presence of oxygen. As cells become oxygen 
deprived the process of oxidative phosphorylation hampers, which results in an increase 
in glycolytic flux because of anaerobic glycolysis. This is called the Pasteur effect 42. From 
this it can be hypothesized that increased [18F]FDG uptake reflects the increased glycolytic 
flux in anaerobic circumstances. In this light [18F]FDG might be considered a marker of 
hypoxia. This concept was studied in a pre-clinical study evaluating [18F]FMISO and [18F]
FDG uptake in tumor bearing mice. It was concluded that [18F]FMISO might be able to 
identify hypoxia whereas this was unlikely for [18F]FDG 43. Rajendran et al. evaluated the 
possible role of [18F]FDG as a hypoxia marker in 49 patients suffering from head and neck 
cancer (n=26), soft tissue sarcoma (n=11), breast cancer (n=7) and glioblastoma multiforme 
(n=5). The pre-treatment [18F]FDG PET and [18F]FMISO PET scans were evaluated. 
Comparison of whole tumor images showed a small but significant correlation between 
[18F]FDG uptake and the hypoxic volume, especially for head and neck tumors. There was, 
however, no correlation when the tumor types were analyzed separately indicating a 
wide variation in the relationship of hypoxia and metabolism as visualized by [18F]FMISO 
and [18F]FDG 44. The correlation between [18F]FDG, [18F]FMISO and pO(2)-polarography 
has been studied in 24 patients with head and neck cancer. Despite a moderate correlation 
of the standardized uptake value of [18F]FDG with the T/B ratio of [18F]FMISO, the uptake of 
the [18F]FDG tracer did not correlate with the results of pO(2)-polarography 45. Another 
tracer, [14C]EF3, has been tested in this setting in tumor bearing mice. Both [18F]FDG 
and [14C]EF3 were administered after which PET imaging and autoradiography were 
performed. A low correspondence was shown between the two tracers as the computed 
matching indices were low 46. The hypoxia specific tracer [18F]FAZA has been compared 
to [18F]FDG in four carcinoma cell lines. An excellent display of hypoxia by [18F]FAZA was 
found while [18F]FDG did not show high specificity for hypoxia 47. It can be concluded 
that several attempts have been made to correlate [18F]FDG uptake to hypoxia, however, 
up to now none have indicated that [18F]FDG is a specific tracer for hypoxia. This may be 
explained by the mechanisms malignant cells use to fulfill in their energy demands. 
Malignant cells do only to a limited extend generate ATP by means of anaerobic glycolysis 
(Pasteur effect), they mainly generate energy by means of aerobic glycolysis. This is called 
the Warburg effect 48 and indicates glycolytic ATP production under normoxic conditions. 
It is the aerobic glycolysis that causes high [18F]FDG uptake as is visualized on PET. 
This implies that the glycolytic flux, which is visualized by [18F]FDG uptake, is only to a 
limited extend revealing hypoxic conditions (Pasteur effect) because of the generally 
enhanced glycolysis under aerobic conditions (Warburg effect) in tumors.
 Although [18F]FDG is not a hypoxia tracer, it is of value as its accumulation reflects 
overall metabolic activity and tumor load. For this reason, targeting tumor areas with an 
increased metabolic burden may be beneficial in tumor eradication. 
521543-L-sub01-bw-Wijsman
Processed on: 20-7-2018 PDF page: 27
27
RADIOTHERAPY TARGETS VISUALIZED BY PET
2
The metabolic tumor burden on [18F]FDG PET measured at baseline for NSCLC patients 
has shown to be of prognostic value. For 169 patients diagnosed with NSCLC the 
pre-treatment [18F]FDG PET scans were reviewed retrospectively. The Metabolic Tumor 
Volume (MTV) and Total Lesion Glycolysis (TLG) at baseline of primary tumor and involved 
lymph nodes showed prognostic significance independent of clinical stage. These results 
suggest that MTV and TLG are better prognostic measures than SUVmax and SUVmean 49. In 
61 patients with NSCLC, the staging [18F]FDG PET scan was analyzed with regard to MTV 
and treatment outcome. In a subgroup of 39 patients treated with definitive intent, 
multivariate analysis showed an independent significant prognostic value of MTV for 
overall survival and a trend for progression free survival 50. A study in 51 inoperable NSCLC 
patients showed that the SUVmax was a prognostic factor for disease specific survival, 
overall survival and also predictive for tumor response 51. Similar results have been 
reported for several other tumor sites including head and neck cancer 52 and esophageal 
cancer 53.
 A major advantage of PET imaging is the ability to monitor treatment effects over 
time, and by doing so, to modify and optimize treatment. Clinical data have shown the 
potential role of [18F]FDG PET in providing insight in tumor response to therapy 54. 
Sequential imaging during treatment by means of [18F]FDG PET reveals glucose uptake 
patterns that may predict treatment outcome. Hentschel et al. evaluated repeated [18F]
FDG PET scans during chemoradiotherapy for 37 patients with head and neck cancer. One 
scan was performed before start of treatment and 3 scans were obtained during treatment. 
The two year overall survival and locoregional control rates were significantly better if the 
SUVmax of the primary tumor decreased 50% or more in the first two weeks of treatment 
55. Another prospective trial evaluating the prospective value of [18F]FDG PET in 77 head 
and neck cancer patients showed that only the method of visual interpretation of [18F]
FDG uptake could predict treatment outcome in patients with oral cavity or oropharyngeal 
carcinoma 56. The authors suggest that for head and neck cancer further research is 
needed regarding the predictive role of [18F]FDG PET imaging during treatment as several 
studies have been undertaken with inconsistent outcomes. 
 For 23 patients with inoperable NSCLC the metabolic changes during cytotoxic 
treatment have been studied by means of repeated [18F]FDG PET scans before, during and 
after treatment with accelerated radiotherapy 57. The evolution of SUVmax was subject to 
large intra-individual variation. All 23 patients showed a non significant increase in the first 
week of radiotherapy whereas in the second week and at the end of treatment a significant 
decrease in SUVmax was observed. No change during therapy was observed for responders 
while non responders showed a significant 48% increase in the first week and a significant 
15% decrease in the second week. These findings illustrate the need for treatment 
adaptation as [18F]FDG PET reveals different metabolic responses reflecting different 
tumor characteristics. During treatment [18F]FDG PET evaluation was also studied by 
Usmanij et al. [18F]FDG PET scans were performed pre-treatment, at the end of the second 
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week of treatment and two weeks and three months after completion of chemoradiation 
in 28 patients with locally advanced NSCLC. Progression free survival showed to be 
significantly longer with a decrease in total lesion glycolysis of 38% or more as seen on the 
PET at the end of the second week of treatment 58. Recent studies have shown similar 
results for patients with rectal cancer 59, esophageal cancer 60, breast cancer 61 and cervical 
cancer 62. These findings indicate that it is possible to select patients prior to treatment 
and also early during treatment for an individualized treatment approach based on [18F]
FDG PET imaging.
Directing treatment intensification towards  
the unfavorable tumor microenvironment
Radiation dose escalation is a way to improve tumor cell kill in for example hypoxic solid 
tumors 1. This higher dose will eradicate more clonogenic cells and thus may improve 
local control. The introduction of intensity-modulated radiation therapy (IMRT) made it 
technical possible to increase the dose to unfavorable subvolumes within the tumor 63.
 The question remains whether or not the hypoxic areas as visualized by a single 
pre-treatment PET scan remain stable over time so this information can be used to direct 
a higher dose of irradiation to these subvolumes over a course of fractionated radiotherapy 
lasting several weeks. Various attempts have been made to answer this question, as 
concerns may arise about the reproducibility of hypoxic tumor areas for hypoxia is a 
dynamic process. The reproducibility of [18F]FMISO imaging was tested in 13 head and 
neck cancer patients undergoing 2 sequential [18F]FMISO PET scans three days apart. 
Tracer distribution was analyzed on a voxel-by voxel basis. Considering the entire tumor 
volume, strong correlation was found in 71% of patients. However, this percentage was 
reduced to 46% when the hypoxic subvolume was analyzed. This finding is possibly due 
to the amount of acute, perfusion limited, hypoxia that fluctuates over time 64. The 
consequences of these findings for the dose distribution of the IMRT dose escalated 
treatment plans were evaluated for seven of these patients. The spatial distribution of 
hypoxia changed, compromising the coverage of the irradiation boost to the hypoxic 
tumor volume 65. Contrary to this are the results of a recent study with repetitive [18F]
FMISO imaging in 11 patients with head and neck cancer. The quantitative evaluation of 
the two repetitive PET scans performed were highly reproducible 66. The evaluation 
parameters proved to be similar for the two scans. The tumor area with maximum uptake 
on the first scan was slightly different from that on the second scan, with a mean difference 
of 4.3 mm (range 0.9-5.7 excluding one outlier of 11.8 mm). These findings indicate that, 
although hypoxia is in part considered a dynamic phenomenon, some tumor areas have 
a near stable degree and localization of hypoxia. The conflicting results can be explained 
by the small number of patients evaluated in each trial. Furthermore, there are several 
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discrepancies regarding the setup and acquisition protocol of the scans performed. For 
example, different time intervals were used between [18F]FMISO administration and 
scanning (117–195 minutes vs. 262 ± 21 minutes) and the T/B ratio threshold applied was 
different (≥1.2 vs. ≥1.5). Moreover, the conflicting outcomes can also be the result of 
differences in imaging acquisition protocols (2-dimensional versus 3-dimensional) 
resulting in differences in image contrast and statistical noise.
 Recently, the reproducibility of [18F]FAZA imaging has been studied in tumor bearing 
mice during fractionated radiotherapy. The investigators found that these hypoxia PET 
scans were able to represent tumor hypoxia in a quantitatively correct way and that the 
PET scans were highly reproducible 67. The selective boosting of tumor areas has been 
proved feasible in a study in which [18F]FAZA PET revealed hypoxic subvolumes in 11 out 
18 patients with advanced head and neck cancer. The authors suggested a dose escalation 
up to 80.5 Gy for these hypoxic subvolumes 68. Lee et al. performed a feasibility study 
determining hypoxic subvolumes in head and neck cancer patients by means of [18F]
FMISO PET. It was possible to escalate the irradiation dose up to 84 Gy for all ten patients, 
without exceeding the normal-tissue constraints 69. This approach, using [18F]FMISO, 
showed feasible in 2 other planning studies as well 70,71. This principle was also tested for 
hypoxic subvolumes using [64Cu]ATSM PET. The investigators found it possible to 
demarcate a tumor subvolume harboring hypoxia and escalate irradiation dose 72. 
 As for the hypoxic micro-environment, escalated radiation doses may also be directed 
to subvolumes of the tumor that displays a higher metabolic activity based on [18F]FDG 
PET for these subvolumes are more prone to tumor recurrence after radiotherapy. Takeda 
et al. evaluated the SUVmax of the pretreatment [18F]FDG PET in 95 limited stage NSCLC 
patients that underwent stereotactic body radiotherapy 73. By multivariate analysis, only 
the SUVmax of these primary tumors was a significant predictor for local recurrence. Similar 
results were found in 39 patients with more advanced stage NSCLC that underwent 
chemoradiation or radiotherapy alone. The SUVmax of the [18F]FDG PET acquired during 
radiotherapy was significantly higher in the tumors that recurred 74. Besides, both the 
volume and location of the subvolumes derived from the 70%–90% SUVmax thresholds of 
the pre-treatment [18F]FDG PET scan were in good agreement with the volume of the 
tumor recurrence delineated at a 40% SUVmax threshold on the post-treatment [18F]FDG 
PET scan. The authors conclude that the 70% SUVmax threshold for areas of high [18F]FDG 
uptake on initial PET scan seems appropriate for radiotherapy dose escalation. The 
approach of directing higher radiotherapy doses to more radioresistant subvolumes in 
NSCLC has been tested for its technical feasibility with either IMRT or volumetric-modulat-
ed arc therapy (VMAT). Feasible treatment plans were generated without compromising 
dose to the organs at risk 75,76. 
 Abovementioned dose escalating approaches seem promising, however, clinical 
trials are needed to evaluate the gain in local tumor control for tumors with unfavorable 
microenvironmental characteristics.
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Conclusion
Several tumor related microenvironmental factors are known to have a negative influence 
on the outcome of cytotoxic treatment. Hypoxic tumors are known to be more 
radioresistant, which results in lower disease control rates. Measurements by oxygen 
electrodes or immunohistochemical staining are invasive and are not able to give a 
longitudinal representation of the oxygen status of a tumor. Functional imaging by means 
of PET with hypoxia tracers such as [18F]FMISO has the advantage that it is non-invasive 
and that it visualizes the tumor as a whole. PET imaging informs the clinician about 
the oxygenation status and the geographical distribution of tumor hypoxia. Although not 
a specific hypoxia tracer, [18F]FDG displayed prognostic value in several solid tumor 
types. Higher [18F]FDG uptake is indicative of increased cell proliferation and glycolysis, 
 characteristics of a tumor microenvironment that may be unfavorable in terms of local 
tumor control after treatment.
 Visualization of treatment resistant tumor subvolumes based on PET imaging allows 
individualization of treatment and specific targeting of these subvolumes. PET imaging 
seems promising for this purpose, although uncertainties remain regarding its reproduc-
ibility. Once this has been clarified, functional PET imaging gives the opportunity to adapt 
radiation dose according to the specific microenvironmental circumstances which may 
result in improved local control and reduced toxicity.
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Abstract
Objective: This radiotherapy planning study evaluated tumor delineation using both 
optimally respiratory gated and non-gated fluorine-18 fluorodeoxyglucose positron emission 
tomography (18F-FDG-PET).
Methods: For 22 non-small cell lung tumors both scans were used to create the non-gated 
and gated (g) gross tumor volumes (GTVg) together with the accompanying clinical target 
volumes (CTV) and planning target volumes (PTV). The size of the target volumes (TV) was 
evaluated and the accompanying radiotherapy plans were created to study the radiation 
doses to the organs at risk (OAR).
Results: The median volumes of GTVg, CTVg and PTVg were statistically significantly 
smaller compared with the corresponding non-gated volumes, resulting in a median TV 
reduction of 0.5 cm3 (inter quartile range (IQR) 0.1 to 1.2),  1.5 cm3 (–0.2 to 7.0) and 2.3 cm3 
(–0.5 to 11.3) for the GTVg, CTVg and PTVg, respectively. For the OAR, only the percentage of 
lung (GTV included) receiving at least 35 Gy was significantly smaller after gating, with a 
median difference in lung volume receiving at least 35 Gy of 5.7 cm3 (IQR –0.8 to 30.50). 
Conclusion: Compared with non-gated 18F-FDG-PET, the TVs obtained with optimally 
respiratory gated 18F-FDG-PET were significantly smaller, however, without a clinically 
relevant difference in radiation dose to the OAR.
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Introduction
The overall survival rates for advanced stage non-small cell lung cancer (NSCLC) remain 
poor 1. Treatment intensification such as concurrent chemoradiotherapy showed some 
benefit compared with sequential regimens increasing the 2-year overall survival from 
30.3% to 35.6% at the cost of increased acute oesophageal toxicity 2. For radiotherapy 
dose escalation strategies with three-dimensional conformal radiotherapy, treatment- 
related toxicity is often the dose-limiting factor 3. Compared with these older techniques, 
modern intensity-modulated radiation therapy (IMRT) and volumetric-modulated arc 
therapy (VMAT) techniques enable more conformal high-dose irradiation of the tumor 4,5. 
Hence, radiation dose escalation is possible at the cost of a limited increase in toxicity 6-8.
 Besides improved radiotherapy delivery techniques, a better depiction of the primary 
tumor decreases uncertainties regarding tumor delineation, which may contribute towards 
smaller target volumes. Bradley et al. 9 showed that the gross tumor volume (GTV) as 
delineated on fluorine-18 fluorodeoxyglucose (18F-FDG) positron emission tomography 
(PET) was significantly smaller than the GTV derived from computed tomography (CT) 
alone. This increased accuracy of 18F-FDG-PET tumor delineation was confirmed in studies 
comparing the delineated CT and 18F-FDG-PET volumes with the pathology specimens 10,11. 
Thus, 18F-FDG-PET/CT incorporated into radiotherapy planning may contribute towards 
more conformal treatment plans. Moreover, 18F-FDG-PET/CT can be used for functional 
response monitoring 12 and it provides the possibility to define certain tumor subvolumes 
harbouring unfavourable tumor characteristics (e.g., high metabolic activity) that can be 
a specific target for radiotherapy dose escalation 13,14. 
Because of the relative long acquisition time of 18F-FDG-PET, patients breathe freely during 
image acquisition. For lung tumors this results in motion artefacts underestimating tracer 
uptake and overestimating the tumor volume 15. To overcome this problem several 
respiratory gating systems have been developed 16. These systems usually rely on the 
simultaneous acquisition of a respiratory signal that is used to select specific parts of the 
18F-FDG-PET data corresponding to the same respiratory phase. This results in a decrease 
of respiratory motion from the 18F-FDG-PET image showing reduced blurring of the 
tumor. Amplitude-based optimal respiratory gating in 18F-FDG-PET imaging resulted in a 
significant increase in mean tracer uptake 17,18 with a concordant significant decrease in 
lesion volume, while safeguarding good image quality 18. This indicates that the use of 
gated 18F-FDG-PET improves tumor visualization and the quantification of tumor volume, 
which is important in tumor staging, treatment response assessment, and probably also 
for radiotherapy planning. 
 We hypothesize that the smaller target volumes obtained with gated 18F-FDG-PET 
lead to smaller target volumes for radiotherapy planning and thus improve healthy tissue 
sparing. Therefore, we investigated the effect of amplitude-based optimally respiratory 
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gated 18F-FDG-PET imaging compared with conventional non-gated 18F-FDG-PET imaging 
on radiotherapy planning with respect to the radiation dose delivered to healthy tissues.
Methods
This retrospective study evaluated the added value of high-resolution optimally respiratory 
gated 18F-FDG-PET imaging on radiotherapy planning. We used the diagnostic 
18F-FDG-PET scans of patients with NSCLC as acquired in the study by Grootjans et al. 18. 
In 21 patients, 22 equally distributed primary tumors (8 upper lobe, 8 lower lobe and 6 
located at the lung hilum) were analyzed showing the largest differences in the gated 
versus non-gated tumor volumes. After co-registration with the low dose CT scans, the 
18F-FDG-PET/CT images were transferred to the radiotherapy planning system Pinnacle3 
(Version 9.6; Philips Radiation Oncology Systems, Best, The Netherlands). Information on 
image acquisition and image reconstruction will be described briefly as more detailed 
information has been described elsewhere 18. After administration of 18F-FDG (adjusted to 
patients’ weight; 3.2 ± 0.2 MBq/kg), whole body 18F-FDG-PET gated and non-gated 
images covering the thorax and upper abdomen were acquired using a Siemens Biograph 
40 mCT PET/CT scanner (Siemens Medical Solutions USA Inc., Knoxville, TN, USA). The 
respiratory signal was obtained using an Anzai AZ-733V respiratory gating system (Anzai 
Medical Co., Tokyo, Japan). Respiratory gating of the PET data was performed using an 
optimal amplitude-based respiratory gating algorithm (HD·Chest) using 35% of the 
acquired PET data, providing a good balance between motion rejection and image quality 
18. For the purpose of attenuation correction, anatomical reference and radiotherapy 
planning, a free-breathing total-body low-dose CT was performed. The 18F-FDG-PET 
images were reconstructed with the TrueX algorithm (Siemens Medical Solutions USA 
Inc.) with time of flight measurements incorporated. Image reconstruction was performed 
with 3 iterations, 21 subsets, and a matrix size of 400 × 400 (2.04 mm × 2.04 mm). 
 All primary tumors were delineated twice. Once using the non-gated 18F-FDG-PET 
images and once using the respiratory gated 18F-FDG-PET images. To minimize intra -
observer variation because of manual contouring, automatic delineation of the tumor was 
performed with a fixed threshold region growing segmentation algorithm. The threshold 
chosen to represent the GTV was 40% of the maximum standardized uptake value (40% 
SUVmax; Figure 1) 19, which was checked visually for plausible segmentation results. 
According to the local protocol a 10 mm circumferential margin for the clinical target 
volume (CTV) was added to both GTVng and GTVg (ng and g refer to non-gated and gated, 
respectively). Organs at risk (OAR), that is healthy lung tissue (delineated twice, once 
including the GTV and once excluding the GTV), heart, esophagus and spinal cord, were 
delineated as well (for detailed information see methods and materials section in the 
study by Hoffmann et al. 8) and subtracted from the CTV in case tumor involvement was 
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absent. When the tumor was located near other healthy tissues such as the thoracic wall 
or spine, these non-involved structures were manually delineated creating a single 
contour, which could also be subtracted from CTVng and CTVg. The planning target 
volume (PTV) was generated by expanding the CTVng and CTVg with a 5 mm circum-
ferential margin. Although this margin may seem inappropriate (especially in case of 
increased tumor motion), this approach was considered adequate for the evaluation of 
the added value of gated 18F-FDG-PET imaging in radiotherapy planning. Treatment plans 
were generated for both the PTVng and PTVg planning 66 Gy in 33 fractions using a VMAT 
technique. To avoid differences in outcome because of different planning strategies, 
all factors involved in treatment planning (such as beam angles, number of segments, 
objectives and constraints) were maintained equal for both treatment plans. A dose 
coverage of 99% for the 95% isodose for the PTV was aimed for. If a 99% coverage was not 
obtained because of unacceptable high doses to the OAR, a lower coverage was accepted 
Figure 1 |   A clinical example of target volume reduction achieved with gated PET.
Target volume reduction: a clinical example. An optimally gated fluorine-18 fluorodeoxyglucose 
PET image (fused with the accompanying low-dose computed tomography) showing a remarkable 
reduction in gated (g) gross tumor volume (GTV, red; 0.45 cm3) compared with the non-gated (ng) 
GTV (yellow; 0.87 cm3). The bar graph shows both the non-gated and gated GTV, clinical target 
volume (CTV) and planning target volume (PTV) for this patient. SUV; standardized uptake value.
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to generate a clinical acceptable treatment plan. For both plans the dose coverage for the 
PTV was equalized manually by adjusting the number of monitor units (which quantifies 
the amount of radiation delivered by the linear accelerator). Treatment plans were evaluated 
for the following endpoints: PTV dose coverage, maximum dose to the organ at risk (Dmax), 
mean dose to the organ at risk (Dmean) and the percentage of an organ exceeding a certain 
dose (for example 20% of lung receiving 5 Gy or more, denoted as V5lung=20%). The latter 
was done for organ volumes receiving doses from 5 to 70 Gy with 5 Gy intervals. 
The isodose lines (range 5 to 70 Gy, again with 5 Gy intervals) were converted to contours 
so the actual volume (cm3) of an organ receiving a certain radiation dose was calculated. 
 The study was carried out in accordance with the national applicable rules concerning 
the review of research ethics committees and informed consent.
Statistics
All statistical analyses were carried out using the Wilcoxon signed-rank test for paired 
variables (SPSS software, version 20.0; Chicago, IL). A p-value of less than 0.05 was 
considered statistically significant. The reported p-values are adjusted for multiple testing 
using the Bonferroni correction.
Results
As reported by Grootjans et al. 18, optimally respiratory gated 18F-FDG-PET resulted in a 
significant increase in SUVmean (mean standardized uptake value), with a concomitant 
significant decrease in lesion volume. The latter was also true for our results as all except 
two of the gated GTVs were smaller compared with the non-gated GTVs (Table 1). 
The median volume of GTVg, CTVg and PTVg  [4.6 cm3 (inter-quartile range; IQR 2.2-13.9), 
50.8 cm3 (32.8-109.6) and 99.8 cm3 (70.7-189.8), respectively] were statistically significantly 
smaller compared with the corresponding non-gated volumes [5.8 cm3 (2.7-15.4), 52.8 cm3 
(32.4-112.1) and 103.7 cm3 (69.8-193.4); p=0.003, p=0.021 and p=0.036, respectively]. This 
resulted in a median target volume reduction of 0.5 cm3 (IQR 0.1-1.2), 1.5 cm3 (-0.2 to 7.0) 
and 2.3 cm3 (-0.5 to 11.3) for the GTVg, CTVg and PTVg, respectively (Figure 2).
 Subsequently, we analyzed the effect of these smaller target volumes on the radiation 
doses to the OARs. Only the volume of lung (GTV included) receiving at least 35 Gy was 
significantly smaller for the treatment plans with the gated target volumes [median 
volume 265 cm3 (gated) versus 284 cm3 (non-gated); p=0.048]. This corresponded to a 
median difference in lung volume of 5.7 cm3 (IQR -0.8 to 30.5) comprising 0.15% of the 
median total lung volume. Dose distributions for the lung minus GTV and the other OAR 
did not show any significant difference (Figure 3). Dose coverage for PTVng and PTVg were 
identical (median coverage by the 95% isodose was 99% for both PTVs; p=0.878). 
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We repeated the analysis taking into account anatomical differences that may influence 
tumor motion. Three subgroups were defined (upper lobes, lung hilum and lower lobes) 
showing only the gated upper lobe GTVs to be significantly smaller. The differences were 
small, with a median volume of the gated upper and lower lobe GTVs of 3.1 cm3 (IQR 
1.7-7.5) and 3.0 cm3 (1.7-14.2), respectively, compared with the respective non-gated GTVs 
[3.3 cm3 (1.9-8.3) and 3.5 cm3 (1.7-14.9); p=0.036 and p=0.051, respectively]. No statistical 
significant reductions in the median volume of the upper lobe CTVs (non-gated 37.7 cm3 
versus gated 34.6 cm3; p=1.0), lower lobe CTVs (non-gated 43.1 cm3 versus gated 38.7 cm3; 
p=0.28), upper lobe PTVs (non-gated 79.5 cm3 versus gated 73.9 cm3; p=1.0) and lower 
lobe PTVs (non-gated 88.3 cm3 versus gated 79.4 cm3; p=1.0) were found. Accordingly, no 
significant differences in dose volume distribution could be identified. 
Figure 2 |   Bar graphs showing the median target volume reduction.
A: median volumes of the non-gated (ng) and gated (g) gross tumour volume (GTV), clinical target 
volume (CTV) and planning target volume (PTV). B: median differences (ng volume minus g volume) 
for GTV, CTV and PTV. *Statistically significant
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Figure 3 |   The effect of target volume reduction on the dose distributions for  
the organs at risk.
The bar graphs show the paired (ng=non-gated and g=gated) median volume percentages of a 
certain dose level for the specific organ at risk (e.g. V5 denotes percentage receiving ≥5 Gy). 
GTV: gross tumour volume; CTV: clinical target volume; PTV: planning target volume; MLD: mean 
lung dose. *Statistically significant
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Discussion
The incorporation of optimally respiratory gated 18F-FDG-PET imaging in radiotherapy 
planning for NSCLC shows that the acquired gated GTVs, CTVs and PTVs are significantly 
smaller, however, without the desirable relevant reduction of radiation dose to the OAR. 
Although the lung volume receiving  at least 35 Gy (V35lung) was significantly smaller for 
the gated 18F-FDG-PET planned treatment plans, the actual median V35lung reduction was 
minimal. The evaluation of tumor localization on target volume resulted in smaller GTVs 
for the upper lobes, but again, without any effect on the corresponding dose distributions. 
 Although smaller target volumes are generated using gated 18F-FDG-PET, the 
expected beneficial effect on treatment planning was small. This is indicated by the fact 
that only one isodose level appeared to be significantly different showing a relative 
decrease in volume of the lung receiving at least 35 Gy of only 0.15%. Albeit statistically 
significant, this small decrease of radiation exposure to healthy lung tissue is most likely 
clinically irrelevant. 
 The explanation for the discrepancy between reduced target volumes with almost 
no gain in radiotherapy planning lies in the fact that the absolute reduction in target 
volume is small. This might be a result of the method that we used for gating as the 
software identifies the smallest amplitude range of the respiratory signal while still using 
35% of the total acquired PET data (duty cycle). This ‘movement-weighted’ approach often 
selects the 18F-FDG-PET data from the end-expiration phase to reconstruct the image 17. 
Notwithstanding that reduction of tumor motion is achieved, residual tumor motion may 
still be present. This residual tumor motion still causes blurring of the 18F-FDG-PET image, 
diminishing the potential reduction in target volume. Another physical aspect is the wider 
photon beam penumbra in lung tissue. Due to extended electron ranges in lung tissue, 
the distance from beam edge to target volume increases in order to obtain full dose 
coverage of the target volume. From our results, the target volume reduction is apparently 
not large enough to compensate for this. Moreover, the applied identification of the 40% 
SUVmax by means of interpolation of pixel values may not be optimal. Compared with 
pixel-per-pixel delineated volumes, this interpolation of pixels at the border of the 40% 
SUVmax volume may possibly increase the delineated volume. 
 Although a limited number of tumors has been assessed, increasing the number of 
patients studied will most probably not significantly increase the differences in radiation 
dose to the OAR. This is because the tumors have been selected beforehand as they 
showed the largest reduction in gated tumor volumes compared with the corresponding 
non-gated volumes.
 After sorting the tumors according to localization within the lungs, the reduction of 
CTV and PTV lost significance. This is counterintuitive as one may expect a larger effect on 
lower lobe tumors compared with upper lobe tumors as tumor movement has shown to 
be larger for that lung subvolume 20. The loss of significance is probably due to the 
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avoidance of healthy tissue when the CTV is created by circumferential expansion of the 
GTV. Furthermore, as the GTV shape is often irregular, circumferential expansion of such an 
irregular GTV (resembling for example a horseshoe figure) creates a sphere like CTV 
resulting in a (partial) loss of the target volume reduction achieved with respiratory gating. 
 The target volumes created with gated 18F-FDG-PET were the subject of investigation 
in two other studies. Guerra et al. 21 analyzed 13 lung cancer patients undergoing a free 
breathing CT together with a gated 18F-FDG-PET/CT. The latter was reconstructed into 6 
breathing phases used for the delineation of one internal target volume (ITV). Despite the 
fact the ITVs were significantly increased using gated 18F-FDG-PET/CT, the accompanying 
PTVs were significantly reduced. This unexpected result can be explained by the different 
expansion margins used: 10 mm circumferential margin for free-breathing target volumes 
versus anisotropic margins of 7-8 mm and 5 mm for gated target volumes. Indeed, a target 
volume margin reduction may be appropriate as tumor motion is already (in part) 
incorporated in the CTV. However, it remains unclear whether or not the smaller PTVs are 
due to this margin reduction, the use of gated imaging or a combination of both. For this 
reason, we decided to apply equal margins for non-gated and gated treatment plans as 
only the added value of gated 18F-FDG-PET was under investigation, not the delivery of 
gated radiotherapy. 
 Aristophanous et al. 22 evaluated 22 lung tumors in 10 patients undergoing gated 
18F-FDG-PET/CT imaging prior to radiotherapy. The mean gated target volume was 35% 
larger compared with the non-gated target volume with the lower lobe target volumes 
showing a more pronounced increase compared with the upper lobe target volumes. In 
both the abovementioned studies, the ITV concept was applied. This concept considers 
the extreme ends of tumor motion to be the boundary of the GTV, which often results in 
overestimation of the target volume as the  tumor is located relatively short in that 
extreme position during the breathing cycle 23. Without being at the expense of good 
dose coverage, this overestimation can be decreased by avoiding the incorporation of the 
extreme ends of tumor motion using an average position method as described by 
Wolthaus et al. 23. Although not yet evaluated, our method of GTV delineation using 
optimally respiratory gated 18F-FDG-PET may be considered such an average position 
approach. This explains the fact that, compared with the ITV concept, our target volumes 
are on average reduced instead of increased as the incorporation of the extreme ends of 
tumor motion is avoided. 
 In our study, we not only analyzed the target volumes created with gated 18F-FDG-PET 
imaging but also evaluated the actual impact on the dose distributions with respect to 
the radiation doses for the OAR. The latter being of special interest in, for example, 
radiation dose-escalation strategies to the entire tumor volume where the avoidance of 
high dose to healthy tissues is of utmost importance. Although the incorporation of gated 
PET in radiation therapy planning failed to show clinically relevant dose reductions for the 
OAR in our study, it may still be useful in defining biologically unfavourable subvolumes 
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within the GTV that are suitable for dose painting as the true tumor volume and tracer 
uptake can be more accurately assessed with gated PET 24. 
 Instead of the commonly used 40% SUVmax, one may consider different thresholds 
or other segmentation techniques. However, there is no consensus on the optimal 
segmentation technique. Although one may suggest using, for example, probabilistic or 
gradient-based approaches to reduce the influence of partial volume effects, the partial 
volume effect is small in our scans as we applied high-resolution PET with a matrix size of 
400 × 400 (pixel spacing of 2.04 mm). Furthermore, the autosegmentations were visually 
checked for plausibility; hence, major delineation inconsistencies are unlikely. Because 
our primary goal was to evaluate the impact of gated PET on treatment planning and 
its theoretical sparing of healthy tissues, we studied only one segmentation method, 
not the differences between segmentation methods per se. The methodology we applied 
may have introduced a mismatch in attenuation correction because a phase-matched 
low-dose CT for attenuation correction of the gated 18F-FDG-PET was not available. 
We used the non-gated low-dose CT for this purpose instead, which may result in a small 
bias in PET data. This is subject of further research at our institution.  
In conclusion, this study evaluated the impact of optimally respiratory gated 18F-FDG-PET 
on radiotherapy target volumes including the effect on radiotherapy planning and the 
radiation doses for healthy tissues. Although the respiratory gated target volumes were 
reduced, the benefit in this selected group of NSCLC patients was too small to show 
clinically significant dose reduction for the healthy tissues. 
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Abstract
Background: This planning study evaluated stereotactic body radiation therapy (SBRT) 
for 18F-FDG-PET/CT guided dose escalation to improve local control after concurrent 
chemoradiotherapy (30x2 Gy) in advanced stage non-small cell lung cancer (NSCLC) 
patients. The maximum achievable SBRT boost directed to radioresistant subvolumes of 
the primary tumor as determined by an 18F-FDG-PET/CT before start of chemoradiation 
(pre-treatment PET) and an early response monitoring 18F-FDG-PET/CT (ERM-PET) was 
evaluated. 
Methods: Ten advanced stage NSCLC patients underwent pre-treatment-PET and 
ERM-PET. A SBRT boost (using a volumetric-modulated arc technique) was planned for 
primary tumor areas with persistent 18F-FDG-uptake on the ERM-PET (PTVboost;ERM) and 
for primary tumor areas with high 18F-FDG-uptake before treatment (PTVboost;pre-treatment), 
using a 70% SUVmax threshold with 7 mm margin. Dose was escalated till organ at risk 
(OAR) constraints were met, aiming to deliver a minimal dose of 18 Gy in 3 fractions 
resulting in a minimum total EQD2 of 84 Gy (BED 100.8 Gy).  
Results: In five patients, PTVboost;ERM was 9-40% smaller relative to PTVboost;pre-treatment. 
Overlap of PTVboost;ERM with OARs decreased also compared to the overlap of PTV-
boost;pre-treatment with OARs. However, any overlap with OAR remained in 4/5 patients. 
Median dose covering 99% and 95% of PTVboost;ERM were 15.4 Gy (range 3.2-30) and 18.4 
Gy (range 5.9-32.3), respectively. Median boost volume receiving a physical dose of ≥18 
(which equals a total EQD2 of 84 Gy) was 87.5% (range 50.6-100). 
Conclusion: A clinical significant stereotactic boost, resulting in an EQD2 ≥84 Gy, to volumes 
with persistent uptake on ERM-PET is feasible after 60 Gy concurrent chemoradiation.
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Introduction
In 1986, it was shown that a total dose of 60 Gy yields a greater proportion of complete 
response, higher intrathoracic tumor control and better survival compared to 40-50 Gy 
for the treatment of irresectable advanced stage non-small cell lung cancer (NSCLC) 1. 
In patients treated with radiotherapy up to a dose of 60 Gy, still about 30% of patients have 
loco-regional recurrence in absence of distant metastasis 2. A meta-analysis of randomized 
trials demonstrated that in trials with sequential/concurrent chemoradiotherapy, dose 
escalation beyond 60 Gy does not lead to further improvements in overall survival 3. 
The RTOG 0617 trial demonstrated that 74 Gy in 2 Gy fractions concurrent chemoradiation 
might even result in a survival decrement compared to 60 Gy in 2 Gy fractions 4. In case of 
radiation therapy alone, higher radiation dose results in longer survival without an upper 
dose level above which there is no further benefit 3. Therefore, radiation dose intensifica-
tion combined with chemotherapy should not be discouraged based on the RTOG 0617 
results. Especially since in RTOG 0617 compliance with normal tissue dose constraints was 
not mandatory, older (less conformal) radiotherapy techniques were allowed, and the 
prolonged overall treatment time could be associated with poorer survival because of 
accelerated repopulation 4,5.
 Intensity-modulated radiation therapy (IMRT) and volumetric-modulated arc therapy 
(VMAT) enable more conformal irradiation, thereby lowering dose to organs at risk (OAR) 6. 
Currently, it is possible to identify subvolumes within the planning target volume (PTV) 
that are more radioresistant 7-9. Usmanij et al. demonstrated that NSCLC metabolic non-
responders, as determined by a poor decrease in total lesion glycolysis (TLG) on fluorine 
18 fluorodeoxyglucose positron emission tomography/computed tomography 
(18F-FDG-PET/CT) at the beginning of the third week of radiotherapy, have a worse pro-
gression-free survival compared to early metabolic responders 8. Thus, early response 
measurement using 18F-FDG-PET/CT enables the identification of patients that may 
benefit most from dose escalation.
 Stereotactic body radiotherapy (SBRT) delivers very conformal high radiation doses 
resulting in excellent local control rates (>90%) with low toxicity in inoperable stage I-II 
NSCLC patients 10. It was shown that a biologically effective dose (BED) prescription of at 
least 100 Gy is required for acceptable tumor control probability 11. Therefore, a SBRT 
radiation boost directed towards 18F-FDG-PET/CT defined radioresistant subvolumes may 
increase local control in advanced stage NSCLC. Furthermore, by using SBRT, high 
maximum dose (Dmax) within the PTV is achieved with limited dose to OAR due to steep 
dose decline just outside the PTV, enabling higher dose escalation compared to other 
approaches. Limiting prolongation of overall treatment time (OTT) is another advantage 
of SBRT boosting as the booster dose is delivered in only a few fractions. 
 The aim of this study is to compare the maximum achievable dose escalation for 
locally advanced NSCLC treated with concurrent chemoradiation by using a stereotactic 
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boost directed to radioresistant subvolumes of the primary tumor as determined by an 
18F-FDG-PET/CT before start of chemoradiation (pre-treatment PET) and an early response 
monitoring 18F-FDG-PET/CT (ERM-PET). 
Material and methods
18F-FDG-PET/CTs acquired for the ERM study by Usmanij et al. were used for this planning 
study 8. This ERM study was approved by the Institutional Review Board of the Radboud 
university medical center. All patients gave written informed consent. Twenty-eight 
patients with stage IIIA-B NSCLC eligible for concomitant chemoradiotherapy were 
enrolled in this study. A prescription dose of 60 Gy in 2 Gy fractions was applied in this 
planning study for the entire tumor and involved lymph nodes with margin (PTV60Gy). 
Detailed information upon radiation treatment planning for PTV60Gy is described in 
Supplementary data 1.
 For every patient, a pre-treatment 18F-FDG-PET/CT was acquired before start of 
chemoradiation and an ERM 18F-FDG-PET/CT was performed at the beginning of the third 
week of treatment (after a median dose of 20 Gy; range 20-24 Gy). We selected those 14 
patients with a poor response to treatment as assessed by a TLG decrease <45% on the 
ERM PET relative to the pre-treatment PET. These poor responders showed worse 
disease-free survival, possibly due to the fact that they harbour more radioresistant tumors 
8. Three patients were ineligible for this planning study, because they had only a small 
primary tumor with the bulk of gross tumor volume (GTV) located in the mediastinum. 
Furthermore, one radiotherapy CT and radiation treatment plan could not be restored. 
So, 10 patients were included in this planning study. 
18F-FDG-PET/CT image acquisition
All PET scans were performed with a hybrid PET/CT scanner (Biography Duo Siemens 
Medical Solutions, USA, Inc.). Patients fasted for at least 6 hours. A venous blood sample 
was drawn to measure blood glucose level (<8.2 mmol/L in all patients (mean, 6.0 
mmol/L)). Prior to the PET scan, a low dose breath-hold CT was acquired for PET attenuation 
correction and anatomical matching. Sixty minutes after intravenous injection of 18F-FDG 
(3.45 MBq/kg; Covidien) and furosemide (10 mg), static emission scans in 3-dimensional 
mode were obtained with an acquisition time of 4 minutes per bed position. Images were 
iteratively reconstructed in 128x128 matrices by ordered subsets expectation maximization 
(OSEM) algorithm using 4 iterations/16 subsets (4i/16s) with a 5 mm Gaussian filter. 
Correction for photon attenuation (by using the low dose CT) and decay of 18F-FDG was 
performed for images.
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Boost volume definition
Radioresistant subvolumes of the primary tumor, to which the boost must be directed, 
were delineated on the pre-treatment PET and ERM-PET. For automated segmentation of 
biological target boost volumes (BTVboost), a threshold of 70% of maximum intensity level 
was used to identify tumor subvolumes at greatest risk of relapse 9. Adding a 7 mm 
 circumferential margin to BTVboost created PTVboost. Volumes (cm3) of PTVboost based on 
the pre-treatment PET (PTVboost;pre-treatment) and ERM-PET (PTVboost;ERM) were recorded. 
To assess the effect of timing of PET scans on the delivered dose to PTVboost, a stereotactic 
boost was planned at both time points for 5 patients showing a reduction in PTVboost;ERM 
relative to PTVboost;pre-treatment (reductions ranging from 9-40%). For the other patients, a 
stereotactic boost was planned only for PTVboost;ERM. 
Organs at risk definition and constraints 
The bronchial tree (up to and including lobar bronchi), heart, great vessels, esophagus, 
lungs minus GTV60Gy, spinal cord and brachial plexus were considered OAR. Adding a 
5 mm margin to the first four OAR contours created the planning OAR volumes (PRV). 
For the latter two OAR, PRVs were created adding a 2 mm margin. No PRV margin was 
used for the lungs. The following constraints were applied: Lungs minus GTV60Gy: mean 
lung dose <20 Gy, V20<35%; V5<65-70% for lungs minus GTV60Gy and V5<55% for 
contralateral lung (‘soft’ constraint) 12-14. PRV esophagus: Dmax 70 Gy equivalent dose in 2 
Gy fractions (EQD2) (α/β-value 3) 15. PRV brachial plexus: Dmax 66 Gy EQD2 (α/β-value 2) 16. 
PRV heart, great vessels, bronchial tree: Dmax 94 Gy EQD2 (α/β-value 3) 16. PRV spinal cord: 
Dmax 53 Gy EQD2 (α/β-value 2) 16.
Boost planning
Doses to OARs were determined for the 60 Gy treatment plan. These doses were computed 
into EQD2 doses using the formula EQD2=total dose*((fraction dose+ α/β)/(2+α/β)). 
Thereafter, the extra allowed EQD2 dose to OAR was calculated (i.e., maximum allowed 
EQD2 minus maximum EQD2 delivered after 60 Gy). Subsequently, this extra allowed EQD2 
was converted into a physical dose (delivered in 3 fractions). This physical dose was 
calculated for every separate OAR and used as maximum allowed dose for boost treatment 
planning. The stereotactic boosts were planned by RW (resident radiation oncology, 
6 years of experience) and TM (resident radiation oncology, 5 years of experience) under 
supervision of PvK (25 years of experience in radiation treatment planning). 
 A BED prescription dose of at least 100 Gy is required for acceptable tumor control 
probability 11. A dose of 60 Gy in 2 Gy fractions is 60 Gy EQD2 and is equal with a BED of 72 
Gy (α/β-value=10 for tumor). Delivering 18 Gy in 3 fractions results in a boost of 24 Gy EQD2 
(total EQD2 84 Gy) and a BED of 28.8 Gy (total BED 100.8 Gy). Therefore, it was attempted to 
deliver a boost with a minimum dose of 18 Gy in 3 fractions.
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All boost plans were generated using a single VMAT arc avoiding the contralateral lung. 
To ensure a rapid dose decline outside the PTV, a ring contour (1 cm) around the PTV was 
created. In case of overlap of PTVboost with PRV, two separate PTVs were created: PTV 
inside PRV and PTV outside PRV. This enabled better dose coverage for the PTV outside 
the PRV, thereby limiting underdosage of the PTV. The optimization objectives were 
individually set according to calculated constraints. 
Results
Patient characteristics are listed in Table 1. Nine patients presented with stage IIIA disease, 
and one patient with stage IIIB. Five tumors were adenocarcinomas, three squamous cell 
carcinomas and two were NSCLC not otherwise specified. In only two of ten patients, 
PTVboost did not overlap with any of the PRVs. 
Table 1 |   Patient and tumor characteristics.
Patient Sex Age cTNM* Pathology Location primary tumor
1 F 55 T2N2 AC RUL
PTV0 + PTV3 not near PRV
2 M 61 T2N2 SCC LLL
PTV0 + PTV3 overlap aorta PRV, near SC and BT
3 M 49 T2N2 AC ML
PTV0 + PTV3 overlap heart PRV
4 M 60 T3N2 SCC RUL
PTV0 overlap BT PRV
5 F 49 T3N2 AC LUL
PTV0 + PTV3 overlap heart, aorta and BT PRV
6 F 52 T4N3 NSCLCNOS LH
PTV0 + PTV3 overlap heart, aorta and BT PRV
7 M 70 T3N2 AC RUL
PTV0 + PTV3 overlap heart PRV
8 M 66 T4N0 SCC LUL
PTV0 + PTV3 overlap BP/GV PRVs. Near SC/esophagus
9 M 61 T1N2 AC ML
PTV0 + PTV3 not near PRV
10 F 49 T2N2 NSCLCNOS LUL
PTV0 + PTV3 overlap heart PRV
Abbreviations: AC = adenocarcinoma; cTNM = clinical tumor node metastasis staging system 7th edition; LLL = left 
lower lobe; LUL = left upper lobe; LH = left hilum; ML = middle lobe; RUL = right upper lobe; NOS = not otherwise 
specified; PTV0 = boost planning target volume determined on pre-treatment 18F-FDG-PET/CT; PTV3 = boost planning 
target volume determined on the early response monitoring 18F-FDG-PET/CT; PRV = planning organ at risk volume; 
SCC = squamous cell carcinoma; SC = spinal cord; BT = bronchial tree; GV = great vessles. *All patients were staged M0.
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PTVboost volumes
In five of ten patients, PTVboost;ERM was 9-40% smaller relative to PTVboost;pre-treatment. See 
Table 2 for absolute volumes, absolute differences and relative differences.
 Furthermore, it was examined whether this PTVboost reduction in these 5 patients 
resulted in less overlap with PRVs (Supplementary data 2). Overlap did decrease in four 
patients. Unfortunately, overlap with PRVs disappeared in only one patient (Figure 1, 
Supplementary data 2). Allowed dose to OAR, planned dose to OAR and dose limiting OAR 
for boost planning in week 3 are shown in Table 3.
PTVboost and BTVboost dose
Minimum dose delivered to 99% of PTVboost (D99), minimum dose delivered to 95% of 
PTVboost (D95), Dmax, and percentage of PTVboost receiving ≥18 Gy (V18) are shown in Table 
4 for PTVboost;pre-treatment and PTVboost;ERM. Median D99 and D95 of PTVboost;ERM were 15.4 
Gy (range 3.2-30) and 18.4 Gy (range 5.9-32.3), respectively. Median V18 was 87.5% (range 
50.6-100). Differences between the delivered dose in week 0 and 3 were minimal due to 
the fact that overlap with PRVs remained in most patients (Table 4; Figure 2). 
 In six patients, D95 PTVboost was substantially higher than the prescribed dose (74 Gy) 
of the RTOG 0617 study (Figure 2A). For PTVboost minus the overlap with PRV, seven 
patients received a D95 ≥80 Gy and for another patient the D95 was 79.3 Gy (Figure 2B). 
Table 2 |   Boost planning target volume determined on pre-treatment and  
early response monitoring 18F-FDG-PET/CT.
Patient PTV0
(cm3)
PTV3 
(cm3)
Absolute 
difference (cm3)
Relative 
difference (%)
1 19.2 19.3 0.1 0.5
2 213.5 182.6 -30.9 -14.5
3 13.5 20.8 7.3 53.9
4 163.9 98.4 -65.5 -40
5 94.4 56.4 -38 -40.3
6 127.2 132.8 5.6 4.4
7 42.7 33.9 -8.8 -20.6
8 208.1 189.4 -18.7 -9.0
9 14.3 15.0 0.7 4.9
10 14.6 15.8 1.2 8.2
Abbreviations: PTV0 = boost planning target volume determined on pre-treatment 18F-FDG-PET/CT; PTV3 =boost 
planning target volume determined on the early response monitoring 18F-FDG-PET/CT; Absolute difference: PTV3 
volume minus PTV0 volume; Relative difference: (absolute difference/PTV0)*100.
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V18, which equals an ablative dose, was ≥80% for the whole PTVboost in 6 patients 
(Figure 2D) and ≥80% in 8 patients for PTVboost minus overlap with PRV (Figure 2E). 
In current clinical practice, clinical target volume (CTV) coverage is also evaluated in case 
of overlap with OAR as online position verification with cone-beam CT imaging reduces 
uncertainty in the actual dose delivered to the tumor. D95 BTVboost (considering BTVboost 
as CTV) was considerably larger than D95 PTVboost (Figure 2C): seven patients received a 
total BTV dose of ≥80 Gy. BTVboost;ERM V18 was (almost) 100% in 6 patients (Figure 2F). 
In the other patients, BTV-PRV overlap remained hampering delivery of an ablative dose 
for the complete BTVboost.
Figure 1 |   Boost PTVs of two patients delineated on 18F-FDG-PET/CT scans before start 
of treatment and at the beginning of week 3 during treatment.
18F-FDG-PET/CT scans of patient number 4 and 8. The green line represents PTVboost before start 
of treatment (upper panel), the red line represents PTVboost at the beginning of the third week of 
treatment (lower panel). For patient number 4 (right), there was a remarkable decrease in PTVboost 
volume in contrast to PTVboost volume of patient number 8 (left) whose PTVboost volume was similar 
for both time points. The blue line indicates the planning organs at risk volumes.
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Table 3 |   Dose limiting organs at risk for boost planning.
Patient Heart PRV Bronchial tree PRV Esophagus PRV
Allowed  
Dmax
Planned  
Dmax
 Allowed  
Dmax
Planned  
Dmax
 Allowed  
Dmax
Planned  
Dmax
1 27.1 13.6 31.5 9.7 8.7 8.7
2 29.7 26.7 30.6 23.1 6.6 6.6
3 29.3 29.3 28.9 23.8 7.0 2.6
4 26.2 11.1 29.3 18.8 9.6 5.1
5 30.6 30.6 30.6 30.4 8.3 7.9
6 28.0 26.5 28.0 25.1 7.0 7.0
7 31.0 30.9 30.6 18.9 7.0 3.0
8 30.6 30.6 33.2 11.2 10.0 9.7
9 29.7 9.1 34.8 1.9 7.0 2.3
10 29.3 29.2 29.3 6.8 11.7 4.7
  Brachial plexus PRV  Spinal cord PRV  Lungs minus GTV60Gy
Patient Allowed  
Dmax
Planned  
Dmax
 Allowed  
Dmax
Planned  
Dmax
 MLD 60 Gy plus boost
1 6.9 3.8 17.3 4.4 15.7
2 N/A N/A 29.9 15.2 16.1
3 N/A N/A 14.7 3.6 18.3
4 N/A N/A 6.4 4.3 20.4
5 8.2 0.5 15.1 7.5 18.4
6 7.3 0.7 11.7 3.8 14.9
7 N/A N/A 20.1 1.8 13.2
8 4.6 4.3 3.8 3.6 11.2
9 N/A N/A 14.4 1.1 19.9
10 N/A N/A  7.4 2.0  16.5
Allowed and planned dose in EQD2 (except for mean lung dose) for stereotactic boost planning based on early 
reponse monitoring 18F-FDG-PET/CT. 
Abbreviations: Dmax = maximum dose; MLD = mean lung dose; GTV60Gy = gross target volume receiving 60 Gy; 
PRV = planning organ at risk volume; EQD2 = equivalent dose in 2 Gy fractions; N/A = not applicable. Underlined 
values represent the radiation dose at which that organ at risk limited further dose escalation.
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Table 4 |   Dose delivered to PTVboost
PTVboost
Patient D99* D95* Dmax* V18
  wk 0 wk 3  wk 0 wk 3  wk 0 wk 3  wk 0 wk 3
1 - 25.4 - 28.4 - 84.8 - 99.7
2 17.9 18.9 21.9 21.2 41.4 40.5 92.6 91.3
3 - 13.2 - 17.8 - 79.6 - 90.6
4 22.5 30.0 28.3 32.3 50.9 48.2 98.7 100.0
5 5.4 11.3 8.3 13.0 67.5 55.1 63.2 60.0
6 - 6.8 - 9.0 - 41.2 - 50.6
7 16.5 17.5 17.0 19.0 47.5 58.9 49.0 60.9
8 3.6 3.2 6.7 5.9 47.3 50.8 72.3 72.8
9 - 27.8 - 30.5 - 77.1 - 100.0
10 - 12.3  - 15.7  - 65.7  - 84.4
Abbreviations: PTVboost = boost planning target volume; D99 = minimum dose delivered to 99% of PTVboost; D95 = 
minimum dose delivered to 95% of PTVboost; Dmax = maximum dose; V18 = percentage of planning target volume 
receiving ≥18 Gy; wk 0 = boost plan based on pre-treatment 18F-FDG-PET/CT; wk 3 = boost plan based on early 
response monitoring 18F-FDG-PET/CT. *Dose in EQD2 (equivalent dose in 2 Gy fractions).
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Discussion
Some studies have investigated the feasibility of dose escalation in advanced stage 
NSCLC, all with different treatment strategies 16-18. For example, a prospective single 
institution trial examined stereotactic boosting (2 fractions of 10 Gy, or 3 fractions of 6.5 
Gy) of residual primary tumor <5 cm 1-2 months after chemoradiation (60 Gy). Mean 
coverage of SBRT boost was 96.4%, but was not described for patients individually 17. 
Disadvantage of this strategy is prolonging of OTT, which is biologically less effective. 
Furthermore, only small tumors were eligible. In clinical practice, we advice to deliver the 
3 SBRT boost fractions immediately after the total dose of 60 Gy is given, so without a 
treatment gap. In this way, prolongation of the OTT is very limited and the boost dose is 
not delivered simultaneously with chemotherapy.
 The RTOG 1106 study is an ongoing phase 2 randomised trial comparing 60 Gy in 30 
fractions (IMRT) versus adaptive radiotherapy to residual tumor based on during-treat-
ment 18F-FDG-PET (fraction 18-19) to deliver a boost in the final 9 fractions (2.2-3.8 Gy/
fraction) to a maximum total physical dose of 80.4 Gy in 30 fractions. Primary goal of this 
study is to determine whether dose can be escalated to improve locoregional control. 
PTVboost consists of residual primary and nodal metabolic-active volumes, which are 
automatically delineated at a threshold of 1.5 x mean intensity of the aortic arch (1 cm3) 
plus 0.5 cm expansion. Contrary to our study, a simultaneously integrated boost (SIB) is 
planned for the aforementioned volume. The SBRT boost is advantageous over this SIB 
procedure as applied by the RTOG 1106 due to its dose inhomogeneity with high Dmax 
resulting in a higher biologically effective dose. 
 The PET-boost randomized phase II trial randomized patients between dose- 
escalation (IMRT-SIB) of the entire primary tumor or dose-escalation of the high FDG-uptake 
region (>50% SUVmax) inside the primary tumor 16. Mean boost dose was 79.2 Gy for the 
entire tumor and 86.9 Gy for the high FDG-uptake area (p=0.001). However, in case of 
overlap of PTV with an OAR, PTV was allowed to have a reduced coverage for 15% of the 
volume. D95-99 for boost volumes were not described. Aerts et al. concluded that residual 
metabolic-active areas after (chemo)radiation had a high overlap with pre-treatment 
volume defined by 50% SUVmax 7. However, a threshold of 50% SUVmax is in general 
regarded as a segmentation method to quantify 18F-FDG-uptake of the entire tumor 19. 
Therefore, it is likely that residual metabolic active disease remains within this 50% SUVmax 
volume. Calais et al. propose a 70% SUVmax threshold on pre-treatment 18F-FDG-PET/CT 
scans to define treatment resistant tumor subvolumes 9. This smaller volume will facilitate 
radiotherapy dose escalation. Therefore we decided to use this segmentation method. 
Spatial distribution of high 18F-FDG uptake subvolumes remains stable during radiotherapy 
7,9, thus the initial 18F-FDG-PET/CT enables identification of areas at risk for recurrence. The 
advantage of using an ERM-PET is the fact that poor responding patients, who are likely to 
benefit most from radiotherapy dose escalation, can be selected and treatment can be 
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individualized 8. In this way, not all patients are exposed to higher radiation doses that may 
increase the risk of toxicity. Unfortunately, the PTV defined on ERM-PET did not decrease 
that much relative to pre-treatment defined PTV. It is likely that SUV changes minimally in 
poor responders, which results in quite similar PTV volumes. Furthermore, it is not known 
which segmentation method is optimal for boost volume segmentation. A threshold of 
80-90% during radiotherapy could be sufficient as well and will result in smaller boost 
volumes. However, smaller volumes increase the risk of geographical miss. For adequate 
radiation delivery, determination of tumor movement is very important. Therefore, we 
advice to use a 4D-CT for radiation treatment planning to calculate individual PTV margins 
based on the midventilation concept 20. 
 The feasibility of dose escalation fully depends on the accepted dose to OAR and the 
accepted risk of toxicity. It is suggested that the negative result of the 0617 trial is due to 
cardiac toxicity as compliance with normal tissue dose constraints was encouraged but 
not necessary. The effect of heart dose on overall survival is complex. It is advised to keep 
heart V50 <25% 21. We did not exceed this constraint (Supplementary data 3). Hepel and 
colleagues tried to deliver a SBRT boost in 2 fractions with a total boost dose of 16-28 Gy 
on primary and nodal disease after 50.4 Gy concurrent chemoradiation (phase I dose 
escalation trial) 18. There was no dose constraint for the proximal bronchial-vascular tree. 
One of 12 patients (8.3%) died due to fatal bronchopulmonary hemorrhage. Dose 
delivered to 4 cm3 of bronchial-vascular tree was substantially higher in this patient: 20.3 
Gy (EQD2 53.4 Gy, α/β-value 3) for SBRT boost and total dose of 73.5 Gy (EQD2 105.5 Gy, 
α/β-value 3). So, a mediastinal SBRT boost increases the risk of fatal toxicity substantially 
and therefore a dose constraint to the bronchial-vascular tree is mandatory. Our maximum 
dose of 94 Gy (EQD2) delivered to the bronchial-vascular tree PRV is considered safe 16. We 
excluded patients with the bulk of tumor located in the mediastinum, as the chances for 
cure for these patients are more likely depending on controlling mediastinal tumor load 
instead of improving primary tumor control. Severe late esophageal toxicity (stenosis and 
fistula) is observed in 6% of patients receiving a maximum dose of ≥70 Gy 15. Based on 
these results we set a maximum of 70 Gy to the esophagus with 0.5 cm margin. However, 
the RTOG 1106 protocol allows a maximum dose of 74-76 Gy. 
 The question remains which patients benefit most from dose escalation. Usmanij et 
al. have shown that patients with a poor metabolic response on ERM-PET have a worse 
progression-free survival compared to early metabolic responders 8. Therefore, it seems 
reasonable that these poor metabolic responders may benefit most from a stereotactic 
boost. Albain et al. have shown that patients with advanced stage NSCLC without disease 
progression on CT after 45 Gy concurrent chemoradiation benefit from local treatment 
(lobectomy) in terms of overall survival relative to continuation of chemoradiotherapy up 
to 61 Gy 22. We consider a SBRT boost with total EQD2 ≥84 Gy/BED ≥100 Gy as a good 
alternative for this surgical approach. Also histology could influence the decision to apply 
a boost. In general, squamous cell carcinomas present with larger and more hypoxic 
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tumors compared to adenocarcinomas 23. Frequency of local recurrence is much higher 
in squamous cell carcinomas (66%) than adenocarcinomas (10%) 9. Furthermore, adeno-
carcinomas have a much higher potential to metastasize: 53% of adenocarcinomas 
demonstrate distant metastases at diagnosis versus 27% of squamous cell carcinomas 
(written personal communication with E.A. Usmanij). So, especially squamous cell 
carcinomas may benefit from dose escalation, while adenocarcinomas may require inten-
sification of systemic treatment. A randomized phase III trial evaluating poor responders, 
stratified for histology, is warranted to answer these questions.
In conclusion, planning a stereotactic boost to regions within the primary tumor with 
persistent high 18F-FDG uptake (poor-responding areas), as assessed by 70% SUVmax, is 
feasible in combination with 60 Gy concurrent chemoradiation. Therefore, a stereotactic 
boost to regions with persisting high 18F-FDG-uptake is an attractive treatment strategy to 
optimize NSCLC therapy.
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Supplementary data 1
Radiation treatment planning for PTV60Gy
Both 18F-FDG-PET/CTs were transferred to the Pinnacle3 treatment planning system 
(Version 9.10; Philips Radiation Oncology Systems, Fitchburg, WI) and rigid fusion of these 
images with the initial radiotherapy planning CT was performed. The initial gross target 
volume (GTV) had been depicted on the 3 dimensional (3D) radiotherapy planning CT 
using the information of the pre-treatment 18F-FDG-PET/CT and consisted of the primary 
tumor and involved lymph nodes. The clinical target volume (CTV) enclosed the GTV of 
the primary tumor and lymph nodes with 10 mm and 5 mm margins, respectively. 
Isotropic expansion of 5 mm of the CTVs created the planning target volume (PTV). Dose 
coverage for all the initially created PTVs was re-planned by an experienced radiation 
treatment planning technician (PvK, 25 years of experience in radiation treatment 
planning). Using a VMAT technique, a prescription dose of 60 Gy in 30 fractions was 
applied, based on our national treatment protocol and ESMO guideline (Ref A). A standard 
10 MV photon arc beam set-up was used avoiding the contralateral uninvolved lung. 
Predicted dose deposition was calculated using a 3D collapsed-cone convolution 
superposition algorithm. According to the ICRU 50/62 guidelines the -5% and +7% dose 
heterogeneity criteria for the PTV were aimed for (Ref B,C). Planning parameters for 
PTV60Gy are described in the table below.
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Supplementary data 3
Table S3 |   Heart dose data.
Patient Heart V50 Heart Dmean
1 4.5 7.9
2 6.6 32.4
3 15.0 19.3
4 7.7 17.6
5 5.2 11.3
6 9.4 11.2
7 5.6 7.5
8 0.0 2.1
9 5.7 17.0
10 12.0 16.1
Abbreviations: Dmean = mean dose; V50 denotes the percentage of heart receiving ≥50 Gy. The presented data in 
this table are derived from the summed radiation plan (thus 60 Gy plus boost dose). 
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Summary
Retrospective evaluation of 188 advanced stage non-small cell lung cancer patients 
treated with IMRT or VMAT revealed a limited increase of moderate to severe acute 
esophageal toxicity after VMAT. Acute pulmonary toxicity and severe late toxicity were 
low. Overall survival did not differ between the IMRT and VMAT groups.  
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Introduction
Intensity-modulated radiation therapy (IMRT) and volumetric-modulated arc therapy 
(VMAT) are widely used for the treatment of advanced stage non-small cell lung cancer 
(AS-NSCLC) because of the superior target dose conformality compared to three- 
dimensional conformal radiotherapy 1-3. This increased dose conformality comes at the 
cost of increased low-dose deposition in surrounding tissues, the so-called ‘low-dose bath’, 
which may increase toxicity 4-6. For VMAT, this phenomenon may be even more 
pronounced, however, contradicting results have been reported 7,8. 
 We evaluated whether differences in planned dose distributions between IMRT and 
VMAT affected treatment related toxicity and outcome in a cohort of AS-NSCLC patients. 
Materials and Methods 
A single institution cohort of 188 consecutive patients that underwent (chemo-)
radiotherapy with IMRT or VMAT (≥60 Gy) for AS-NSCLC between March 2008 and 
December 2014 at the Radboud University Medical Center was investigated. The study 
has been carried out in accordance with the national applicable rules concerning the 
review of research ethics committees and informed consent. The Institutional Review 
Board of the Radboud University Medical Center waived review due to the retrospective 
nature of the study.
 Diagnostic work-up comprised of: 18F-Fluorodeoxyglucose positron emission tomography 
(FDG-PET), magnetic resonance imaging of the brain and histopathologically confirmation 
of malignancy. For radiation treatment planning, an intravenous contrast-enhanced 
computed tomography (CT) scan (in radiotherapy position) of the thorax and upper 
abdomen (including a slow-CT scan of the primary tumor) were acquired and transferred 
to the Pinnacle3 (Version 8.0-9.2; Philips Radiation Oncology Systems, Fitchburg, WI) 
planning system. The primary tumor and suspicious lymph nodes (confirmed by 
histopathology after endobronchial/endoesophageal ultrasonography, enlarged or with 
malignant features on CT scan, and/or FDG-PET positive) were delineated on the 
radiotherapy planning CT (using the diagnostic FDG-PET) and jointly considered gross 
tumor volume (GTV). Clinical target volumes (CTV) enclosed the GTV of the primary tumor 
and lymph nodes with 10 mm and 5 mm margins, respectively. Planning target volumes 
(PTVs) were created by an isotropic 5 mm expansion of the CTVs. These target volume 
concepts were equal for both IMRT and VMAT. 
 To generate accurate dose-volume histogram (DVH) data, the lungs (i.e., lungs minus 
GTV 9) and the esophagus (outer rim of the esophageal wall from the lower border of the 
cricoid cartilage to the gastro-esophageal junction), were re-contoured by one physician 
(RW). 
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The prescribed dose to the PTV was 66 Gy in 33 (once-daily) fractions using IMRT (until 
June 2011) or VMAT (from April 2011 onwards). For 6 patients the prescribed dose violated 
the normal-tissue dose constraints, therefore the number of fractions was reduced to 30. 
Details on treatment planning are listed in Table 1. The treating radiation oncologist made 
the final decision on approval of the treatment plan. Position verification prior to irradiation 
consisted of an off-line set-up and correction protocol. Concurrent chemoradiation (CCR) 
was delivered to patients in good clinical condition; all others underwent sequential 
treatment or radiotherapy alone (Table 1).
Follow-up
Acute esophageal toxicity (AET) and acute pulmonary toxicity (APT) were assessed weekly 
during treatment by the treating radiation oncologist using the Radiation Therapy 
Oncology Group (RTOG) acute radiation morbidity scoring criteria for esophageal and 
pulmonary toxicity 10. This frequency may have varied according to the patients’ perceived 
well-being. Follow-up continued until acute toxicity resolved. Thereafter, follow-up visits 
were planned every three months for the first 2 years and every 6 months for year 3 to 5. 
Table 1 |   Treatment characteristics.
Chemotherapy
Concurrent 2 (3-weekly) courses
Etoposide (100 mg/m2; day 1-3) Cisplatinum (50 mg/m2; day 1 + 8)
Sequential 3 (3-weekly) courses
Gemcitabine (1250 mg/m2; day 1 + 8) Cisplatinum (80 mg/m2; day 1)
PTV dose criteria* V62.7Gy (or V57Gy) ≥99%. Dose heterogeneity between -5% and +10%.
Dose constraints Lungs MLD ≤20 Gy, V20Gy ≤30%
Esophagus V65Gy <35% and Dmax = 66 Gy
Spinal cord Dmax = 50 Gy
Heart V50Gy <40%
Brachial plexus Dmax = 66 Gy
Beam set-up Avoiding uninvolved lung
IMRT 6 co-planar photon beams (10 MV)
Minimum of 10 MU per segment, maximum of 60 segments
VMAT 1 photon arc (10 MV); angular spacing control points 4⁰
Abbreviations: PTV = planning target volume; VxGy = relative volume receiving ≥x Gy; MLD = mean lung dose; 
Dmax = maximum dose; MV = megavolt; MU = monitor units; IMRT = intensity-modulated radiation therapy; VMAT 
= volumetric-modulated arc therapy; * Predicted dose deposition was calculated using a 3D collapsed-cone 
convolution superposition algorithm.
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No artificial cut-off was used to separate acute from late toxicity: late pulmonary and 
esophageal toxicity (LPT and LET, respectively) were scored if toxicity developed or 
persisted after the period of acute toxicity using the RTOG Late Radiation Morbidity 
Scoring criteria 11. The retrospective nature of this study hampered late toxicity scoring, 
therefore only severe (i.e., Grade ≥3) LPT and LET was scored as this often needs medical 
intervention. LPT was scored if the patient received steroids for radiation pneumonitis 
or had increased pulmonary complaints requiring oxygen. LET was scored in case of 
perforation or fistula of the esophagus, persisting radiation ulcer requiring tube feeding or 
stenosis requiring dilatations. 
Data collection and statistical analysis
All medical records were retrospectively reviewed. Anonymous patient and tumor charac-
teristics together with the toxicity scores were collected in a secured and audit 
trail-equipped database (OpenClinica, version 3.4, Waltham, MA). The following parameters 
were extracted from the treatment planning system: PTV volume, mean esophagus dose 
(MED), mean lung dose (MLD), LV5Gy to LV60Gy (percentage of lung receiving ≥5 Gy to ≥60 
Gy) and EV5Gy to EV60Gy (percentage of esophagus receiving ≥5 Gy to ≥60 Gy) in 5 Gy 
increments. Associations of relevant clinical characteristics and dosimetric parameters 
with Grade ≥2 AET were evaluated using logistic regression analysis (SPSS software version 
22.0; Chicago, IL). Differences between the IMRT and VMAT groups were evaluated using 
the Mann-Whitney-U or Fisher’s Exact test, where appropriate. A p-value of <0.05 was 
considered statistically significant.
 Overall survival (OS) and progression-free survival (PFS) were calculated from the date 
of the last treatment day until death or any clinical disease progression, respectively. 
Patients alive were censored at the date of last follow-up. The Kaplan-Meier method was 
used to evaluate survival, between group differences were tested using the Log-rank test.
Results
Fewer patients received CCR in the IMRT group (55.4% vs 74.0%; p=0.009) compared to 
the VMAT group (Table 2). The median LV5Gy was significantly lower (60% vs 67%; p=0.02) 
and the median EV50Gy was significantly higher with VMAT (32% vs 26%, p=0.04; Table 3). 
All other variables did not differ between groups.  
 The median follow-up for all patients was 18.4 months (range 0.2-82.8). The median 
follow-up was 19.3 months (range 1.4-82.8) and 16.5 months (range 0.2-56.6) for IMRT and 
VMAT, respectively. Median OS was 20.2 months (95% confidence interval (CI) 16.2-24.2) 
and did not differ significantly between the groups with 19.3 months (95% CI 13.6-25.0) 
and 22.5 months (95% CI 16.1-28.8) for IMRT and VMAT, respectively (p=0.71; Figure 1). 
Median PFS was 11.5 months (95% CI 7.1-16.0) without a statistically significant difference 
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between IMRT and VMAT [9.9 months (95% CI 7.4-12.4) and 15.1 months (95% CI 9.7-20.5), 
respectively; p=0.18]. 
 Weekly toxicity assessment was available for 142 patients (75.5%), only 3 patients 
(1.6%) were seen less than 4 times during radiotherapy. During the ten weeks after 
treatment, 163 patients (86.7%) were seen at least once to evaluate toxicity. Compared to 
IMRT, less Grade 1 AET occurred after VMAT (32.3% vs 57.6%,  p=0.001) at the cost of 
Figure 1 |   Kaplan-Meier overall survival curve.
Kaplan-Meier overall survival curve showing no statistically significant differences in overall survival 
between intensity-modulated radiation therapy (IMRT) and volumetric-modulated arc therapy 
(VMAT) (p=0.71)
No. at risk
IMRT  92 75 57 50 39
VMAT  96 76 57 46 33
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increased Grade 2 (41.7% vs 23.9%, p=0.013) and Grade 3 AET (17.7% vs 6.5%, p=0.025). 
Statistically significant differences in APT for IMRT and VMAT could not be observed 
(Table 2). Likewise, Grade ≥3 LPT and Grade ≥3 LET did not significantly differ. Grade 4 
(2.1% and 1.0% of the patients suffered from LPT and LET, respectively) and Grade 5 late 
toxicity (1 patient died due to radiation pneumonitis) were only observed in patients 
treated with VMAT.
 On univariate logistic regression analysis, Grade ≥2 AET was statistically significantly 
increased in females, in younger patients, in those treated with VMAT, when patients 
received CCR and with increased MED. Besides age, all these parameters remained 
statistically significant on multivariate logistic regression analysis (Supplemental material, 
Table S1).
Table 2 |   Treatment characteristics and toxicity.
Characteristics Whole group IMRT VMAT  
n=188 (%) n=92 (48.9) n=96 (51.1) p
Gender (%)
Female 79 (42.0) 33 (35.9) 46 (47.9) 0.11
Age (y) (range)
Median 63 63 (36-78) 64.5 (40-82) 0.35
Karnofsky performance
≥ 90 125 (66.5) 63 (68.5) 62 (64.6) 0.57
Clinical Stage (%)
IIIa 113 (60.1) 60 (65.2) 53 (55.2)
IIIb 75 (39.9) 32 (34.8) 43 (44.8) 0.18
T-stage (%)
0/1/X 43 (22.9) 20 (21.7) 23 (24)
2 51 (27.1) 28 (30.4) 23 (24)
3 49 (26.1) 23 (25) 26 (27.1)
4 45 (23.9) 21 (22.8) 24 (25) 0.80
N-stage (%)
0/1/X 18 (9.6) 10 (10.9) 8 (8.3)
2 117 (62.2) 59 (64.1) 58 (60.4)
3 53 (28.2) 23 (25) 30 (31.3) 0.59
FEV1
Median (IQR) 78% (67-91) 81% (69-91) 76% (63-93) 0.41
Chemotherapy (%)
Concurrent 122 (64.9) 51 (55.4) 71 (74)
 Sequential/None 66 (35.1) 41 (44.6) 25 (26) 0.009
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Table 2 |   Continued. Treatment characteristics and toxicity.
Characteristics Whole group IMRT VMAT  
n=188 (%) n=92 (48.9) n=96 (51.1) p
Radiation dose (%)
66 Gy 182 (96.8) 90 (97.8) 92 (95.8)
60 Gy 6 (3.2) 2 (2.2) 4 (4.2) N/A
Planning target volume
 Median 
(IQR)
497 cm3 
(359-645)
480 cm3 
(400-613)
516 cm3 
(280-667)
0.99
Toxicity  
Maximum APT (%)
Grade 0 42 (22.3) 18 (19.6) 24 (25) 0.39
Grade 1 105 (55.9) 51 (55.4) 54 (56.3) 1.00
Grade 2 40 (21.3) 22 (23.9) 18 (18.8) 0.48
Grade 3 1 (0.5) 1 (1.1) 0 (0) N/A
Maximum AET (%)
Grade 0 19 (10.1) 11 (12) 8 (8.3) 0.47
Grade 1 84 (44.7) 53 (57.6) 31 (32.3) 0.001
Grade 2 62 (33) 22 (23.9) 40 (41.7) 0.013
Grade 3 23 (12.2) 6  (6.5) 17 (17.7) 0.025
Maximum LPT (%)
Grade ≥3 26 (13.8) 9 (9.8) 17 (17.7) 0.14
Maximum LET (%)
Grade ≥3 4 (2.1) 1 (1.1) 3 (3.1) N/A
Abbreviations: IMRT = intensity-modulated radiation therapy; VMAT = volumetric-modulated arc therapy; FEV1 = 
Forced Expiratory Volume in 1 second (displayed as % of predicted value; data missing for 5 patients); IQR = inter-
quartile range; APT = acute pulmonary toxicity; AET = acute esophageal toxicity; LPT = late pulmonary toxicity; LET 
= late esophageal toxicity; N/A = not applicable.
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Discussion
The aim of this study was to evaluate if toxicity and outcome differed between AS-NSCLC 
patients treated with either IMRT or VMAT.
 Severe LPT was seen in 13.8% of our patients. Similar results (14%) were obtained in 
165 NSCLC patients who received IMRT-based (chemo-) radiation 12. In contrast, Uyterlinde 
et al. 13 reported only 7% severe LPT in 188 NSCLC patients undergoing CCR using IMRT, 
however, toxicity was scored differently. Albeit not statistically significantly different, the 
incidence of Grade ≥3 LPT nearly doubled in our VMAT group compared to the IMRT 
treated patients. This could not be explained by differences in variables associated with 
lung toxicity (PTV volume, MLD, LV20Gy and LV5Gy) 4,14,15. The median LV5Gy was expected 
to be higher after VMAT, but surprisingly the median LV5Gy was significantly lower. Hence, 
the increased LPT after VMAT may be caused by patient selection (discussed later).
Table 3 |   Median dose-volume histogram parameters of the treated patients.
DVH parameters Whole group IMRT VMAT p
Lung
LV5Gy (IQR) 63 (54-70) 67 (55-72) 60 (54-68) 0.02
LV10Gy 44 (39-48) 44 (40-50) 44 (39-47) 0.34
LV20Gy 28 (24-31) 27 (23-30) 28 (25-31) 0.33
LV30Gy 20 (17-23) 20 (17-22) 21 (17-24) 0.23
LV40Gy 15 (12-18) 15 (12-18) 15 (12-18) 0.43
LV50Gy 10 (7-13) 10 (7-13) 10 (7-14) 0.92
LV60Gy 6 (4-8) 6 (4-8) 5 (4-8) 0.65
MLD (Gy) 16.6 (14.8-18.3) 16.7 (14.9-18.3) 16.6 (14.7-18.3) 0.99
Esophagus
EV5Gy (IQR) 60 (53-69) 59 (53-70) 62 (52-69) 0.82
EV10Gy 54 (48-64) 54 (48-64) 55 (47-64) 0.81
EV20Gy 48 (39-57) 47 (41-56) 49 (38-58) 0.80
EV30Gy 41 (33-52) 39 (32-50) 43 (33-53) 0.24
EV40Gy 35 (26-46) 33 (25-43) 38 (27-48) 0.07
EV50Gy 29 (18-39) 26 (15-36) 32 (21-43) 0.04
EV60Gy 18 (7-28) 16 (6-26) 20 (8-30) 0.16
 MED (Gy) 25.8 (21.2-32.0) 25.6 (20.7-30.8) 27.1 (21.6-33.4) 0.22
Abbreviations: DVH = dose-volume histogram; IMRT = intensity-modulated radiation therapy; VMAT = volumetric-
modulated arc therapy; LV5Gy = relative percentage of lung receiving ≥5 Gy; IQR = inter-quartile range; MLD = 
mean lung dose; EV5Gy = relative percentage of the esophagus receiving ≥5 Gy; MED = mean esophagus dose.
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The overall incidences of Grade 2 (33%) and Grade 3 AET (12%) in our study are comparable 
to the 27% and 8% observed in a similar cohort of patients treated with IMRT for NSCLC 16. 
A higher incidence of Grade 3 AET (22%) after CCR using IMRT for NSCLC was reported 
by Kwint et al. 17, which may be due to the hypofractionated radiotherapy schedule, 
the different chemotherapy course (daily low-dose cisplatin) and/or the differences in 
toxicity scoring. Likewise, the incidence of Grade ≥3 LET in a similar cohort of patients was 
higher: 6.4% compared to 2.1% in our cohort 18. Again, this may be due to differences in 
radiotherapy and chemotherapy schedules. 
 Compared to IMRT, we found an increased risk of Grade ≥2 AET after VMAT. This is 
partially due to the increasing number of patients receiving CCR at the time VMAT was 
implemented at our department. Platinum-based chemotherapy has a radiosensitizing 
effect resulting in enhanced mucosal toxicity when combined with radiotherapy 19-21. 
More intense chemotherapy regimens (i.e., more full-dose chemotherapy completed, 
reduced need for postponing chemotherapy) may result in increased AET. However, 
we found no differences in chemotherapy intensity between IMRT and VMAT groups 
(data not shown). Besides CCR, the VMAT technique itself appeared independently 
significantly associated with increased Grade ≥2 AET (Supplemental material, Table S1). 
Differences in treatment planning between IMRT and VMAT can account for this, however, 
the allowed OAR doses and criteria for PTV coverage have been equal for IMRT and VMAT. 
Notwithstanding this, the IMRT and VMAT techniques in itself have different dose 
distribution characteristics which may result in differences in radiation exposure to the 
esophagus. This was illustrated by a significantly higher EV50Gy in the VMAT group, which 
has been reported to be predictive for AET 17. A ‘contralateral esophagus-sparing 
technique’ recently developed for IMRT may lower incidental dose to the esophagus, thus 
reducing AET 22.
 Another cause of increased AET (and LPT) after VMAT may be a matter of patient 
selection. Although performance score and age were similar between groups, differences 
in patient characteristics may still exist. Over the last years, doctors have gained more 
experience with CCR. This may have reduced the fear of inducing severe toxicity and 
therefore the somewhat ‘less fit’ patients may have been considered for CCR as well, in a 
time period were VMAT became standard treatment. 
 Currently, CCR is standard of care for patients in a good condition with AS-NSCLC 20. 
In our cohort, approximately one third of patients did not receive CCR. Nevertheless, 
the median OS for the whole group (20.2 months) is comparable to the median OS of 
21 months reported in patients treated with CCR 23. 
 Besides the drawbacks of retrospective studies, some other limitations should be 
noted. Firstly, for some patients toxicity may be underreported as not all patients were 
seen weekly during treatment. Concerning late toxicity, this problem was partially 
overcome by evaluating only severe late toxicity which can be scored more reliably as 
patients will seek doctors advice and medical intervention is often needed. Secondly, 
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the interpretation and scoring of toxicity can be challenging. For future studies, CT-based 
imaging modalities may aid in more reliable toxicity scoring and prediction 24-27. Thirdly, 
longer follow-up may reveal more late toxicity, however, it is well-known that the majority 
of events occur during the first year after treatment 12,13,18. 
 In conclusion, the risk of acute pulmonary toxicity and severe late toxicity were low 
and did not differ between IMRT and VMAT. The group of patients treated with VMAT 
showed significantly increased risk of AET, however, Grade ≥4 AET was low. Overall survival 
did not differ between patients treated with IMRT or VMAT, indicating that VMAT can be 
safely used for the treatment of AS-NSCLC.
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Inclusion of incidental radiation dose 
to the cardiac atria and ventricles 
does not improve the prediction of 
radiation pneumonitis in advanced 
stage non-small cell lung cancer patients 
treated with intensity-modulated 
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Abstract
Purpose: To evaluate whether inclusion of incidental radiation dose to the cardiac atria 
and ventricles improves the prediction of Grade ≥3 radiation pneumonitis (RP) in advanced 
stage non-small cell lung cancer (AS-NSCLC) patients treated with intensity-modulated 
radiation therapy (IMRT) or volumetric-modulated arc therapy (VMAT). 
Methods and materials: Using a bootstrap modeling approach, clinical parameters 
and dose-volume histogram (DVH) parameters of lungs and heart (assessing atria and 
ventricles separately and combined) were evaluated for RP prediction in 188 AS-NSCLC 
patients.
Results: After a median follow-up of 18.4 months, 26 patients (13.8%) developed RP. 
Only the median mean lung dose (MLD) differed between groups (15.3 Gy vs 13.7 Gy for 
the RP and non-RP group, respectively; p=0.004). The MLD showed the highest Spearman 
correlation coefficient (Rs) for RP (Rs=0.21; p<0.01). Most Rs of the lung DVH parameters 
exceeded those of the heart DVH parameters. After predictive modeling using a bootstrap 
procedure, the MLD was always included in the predictive model for Grade ≥3 RP, whereas 
the heart DVH parameters were seldom included in the model. 
Conclusion: Incidental dose to the cardiac atria and ventricles did not improve RP risk 
prediction in our cohort of 188 AS-NSCLC patients treated with IMRT or VMAT.
521543-L-sub01-bw-Wijsman
Processed on: 20-7-2018 PDF page: 93
93
CARDIAC DOSE AND RADIATION PNEUMONITIS PREDICTION
6
Introduction
Concurrent chemoradiation (CCR) is the standard treatment for advanced stage non-small 
cell lung cancer (AS-NSCLC) patients in good clinical condition 1. Although intensity- 
modulated radiation therapy (IMRT) and volumetric-modulated arc therapy (VMAT) enable 
more conformal dose distributions with lower doses to the surrounding organs than 
conventional three-dimensional conformal radiotherapy (3D-CRT), the risk of inducing 
radiation pneumonitis (RP) still limits dose-escalation strategies. Many clinical factors (e.g., 
cardiac comorbidity) and dose-volume histogram (DVH) parameters of the uninvolved 
lung tissue have been reported to predict for RP 2-5. Several (animal) studies have shown 
that radiation dose to the healthy lung may not be the only contributor to increased RP 
risk. Irradiation of the heart and lungs combined may have a synergistic effect on 
developing RP compared with irradiation of the lungs alone 6,7. Modeling RP risk in 209 
NSCLC patients undergoing 3D-CRT indeed resulted in a model consisting of two lung 
parameters and one heart parameter 8. However, Tucker et al. 9 could not confirm this 
finding in an independent cohort of 629 NSCLC patients. The majority of patients in these 
two studies were treated with 3D-CRT, a technique not resembling the dose distributions 
achieved with modern IMRT or VMAT dose delivery techniques. Furthermore, both studies 
assessed radiation exposure to the whole heart, thus not separating doses to the ventricles 
and atria. The latter may be of importance for prediction of RP as radiation-induced 
diastolic dysfunction of the left and/or right ventricle may have a different impact on the 
extent of cardiopulmonary toxicity 6. Taking into account the radiation dose to the 
ventricles and atria of the heart may contribute to refining the currently existing prediction 
models for RP 6-8. 
 Therefore, we investigated whether DVH parameters of the heart, assessing atria and 
ventricles separately and combined, in addition to clinical and DVH parameters of the 
lung, contribute to the prediction of Grade ≥3 RP in AS-NSCLC patients treated with IMRT 
or VMAT. 
Materials and Methods 
We retrospectively assessed a cohort of 188 consecutive patients that underwent (chemo-)
radiotherapy using IMRT (until June 2011) or VMAT (from April 2011 onward) for histo-
pathologically confirmed AS-NSCLC at our institution between March 2008 and December 
2014. This study was carried out in accordance with the national applicable rules 
concerning the review of research ethics committees and informed consent.
 Details concerning patient selection, staging procedures, radiotherapy and chemo - 
therapy have been described elsewhere 10. In brief, the diagnostic 18F-Fluorodeoxyglucose 
positron emission tomography scan and an (intravenous contrast-enhanced) computed 
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tomography (CT) scan (in radiotherapy position) of the thorax and upper abdomen 
(including a slow-CT scan of the primary tumor) were used to delineate the primary tumor 
and suspicious lymph nodes (jointly considered the gross tumor volume; GTV). The dose 
prescribed to the planning target volume (PTV) was 66 Gy in 33 once-daily fractions. Six 
patients received 60 Gy in 30 fractions because planning 66 Gy exceeded organs at risk 
(OARs) dose constraints. Details on the maximum allowed dose to the OARs have been 
described more extensively elsewhere 11; the maximum allowed mean lung dose was 20 
Gy and for the whole heart a V50Gy of <40% (i.e., the relative volume of the whole heart 
receiving 50 Gy) was aimed for. Because of the retrospective nature of this analysis and the 
importance of having accurate DVH data, the lungs and heart (ventricles and atria 
separately in 156 patients that received a contrast enhanced planning CT scan) were 
re-contoured (RW) according to Kong et al. 12 and Feng et al. 13, respectively. 
 Patients in good clinical condition received CCR consisting of 2 courses of etoposide/
cisplatinum. Some patients from a referring hospital received one additional course of 
gemcitabine/cisplatinum 3 weeks before start of CCR. For patients in suboptimal clinical 
condition, the standard sequential chemotherapy regimen typically consisted of 3 courses 
of gemcitabine/cisplatinum or no chemotherapy at all.  
Follow-up
Standard follow-up after the end of treatment consisted of 3-monthly visits for the first 
2 years and biannually thereafter up to 5 years after treatment. 
Data collection 
For the patients included in this analysis, the medical records from the departments of 
radiation oncology and pulmonary diseases were retrospectively reviewed. Anonymous 
patient, tumor and treatment characteristics together with the toxicity scores were 
collected in a secured and audit trail-equipped database (OpenClinica, version 3.4, 
Waltham, USA). Cardiac comorbidity was defined if the patient had a history of myocardial 
infarction, heart failure, valvular heart disease, cardiac arrhythmias and/or hypertension.   
 As derived from the Radiation Therapy Oncology Group acute and late radiation 
morbidity scoring criteria 14,15, severe RP was scored if the patient received steroids (Grade 
3), required oxygen therapy (Grade 4) or died (Grade 5) because of radiotherapy. Owing to 
the retrospective nature of this study, severe (i.e., Grade ≥3) RP was chosen as endpoint 
because it needs medical intervention and can thus be scored more reliably (steroids had 
to be used for at least 1 month). We did not apply an artificial time range for the onset of 
RP; disease progression or other causes of RP-like symptoms had to be excluded. One 
physician scored the medical records (RW). Full DVH data were retrieved from the 
treatment planning system (Pinnacle3 version 8.0-9.2; Philips Radiation Oncology Systems, 
Fitchburg, USA) for the following structures: total lung minus GTV (TL), whole heart (WH), 
left atrium (LA), left ventricle (LV), right atrium (RA) and right ventricle (RV). The DVH 
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parameters extracted from these structures were mean dose, maximum dose and V5Gy to 
V65Gy (the relative volume receiving ≥5 Gy and ≥65 Gy, respectively) in 5-Gy increments. 
For example, V5GyWH indicates the relative volume of the whole heart receiving ≥5 Gy. 
To correct for spatial fractionation effects, these parameters were extracted from the 
DVHs after conversion from physical dose to 2 Gy per fraction equi-effective (EQD2) dose 
assuming an α/β=3 Gy. 
Statistical analysis 
Correlations of relevant clinical parameters and the abovementioned EQD2-corrected 
lung DVH and heart DVH (Lung-DVH and Heart-DVH, respectively) parameters with RP 
were evaluated using Spearman’s rank correlation coefficients (Rs) and logistic regression 
analysis (SPSS software version 22.0; IBM, Armonk, NY). Differences between the groups 
with and without RP were evaluated using the Mann-Whitney-U test or Fisher’s Exact test, 
where appropriate. A p-value of <0.05 was considered statistically significant. Follow-up 
time and time to RP were calculated from the date of the last treatment day until the date 
of last follow-up visit or the date of diagnosis of RP, respectively. Follow-up was updated 
in March 2016; the patients alive were censored at the date of last follow-up.  
Modeling
Spearman cross-correlation matrices of the DVH parameters were first calculated to assess 
the existence of multicollinearity between variables, because in case of high inter-variable 
correlations (correlation coefficient >0.8), this may lead to unrobust model selection 16. 
A high degree of multicollinearity was observed for all DVH parameters (data not shown), 
and therefore it was decided to select the DVH parameters with the highest Rs for the 
actual modeling procedure: mean lung dose (MLD), V30GyWH, V5GyLA, V40GyLV, V50GyRA and 
V55GyRV. Multicollinearity between these 6 parameters was tested and proved to be ≤0.8. 
Therefore, these DVH parameters and the clinical variables (age, gender, performance 
score, smoking habits, lung function, chronic obstructive pulmonary disease, cardiac 
comorbidity, chemotherapy schedule, radiotherapy technique, location of the tumor and 
the planning target volume) were used for the automated multivariable logistic regression 
model selection using the MATLAB-based (version R2013b; The MathWorks, Natick, MA) 
Dose Response Explorer System (DREES; version 1.0 beta) 17. First, the optimal model order 
was estimated by bootstrap resampling (2000 samples) applying a maximum model 
order of two to prevent overfitting due to the relatively low number of events (26 events). 
The second step comprised the estimation of the model parameters by logistic regression 
analysis with forward selection on 2000 bootstrap samples. From these bootstrap 
samples, the 5 most frequently selected models were presented. This procedure was 
repeated 5 times with the imputation of the variables as shown in the results section. 
A total of 30 models (6 iterations, showing 5 models each) were evaluated for the presence 
of Heart-DVH parameters. In addition, the likelihood-ratio test for nested models was used 
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to separately assess the contribution of the previously selected Heart-DVH parameters to 
a model containing the parameter MLD.  
Table 1 |   Patient and treatment characteristics.
Characteristics Whole group   RP No RP   
n=188 (%)  n=26 (%) n=162 (%)  p-value
Gender 1.00
Female 79 (42.0) 11 (42.3) 68 (42.0)
Male 109 (58.0) 15 (57.7) 94 (58.0)
Age (y) (range) 0.18
Median 63 (36-82) 66 (46-81) 63 (36-82)
Karnofsky performance score 1.00
≥90 125 (66.5) 17 (65.4) 108 (66.7)
≤80 63 (33.5) 9 (34.6) 54 (33.3)
Smoking status 0.25
Current smoker 57 (30.3) 5 (19.2) 52 (32.1)
Former/non-smoker 131 (69.7) 21 (80.8) 110 (67.9)
Clinical Stage 0.83
IIIa 113 (60.1) 15 (57.7 98 (60.5)
IIIb 75 (39.9) 11 (42.3) 64 (39.5)
T-stage 0.52
0/1/X 43 (22.9) 6 (23.1) 37 (22.8)
2 51 (27.1) 10 (38.5) 41 (25.3)
3 49 (26.1) 5 (19.2) 44 (27.2)
4 45 (23.9) 5 (19.2) 40 (24.7)
N-stage 0.10
0/1/X 18 (9.6) 3 (11.5) 15 (9.3)
2 117 (62.2) 15 (57.7) 102 (63.0)
3 53 (28.2) 8 (30.8) 45 (27.7)
Tumor position 0.38
Upper lobes 118 (62.8) 14 (53.8) 104 (64.2)
Middle or lower lobes 70 (37.2) 12 (46.2) 58 (35.8)
FEV1 (% of predicted value) 0.78
Median (IQR) 78% (67-90) 79% (68-91) 78% (67-90)
History of cardiac comorbidity 0.09
Yes 77 (41.0) 15 (57.7) 62 (38.3)
No 111 (59.0) 11 (42.3) 100 (61.7)
Table 1  continues on the next page.
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Results
The median follow-up time for all 188 patients was 18.4 months (range 0.2-82.8) and time 
to RP was 3.5 months (range 0-12.6). Grade 3, 4 and 5 RP were scored in 23 (12.2%), 2 (1.1%) 
and 1 (0.5%) patients, respectively. The median MLD was significantly higher in the group 
of patients experiencing RP (15.3 Gy vs 13.7 Gy; p=0.004). All other patient, tumor and 
treatment characteristics did not significantly differ between the RP and non-RP patients 
(Table 1 and Supplementary material Tables S1 and S2). The median DVH parameters of 
the separate anatomic regions of the heart are displayed in Figure 1. 
Table 1 |   Continued. Patient and treatment characteristics.
Characteristics Whole group   RP No RP   
n=188 (%)  n=26 (%) n=162 (%)  p-value
COPD 0.19
Yes 69 (36.7) 13 (50.0) 56 (34.6)
No 119 (63.3) 13 (50.0) 106 (65.4)
Chemotherapy 0.57
Concurrent 122 (64.9) 15 (57.7) 107 (66.0)
Sequential 56 (29.8) 10 (38.5) 46 (28.4)
None 10 (5.3) 1 (3.8) 9 (5.6)
Radiation dose 0.19
66 Gy 182 (96.8) 24 (92.3) 158 (97.5)
60 Gy 6 (3.2) 2 (7.7) 4 (2.5)
Radiotherapy technique 0.14
IMRT 92 (48.9) 9 (34.6) 83 (51.2)
VMAT 96 (51.1)  17 (65.4) 79 (48.8)
Mean lung dose (Gy)
Median (IQR) 14.0 (12.1-15.3) 15.3 (13.7-16.2) 13.7 (12.1-15.2) 0.004
Mean heart dose (Gy)
 Median (IQR) 10.4 (5.7-16.8)  12.9 (8.3-17.8) 10.1 (5.0-16.9)  0.17
Abbreviations: RP = radiation pneumonitis; FEV1 = forced expiratory volume in 1 second (missing for 5 patients); 
IQR = inter-quartile range; COPD = chronic obstructive pulmonary disease; IMRT = intensity-modulated radiation 
therapy; VMAT = volumetric-modulated arc therapy.
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Univariate logistic regression analysis of various clinical factors previously reported to be 
associated with RP (for example, chemotherapy regimen and age) showed no significant 
associations for RP in our cohort (Table 2). However, the presence of cardiac comorbidity 
was borderline associated with RP (p=0.066; Table 2). The Rs for RP in Figure 2 show that 
the majority of the Lung-DVH correlation coefficients are higher than those of the heart. 
The only parameters that significantly correlated with RP are V10GyTL through V30GyTL (all 
p<0.05, except V25GyTL: p<0.01) and MLD (p<0.01).
Figure 1 |   Dose-volume histogram parameters for the separate anatomical structures  
of the heart.
Abbreviations: WH = whole heart; LA = left atrium; LV = left ventricle; RA = right atrium; RV = right 
ventricle; TL = total lung. The percentages displayed are the median values for V5Gy to V65Gy (the 
relative volumes receiving ≥5 Gy and ≥65 Gy, respectively). The accompanying inter-quartile ranges 
are listed separately in Supplemental material Table S3.
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All clinical variables (see Table 2) and MLD, V30GyWH, V5GyLA, V40GyLV, V50GyRA and V55GyRV 
were entered in the bootstrap resampling procedure (in varying combinations; Table 3) 
to find the optimal prediction model for RP. An overview of these models is given in 
Table 3, showing that the optimal model always contained MLD. The only Heart-DVH 
parameter selected (three times out of 30 models) was V55GyRV, it was part of the fourth 
and fifth model resulting from the bootstrap procedure (i.e., V55GyRV was only included in 
the ‘inferior’ models reported by DREES). Thus, the MLD seems a more powerful predictor 
for RP than any Heart-DVH parameter in this cohort. This was confirmed by the likelihood- 
ratio test for nested models: the addition of the Heart-DVH parameters did not significantly 
contribute to the reduced model consisting only of MLD (p>0.6).
Table 2 |   Univariate logistic regression analysis for clinical parameters.
Predictor Radiation Pneumonitis
Odds ratio 95% CI p-value
Age 1.03 0.98-1.08 0.20
Gender (female vs male) 1.01 0.44-2.34 0.98
Karnofsky performance ≥90 (yes vs no) 0.94 0.40-2.26 0.90
Current smoker (yes vs no) 0.50 0.18-1.41 0.19
Forced expiratory volume in 1 second 1.00 0.97-1.02 0.74
COPD (yes vs no) 1.89 0.82-4.36 0.13
Cardiac comorbidity (yes vs no) 2.20 0.95-5.10 0.07
Concurrent chemotherapy (yes vs no) 0.70 0.30-1.63 0.41
Radiation technique (VMAT vs IMRT) 1.99 0.84-4.71 0.12
Involved lung (left vs right) 0.92 0.39-2.20 0.86
Lower/middle lobes vs upper lobes 1.54 0.67-3.54 0.31
Planning target volume 0.99 0.997-1.001 0.32
Abbreviations: COPD = chronic obstructive pulmonary disease; VMAT = volumetric-modulated arc therapy; IMRT = 
intensity-modulated radiation therapy.
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Figure 2 |   Correlation between dose-volume histogram parameters and Grade ≥3 
radiation pneumonitis.
Abbreviations Spearman correlation coefficients (Rs) for all the V5Gy to V65Gy (the relative volumes 
receiving ≥5 Gy and ≥65 Gy, respectively) of the following structures: whole heart (WH), left atrium 
(LA), left ventricle (LV), right atrium (RA), right ventricle (RV) and total lung (TL, black line). The filled 
black dots indicate statistical significant Rs. The lower table displays all the Rs. 
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Discussion
Well-established predictors for RP are, for example, the MLD, V20GyTL, cardiac comorbidity 
and heart exposure 3-5,18-20. Regarding the latter, irradiation of both, heart and lungs, 
increases cardiopulmonary dysfunction in rats markedly compared with irradiation of 
heart or lung alone 6. Clinical studies evaluating the modeling of RP risk, however, 
incorporated radiation dose to the whole heart (neglecting separate radiation doses to 
the atria and ventricles) in patients of whom the majority underwent 3D-CRT 8,9. In our 
cohort 13.8% of patients (all treated with IMRT or VMAT) experienced Grade ≥3 RP, 
comparable to 10.5% of patients that experienced Grade ≥3 RP from another study that 
developed a model for the prediction of Grade ≥2 RP (in 209 NSCLC patients treated with 
3D-CRT) 8. That model consisted of both Lung-DVH and Heart-DVH parameters; radiation 
dose to the whole heart significantly added to the model. We could not confirm this in our 
cohort as adding whole heart exposure to the model consisting of MLD alone did not 
improve the prediction of RP. This may not only be due to differences in treatment and 
toxicity scoring, but also to differences in radiation dose to the OAR. Although our DVH 
data were corrected for fractionation effects and therefore in general somewhat lower, 
the median mean lung and mean heart doses from the abovementioned cohort 8 (18.2 Gy 
and 13.9 Gy, respectively) were higher compared with those from our cohort (14.0 Gy and 
10.4 Gy, respectively). A certain threshold dose (that is not reached by the patients in our 
cohort) for the heart may exist above which the risk of RP induction is markedly higher. 
Moreover, all of our patients were treated with IMRT or VMAT enabling a dose reduction to 
OARs more than 3D-CRT and thus possibly lowering the risk of inducing RP. 
Table 3 |   Optimal model selection for predictive modeling of radiation pneumonitis 
using various variable combinations.
Variables entered in the modeling procedure n Optimal 
model
Heart -DVH 
included?
CV + MLD + V30GyWH 188 MLD + PTV Never included
CV + MLD + V30GyWH + V5GyLA + V40GyLV + V50GyRA + V55GyRV 156 MLD + PTV 4th + 5th model
CV + MLD + V5GyLA 156 MLD + PTV Never included
CV + MLD + V40GyLV 156 MLD + PTV Never included
CV + MLD + V50GyRA 156 MLD + PTV Never included
CV + MLD + V55GyRV 156 MLD + PTV 5th model
Abbreviations: n = number of patients; Heart-DVH = heart dose-volume histogram parameter; CV = clinical 
variables; V30GyWH = relative volume of the whole heart receiving ≥30 Gy; MLD = mean lung dose; V5GyLA = relative 
volume of the left atrium receiving ≥5 Gy; V40GyLV = relative volume of the left ventricle receiving ≥40 Gy; V50GyRA = 
relative volume of the right atrium receiving ≥50 Gy; V55GyRV = relative volume of the right ventricle receiving ≥55 
Gy; PTV = planning target volume.
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The study performed by Tucker et al. 9 could also not confirm the contribution of the 
Heart-DVH parameters to RP prediction in a large cohort of patients with median radiation 
doses to the heart and lungs similar to those reported by Huang et al. 8. An explanation 
may be that considering the heart as a whole (solid) organ may be too simplistic because 
developing RP is a consequence of cardiopulmonary dysfunction from the complex 
physiological changes that follow after thoracic radiotherapy 6. For example, it seems 
reasonable to assume that the impact of radiation exposure on the left ventricle will affect 
the risk of RP differently compared with radiation exposure to the right ventricle. Thus, if 
whole heart exposure is taken into account instead of dose to the atria and ventricles of 
the heart, valuable information may be lost. Therefore, we did not only include MLD and 
V30GyWH in the model, but we incorporated radiation dose to the separate cardiac atria 
and ventricles as well. The DVH parameters of the cardiac atria and ventricles, however, 
were never selected for the optimal model. Apparently, the MLD is a stronger predictor for 
RP than any of the Heart-DVH parameters, which one already may expect given the 
correlations of the DVH parameters with RP shown in Figure 2. Almost all the Rs for RP of 
the Lung-DVH parameters are higher than those of the Heart-DVH parameters, indicating 
that radiation dose to the atria and ventricles correlates worse with RP than does radiation 
dose to the lung. Furthermore, in contrast to Lung-DVH parameters, none of the Heart-DVH 
parameters were statistically significantly correlated with RP. Surprisingly, V45GyRV to V65GyRV 
were negatively correlated with RP, indicating that increasing radiation dose to the right 
ventricle inversely correlates with RP. We hypothesize that this may be due to radiation- 
induced pulmonary edema and inflammation, resulting in increased pulmonary tension 
leading to an increase of right ventricle systolic pressure 6. Incidental radiation dose to the 
heart decreases heart function 6,21. This heart function decline may reduce right ventricle 
pressure, resulting in lowering of the tension in the pulmonary arteries. As a consequence, 
radiation-induced pulmonary hypertension is (partially) counteracted, thus mitigating the 
processes within the lung that causes RP. If this hypothesis holds, it may explain the 
negative correlation of right ventricular dose with RP in our dataset and the incorporation 
of V55GyRV in three of the  predictive models listed in Table 3. Regarding the latter, increasing 
dose to the right ventricle thus inversely predicts for RP due to reduction of pulmonary 
hypertension that may result in RP. This illustrates that considering the heart as a whole 
may be too simplistic for RP prediction. 
 Even though we used a well-established approach for modeling of radiotherapy 
outcome data to evaluate the role of cardiac exposure in predicting RP 16, there are some 
drawbacks. First, the retrospective nature of this study has its accompanying drawbacks 
such as inclusion bias. Second, scoring toxicity retrospectively can be challenging and 
inaccurate. For this reason we only scored Grade ≥3 RP as this often needs medical 
intervention and can thus be retrieved more reliably. Third, DVH parameters may be 
influenced by intra- and interobserver delineation variability. Therefore, the atria and 
ventricles of the heart and the lungs were recontoured by one physician according to 
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published contouring atlases. Although it seems more appropriate to contour only the 
heart muscle, this was not possible with the available CT images due to the lack of image 
contrast between blood and heart muscle. Fourth, for our modeling procedure we only 
used the VxGy DVH parameters. However, other DVH parameters, such as Dx% (i.e., the 
minimum dose to the x% volume receiving the highest dose), have also been reported for 
RP modeling 8,9. We decided to evaluate VxGy, since high correlations have been 
demonstrated between Dx% and VxGy parameters 8. The added value of Dx% over VxGy DVH 
parameters for RP prediction is therefore probably low. Fifth, the power to detect a 
relevant contribution of incidental radiation dose to the heart in RP prediction may be too 
low for this dataset. The low number of patients experiencing Grade ≥3 RP (26 out of 188 
patients) may be insufficient to reveal a true effect of heart exposure on the development 
of RP. Besides, the IMRT and VMAT techniques generate treatment plans with substantially 
lower doses to the heart (V30GyWH of 11.1% (range 0%-58%) in our cohort) compared with 
the heart doses of the treatment plans as reported by Huang et al. [(all patients underwent 
3D-CRT; V30GyWH of 19.1% (range 0%-99.3%)] and Tucker et al. [(73% of patients underwent 
3D-CRT; V30GyWH of 26.3% (range 0%-99.9%)]. The more conformal dose deposition 
combined with the anatomic position of the substructures of the heart (in particular the 
left and right ventricles and the right atrium, see Figure 1) in relation to the target volumes 
result in minimal radiation exposure (with broad inter-quartile ranges) to the cardiac 
substructures, thus hampering the predictive power of incidental cardiac dose. Conversely, 
one may argue that IMRT and VMAT techniques create such highly conformal treatment 
plans that incidental dose to the heart is minimal and therefore not clinically relevant for 
RP prediction.   
 In conclusion, Lung-DVH parameters outperformed the (atria- and ventricle-based) 
Heart-DVH parameters in RP prediction in our cohort of AS-NSCLC patients treated with 
IMRT or VMAT. The MLD seems the best dosimetric parameter to predict for Grade ≥3 RP 
in this cohort. 
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Supplemental material
Table S1 |   The median dose-volume histogram parameters selected for the modeling 
procedure and their differences between patients experiencing radiation 
pneumonitis or not.
DVH parameter RP No RP p
V30Gy WH (IQR) 13.9 (8.7-25.1) 11.1 (4.0-20.9) 0.14
V5Gy LA 78.1 (57.5-97.6) 69.6 (32.9-93.2) 0.22
V40GyLV 0.0 (0.0-2.1) 0.0 (0.00-0.3) 0.08
V50GyRA 0.39 (0.0-4.0) 0.0 (0.00-3.5) 0.09
V55GyRV 0.0 (0.0-0.0) 0.0 (0.0-0.0) 0.14
MLD 15.3 (13.8-16.2) 13.7 (12.1-15.2) 0.004
Abbreviations: DVH = dose-volume histogram; RP = radiation pneumonitis; IQR = inter-quartile range; V30GyWH = 
relative volume of the whole heart receiving ≥30 Gy; V5GyLA = relative volume of the left atrium receiving ≥5 
Gy; V40GyLV = relative volume of the left ventricle receiving ≥40 Gy; V50GyRA = relative volume of the right atrium 
receiving ≥50 Gy; V55GyRV = relative volume of the  right ventricle receiving ≥55 Gy; MLD = mean lung dose.
Table S2 |   The median maximum and mean radiation doses for the atria and ventricles 
of the heart and their differences between patients experiencing radiation 
pneumonitis or not.
RP No RP
 Dmean Dmax Dmean Dmax p* p†
WH 12.9 71.2 10.1 71.1 0.17 0.76
LA 22.2 69.9 17.8 68.9 0.32 0.45
LV 4.9 40.5 2.4 19.0 0.27 0.49
RA 7.6 56.3 6.5 41.0 0.24 0.23
RV 6.7 40.2 4.6 30.7 0.42 0.85
Abbreviations: RP = radiation pneumonitis; Dmean = mean dose; Dmax = maximum dose; WH = whole heart; 
LA = left atrium; LV = left ventricle; RA = right atrium; RV = right ventricle; TL = total lung. All values listed are 
median values. * and † indicate the p-values for the differences between no RP patients and RP patients for Dmean 
and Dmax, respectively
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Table S3 |   The inter-quartile ranges for the dose-volume histogram parameters of  
the separate anatomic structures of the heart presented in Figure 1.
 V5 V10 V15 V20 V25 V30 V35 V40 V45 V50 V55 V60 V65
WH 20-66 14-45 11-37 8-29 6-25 5-21 3-17 2-14 2-10 1-8 1-6 0-5 0-3
LA 35-93 21-80 13-61 10-52 7-47 5-42 4-39 3-35 2-31 1-26 0-21 0-16 0-10
LV 0-47 0-23 0-12 0-7 0-4 0-2 0-1 0-0.4 0-0.1 0-0 0-0 0-0 0-0
RA 8-81 3-55 0-45 0-35 0-26 0-19 0-15 0-11 0-7 0-4 0-2 0-1 0-0
RV 7-47 1-31 0-21 0-16 0-10 0-5 0-2 0-1 0-0 0-0 0-0 0-0 0-0
TL 45-57 30-38 23-30 19-25 16-22 14-20 11-17 9-15 7-13 6-11 5-9 3-7 2-4
Inter-quartile ranges of the dose-volume histogram parameters for the separate anatomical structures of the heart for 
all the V5Gy to V65Gy (the relative volumes receiving ≥5 Gy and ≥65 Gy, respectively). Displayed as: x-y, were x is 
the lower quartile and y is the upper quartile. Abbreviations: WH = whole heart; LA = left atrium; LV = left ventricle; 
RA = right atrium; RV = right ventricle. TL = total lung.
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Abstract
In our previous work, a multivariable normal-tissue complication probability (NTCP) model 
for acute esophageal toxicity (AET) Grade ≥2 after highly conformal (chemo-) radiotherapy 
for non-small cell lung cancer (NSCLC) was developed using multivariable logistic regression 
analysis incorporating clinical parameters and mean esophageal dose (MED). Since the 
esophagus is a tubular organ, spatial information of the esophageal wall dose distribution 
may be important in predicting AET. We investigated whether the incorporation of 
esophageal wall dose-surface data with spatial information improves the predictive 
power of our established NTCP model.
 For 149 NSCLC patients treated with highly conformal radiation therapy esophageal 
wall dose-surface histograms (DSHs) and polar dose-surface maps (DSMs) were generated. 
DSMs were used to generate new DSHs and dose-length-histograms (DLHs) that 
incorporate spatial information of the dose-surface distribution. From these histograms 
dose parameters were derived and univariate logistic regression analysis showed that 
they correlated significantly with AET. Following our previous work, new multivariable 
NTCP models were developed using the most significant dose histogram parameters 
based on univariate analysis (19 in total). However, the 19 new models incorporating 
esophageal wall dose-surface data with spatial information did not show improved 
predictive performance (area under the curve, AUC range 0.79−0.84) over the established 
multivariable NTCP model based on conventional dose-volume data (AUC = 0.84). 
For prediction of AET, based on the proposed multivariable statistical approach, spatial 
information of the esophageal wall dose distribution is of no added value and it is sufficient 
to only consider MED as a predictive dosimetric parameter.
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Introduction
Acute esophageal toxicity (AET) is common in patients receiving (chemo-) radiotherapy 
for advanced stage non-small cell lung cancer (NSCLC), particularly when patients are 
treated with concurrent chemotherapy 2,3. With the introduction of intensity-modulated 
radiation therapy (IMRT) and volumetric-modulated arc therapy (VMAT), it has become 
possible to deposit highly conformal dose distributions in the target volume while 
decreasing dose to the surrounding organs at risk 4-8. However, treatment of centrally 
located tumors and metastatic mediastinal lymph nodes, both of which are in direct 
proximity of the esophagus, may still lead to severe AET. Moreover, AET may increase 
when radiotherapy dose-escalation strategies and combined modality treatments are 
applied in clinical trials 9. AET heavily influences quality of life during and shortly after 
treatment, and the ability to accurately predict AET may allow for personalized treatment 
strategies to reduce risk of AET. 
 Many studies report a variety of clinical and dosimetric predictors for AET, however, 
most of these concern AET after three-dimensional conformal radiotherapy (3D-CRT) 
2,10-22. Even though IMRT and VMAT have the ability to produce highly conformal dose 
distributions, these techniques are associated with an increase in target dose heterogeneity 
and larger proportions of healthy tissue receiving low dose (the so called ‘low-dose bath’) 
4,5,7. It is evident that the employed radiation technique has a direct effect on the dose 
distribution characteristics and therefore will influence the risk of AET. The introduction of 
IMRT has reduced treatment-induced toxicities in various tumor sites 23,24. However, this is 
not always the case, e.g., Gomez et al. 25 found a significant increase in Grade ≥3 AET after 
IMRT compared to 3D-CRT in NSCLC (28% versus 8%, respectively), possibly due to the 
aforementioned ‘low-dose bath’.
 Previously, we analyzed AET in 149 advanced stage NSCLC patients receiving IMRT or 
VMAT with or without chemotherapy and developed a multivariable normal-tissue 
complication probability (NTCP) model 1. The NTCP model consisted of the variables 
concurrent chemoradiotherapy (CCR), gender, tumor stage and the volumetric mean 
esophageal dose (MED). Since MED does not provide information on possible dose-volume 
effects, we additionally analyzed dose-volume histogram (DVH) parameters, but found no 
significant improvement over MED.
 We hypothesize that incorporation of esophageal wall-based dose-surface data 
containing spatial information improves the predictive power of our established 
multivariable NTCP model based on MED. This is motivated by the fact that the esophagus 
is a tubular organ comprising a lumen and a wall, and AET likely results from irradiation of 
the mucosal layer of the esophageal lumen.
 The aim of this study was to extend our DVH-based NTCP model with 2D spatial dose 
information obtained from esophageal wall dose-surface maps (DSMs) and benchmark it 
against the model based on 3D DVH data.
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Materials and methods
In this retrospective study, we assessed a cohort of 149 consecutive patients that were 
treated with (chemo-)radiotherapy for advanced stage or inoperable NSCLC between 
March 2008 and June 2013. The study has been carried out in accordance with the national 
rules concerning the review of research ethics committees and informed consent. 
As previously published, all patients were treated to a dose of ≥60 Gy in 2-Gy fractions 
with IMRT or VMAT 1. The standard sequential chemotherapy regimen consisted of 
3 courses of chemotherapy, whereas most patients undergoing CCR received 2 courses. 
 During treatment, acute toxicity (Radiation Therapy Oncology Group acute radiation 
morbidity scoring criteria 26) was assessed at least on a weekly basis by the treating 
radiation oncologist, and after the end of treatment follow-up continued until acute 
toxicity resolved. Maximum AET scores were retrieved from the medical files together 
with patient and tumor characteristics.
Dose mapping procedure
Because of the retrospective nature of this analysis and the importance of obtaining 
accurate DVH data of the esophagus, the outer rim of the esophageal wall, from the lower 
border of the cricoid cartilage to the gastro-esophageal junction, was re-contoured by 
one radiation oncologist (RW).
 Contours were drawn on transverse computer tomography (CT) slices with an 
in-plane resolution of 1 mm and a slice thickness of 3 mm. The dose grid resolution was 
4 × 4 × 4 mm3. For each patient the delineated contours and the 3D dose distribution 
were exported from the treatment planning system (TPS) Pinnacle3 (Version 8.0-9.2; Philips 
Radiation Oncology Systems, Fitchburg, WI). Conventional esophageal wall dose-surface 
histograms (DSHs) without spatial dose information were calculated by converting 
esophageal contours to approximate polygon meshes. To this end quad faces consisting 
of four edges were generated by connecting adjacent contour points and taking a height 
equal to the slice thickness. For all of the faces the area was calculated and the dose was 
evaluated at their centers by linear interpolation inside the 3D dose matrix (Figure 1a).
 To incorporate spatial dose information in the histograms, esophageal polar dose- 
surface maps (DSMs) were generated. Multiple algorithms for generation of DSM have 
been reported in literature and a similar approach has been followed in this study 27. 
For each CT slice the esophageal contour coordinates were interpolated at angles 1 to 360 
degrees with respect to the contour centroid location and at a one-degree increment 
(Figure 1b). Dose at these new contour coordinates was evaluated by linear interpolation 
inside the 3D dose matrix as originally calculated by the TPS. Performing this procedure for 
all contour slices generated a dose cylinder which was virtually cut at the posterior edge 
and unfolded to acquire the esophageal wall polar DSM (Figure 1c). From the polar DSMs 
four cumulative dose histograms containing spatial information were acquired (Figure 1c, 
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1d). First, a contiguous DSH (cDSH) was constructed by converting the DSM to binary 
masks for dose thresholds from 0 to 75 Gy in 0.1 Gy increments, which determined the 
largest connected surface area (CSA) for each dose level. The entire cDSH was normalized 
with respect to the total DSM area (length of the esophagus times 360 degrees). Care was 
taken to recombine CSAs that were cut in two due to virtual unfolding of the dose map 
at the posterior edge.
 Second, a combined contiguous DSH (ccDSH) was constructed by adding all disjoint 
CSAs receiving at least a certain dose, but scaling their areas reciprocally by their distance 
with respect to the largest CSA. The rationale behind this approach was based on the 
hypothesis that with increasing distance between CSAs enhanced repair of endothelium 
cells after radiation is possible due to cell migration from areas surrounding CSAs receiving 
lower doses. Note that when no scaling of disjoint CSAs is applied all areas are summated 
resulting in the loss of spatial information.
 Next, two dose-length histograms (DLHs) were constructed by evaluation of the DSM 
along a specific direction. A circumferential DLH (cDLH) was constructed by taking the 
maximum horizontal length in the DSM receiving at least a certain dose level. Hence, the 
cDLH represents the maximum circumference of the esophagus receiving a certain dose 
in a transverse plane. Since the quantity along the horizontal axis of the DSM is given in 
units of degrees, it was normalized to one revolution along the circumference. CSAs that 
are cut into two parts by virtual unfolding of the dose cylinder at the posterior edge are 
detected and combined to obtain the correct maximum circumferences. Similarly, a 
longitudinal DLH (lDLH) was constructed by taking the maximum craniocaudal length in 
the DSM receiving at least a certain dose. The lDLH represents the maximum length of the 
esophagus receiving a certain dose in craniocaudal direction.
 For the cumulative dose-surface histograms (i.e., DSH, cDSH and ccDSH) the surface 
areas SxxGy, receiving a minimum dose of xx Gy, are calculated at 5 Gy intervals. Similarly, for 
the dose-length histograms (i.e., cDLH and lDLH) the lengths LxxGy, receiving a minimum 
dose of xx Gy, are calculated at 5 Gy intervals. Additionally, for all five histograms the mean 
histogram dose (MHD) was determined analogous to DVH mean dose calculation. All 
histogram and parameter derivations were performed using in-house developed 
MATLAB-based software (version R2014b; The MathWorks, Natick, MA). 
 To correct for spatial fractionation effects, the dose matrices were converted from 
physical dose to linear-quadratic equivalent dose in 2 Gy fractions 28,29, assuming α/β=10 
Gy (EQD210) for acute esophageal toxicity, prior to histogram derivation. 
Parameter robustness
It has been shown that inter- and intrafraction mobility of the esophagus can be significant 
30,31. Conversely, treatment planning is performed on a single pre-treatment CT scan that 
does not reflect organ mobility. Therefore, the esophageal dose reported in the treatment 
plan does not accurately represent the in vivo accumulated dose over the entire treatment 
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Figure 1 |   Derivation of the five 2D dose histograms.
(a) Conversion from esophageal contours to approximate polygon meshes by construction of 
quad faces between contour coordinates. Each face has a height equal to the CT slice thickness. For 
generation of conventional DSH the area of the faces are calculated and dose at their (b) Interpolation 
of the esophageal contour at 1 degree angle increments with respect to the centroid location. 
Repeating for all CT slices and performing virtual unfolding at the posterior edge results in a polar 
DSM. (c) An esophageal polar DSM for patient with Grade 1 AET after sequential chemoradiotherapy. 
L60Gy in longitudinal and circumferential direction are represented by vertical and horizontal white 
arrows, respectively. Repeating for all dose levels results in lDLH and cDLH. (d) Binary mask of DSM 
for ≥60 Gy showing the primary and secondary largest contiguous surface areas CSA 1 and CSA 2, 
respectively. For cDSH, only CSA 1 is used, whereas for ccDSH CSA 2 is included, but reciprocally 
scaled by its distance to CSA 1.
Abbreviations: DSH = dose-surface histogram; P = posterior, R = right, A = anterior, L = left 
circumferential direction; DSM = dose-surface map; AET = acute esophageal toxicity; L60Gy = 
circumferential or vertical length of dose-surface area receiving at least 60 Gy; lDLH = longitudinal 
dose-length histogram; cDLH = circumferential dose-length histogram; CSA = contiguous surface 
area; cDSH = contiguous dose-surface histogram; ccDSH = combined contiguous dose-surface 
histogram.
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course. Intuitively it seems plausible that 2D dose parameters, derived with high spatial 
resolution from a treatment plan with a heterogeneous dose distribution, may be more 
susceptible to errors due to organ movement than conventional DVH-based parameters.
To investigate the robustness of the derived parameters under esophageal mobility we 
applied the established method of blurring the planned dose to simulate the accumulated 
dose over the entire treatment during organ motion 32,33. Patient individual 3D dose 
distributions were blurred by convolution with Gaussian probability density functions 
over a range of standard deviations, since the actual esophageal motion in our patients 
was unknown. The standard deviation ranged from 1 to 6 dose voxels and filter sizes were 
equal to two times the Gaussian full width at half maximum (FWHM=22ln2σ). After blurring, 
the 2D dose-surface parameters were calculated and subsequently used for multivariable 
logistic regression modeling. The same approach was used for the established NTCP 
model to allow a fair comparison.
Data exploration and predictive modeling
Our established NTCP-model, based on clinical variables (CCR, Gender and tumor stage) 
and a dosimetric parameter (MED), was used to test whether the newly developed NTCP 
models based on 2D dose-surface parameters were of added value in predicting AET 1. 
The three clinical variables in the new NTCP models were similar to those in the original 
model, such that observed differences have to originate from the change in esophageal 
wall-based dosimetric information added to the model. 
 For each of the five newly created 2D dose histograms univariate logistic regression 
analysis was used to determine the parameters that were most significantly associated 
with Grade ≥2 AET. Four- and five-variable predictive models were created for DSH and 
DSM-derived parameters. The four-variable model included the three clinical parameters 
and the MED of the initial model was substituted by the most significant esophageal wall- 
based dose parameters. The five-variable model again included the three clinical variables, 
but this time instead of substituting the MED the most significant esophageal wall-based 
dose parameters were added. Additionally, neighboring cumulative dose histogram parameters 
are strongly correlated, indicating a high degree of multicollinearity. To circumvent the 
challenge of multicollinearity, the MHD of the five histograms was always chosen to 
generate a four-variable and five-variable model regardless of whether it achieved the 
highest significance (analogous to the approach in the reference NTCP model).
 Individual predictions for AET were calculated using multivariable logistic regression 
analysis. The discriminative ability of the model was expressed by the area under the 
curve (AUC) of the receiver operator characteristic for these four- and five-variable models 
(AUC-4 and AUC-5, respectively). Differences between the obtained AUCs were statistically 
tested according to DeLong et al. 34. The statistical analyses were conducted using STATA 
(version 11.2, StataCorp LP, College Station, TX) and SPSS (version 22.0, Chicago, IL). P-values 
below 0.05 were considered to be statistically significant for all conducted statistical tests.
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Results
From the 149 patients evaluated (Table 1), 72 (48.4%) patients had ≥cT3 tumors and 52 
(35%) were female. Ninety-three (62.4%) and 46 (30.9%) patients received concurrent or 
sequential chemoradiotherapy, respectively. Grade ≥2 AET was scored in 53 (35.6%) 
patients. The five dose histograms (DSH, cDSH, ccDSH, cDLH and lDLH) were calculated for 
each patient and the accompanying predictive models for the selected parameters were 
generated.
Table 1 |   Patient, tumor and treatment characteristics.
Characteristics N = 149   Characteristics N = 149
Gender (%) Chemotherapy (%)
Male 97 (65) Concurrent 93 (62.4)
Female 52 (35) Sequential 46 (30.9)
Age (y; range) None 10 (6.7)
Median 63 (36-78) Radiation dose (%)
Karnofsky Performance (%) 66 Gy 145 (97.3)
≥ 90 95 (64) 60 Gy 4 (2.7)
≤ 80 54 (36) Radiotherapy (%)
Histology (%) IMRT 99 (66.4)
SCC 56 (37.6) VMAT 50 (33.6)
AC 59 (39.6)
NSCLC NOS 22 (14.8)
Other/Missing 6/4 (4/4)
Overall Tumor Stage (%)
IIb 2 (1.3)
IIIa 94 (63.1)
IIIb 53 (35.6)
Clinical Tumor stage (%) Clinical Nodal stage (%)
0 7 (4.7) 0 12 (8.1)
1 24 (16.1) 1 7 (4.7)
2 44 (29.6) 2 92 (61.7)
3 36 (24.2) 3 37 (24.8)
4 36 (24.2)
 X 2 (1.3)   X 1 (0.7)
Abbreviations: SCC = squamous cell carcinoma; AC = adenocarcinoma; NSCLC = non-small cell lung cancer; NOS = 
not otherwise specified; IMRT = intensity-modulated radiation therapy; VMAT = volumetric-modulated arc therapy.
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Dose parameter selection
Univariate logistic regression analysis was performed to assess the association of Grade ≥2 
AET with all dosimetric variables described below (Supplemental material, Table S1 and 
S2). The conventional DSH parameters showed a significant increase in Grade ≥2 AET for 
S5Gy to S65Gy parameters, with the most significant increase for S40Gy through S60Gy (p = 
0.001, respectively). Both contiguous and connected contiguous surface histograms, cDSH 
and ccDSH, showed significance for the parameters S5Gy and S15Gy through S65Gy. Again, 
the DSH parameters related to high-dose areas (i.e., S50Gy through S60Gy) reached the 
highest level of significance (p=0.001, for both cDSH and ccDSH, respectively). Analysis of 
the cDLH and lDLH dose length histograms revealed a significant increase in Grade ≥2 
AET for the circumferential parameters L55Gy through L65Gy, and for the longitudinal length 
parameter a significant increase in Grade ≥2 AET was observed for L30Gy through L65Gy. 
The highest level of significance was reached for L60Gy (p = 0.004) of the lDLH and for L60Gy 
and L65Gy for cDLH (p=0.004, respectively). Except for cDLH, univariate logistic regression 
showed that regression coefficients for all MHD parameters were highly statistically 
significant (p=0.001, p=0.003, p=0.009; for DSH, for both cDSH and ccDSH, and for lDLH, 
respectively).
 Selecting the parameters that were most significantly associated with Grade ≥2 AET 
for the five histograms, and always selecting the MHD, resulted in 19 parameters for 
further multivariable modeling.
Comparison of AUCs
The AUC-4 and AUC-5 for the four- and five-parameter NTCP models respectively were 
generated for each of the 19 parameters that were highly significantly associated with 
Grade ≥2 AET on univariate analysis, resulting in 38 models. The calculated AUCs for these 
models are shown in Figure 2 (and Supplemental material, Table S2). For the AUC-4 models 
16 out of 19 models performed less than or equal to (AUC range 0.80−0.84; p>0.05) the 
established DVH-based model (AUC = 0.84 1), but statistical significant decline of 
performance was found only for lDLH L60Gy, lDLH MHD and cDLH MHD (AUC range 
0.79−0.82; p<0.05). The AUC-5 models showed no statistically significant changes in 
performance compared to the reference model (AUC range 0.84−0.85; p>0.05). Simulation 
of interfraction organ motion by blurring of the 3D dose matrix prior to the derivation of 
the 2D dose-surface parameters did not result in distinguishable patterns between 
models based on the esophageal wall-based dose parameters versus the reference model 
based on MED (shown in Figure 3). 
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Figure 3 |   Robustness of 2D dose-surface parameters under esophageal movement.
Influence of esophageal movement on AUC-4 models based on esophageal wall-based dose 
measures (white faces) compared with the established model (black faces). Different amounts 
of esophageal movement are approximated by 3D blurring of the patient dose distributions by 
Gaussian probability density functions with standard deviations ranging from 1 to 6 dose voxels (4 
mm dose grid). After blurring the dose parameters are calculated and, together with the three clinical 
parameters from the established model, used for multivariate logistic regression analysis to generate 
new NTCP models.
Abbreviations: AUC = area under the curve; DVH = dose-volume histogram; DSH = dose-surface 
histogram; cDSH = contiguous dose-surface histogram; ccDSH = combined contiguous dose-
surface histogram; lDLH = longitudinal dose-length histogram; cDLH = circumferential dose-length 
histogram; MED = mean esophageal dose; MHD = mean histogram dose; LxxGy relative length 
receiving at least xx Gy.
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Discussion
One of the drawbacks of DVH and DSH parameters is that they do not reflect spatial 
information on the 3D dose distribution. Several studies have reported on using esophageal 
wall-based dosimetric parameters in modeling of AET based on the hypothesis that dose 
to the mucosal layer of the esophageal lumen is likely prognostic 20,35-38. However, there 
is no consensus regarding an adequate spatial dosimetric predictor for AET.
 Furthermore, patients in these studies were treated with 3D-CRT, whereas modern 
IMRT and VMAT lead to different dose distributions, i.e. dose to the target volume is more 
conformal and more heterogeneous outside the target. It is hypothesized that prediction 
models based on 3D-CRT cannot be extrapolated to IMRT or VMAT based radiotherapy 
techniques. For instance, model performance for prediction of xerostomia in head and 
neck cancer based on 3D-CRT declined in patients treated with IMRT 39. Similarly, NTCP 
modeling of chronic gastrointestinal toxicities following prostate cancer treatment in 
matched 3D-CRT and IMRT patients showed poor performance of 3D-CRT derived optimal 
parameters when applied to IMRT patients and vice versa 40. Therefore, it is important to 
revisit the correlation between the shape and location of the esophageal wall dose 
distribution and clinical outcome measures for the current treatment techniques.
 Previously, we have published an NTCP model for AET in NSCLC patients receiving 
modern highly conformal radiotherapy, but this model did not incorporate esophageal 
wall-based dosimetric parameters 1. In the current work, new methods were developed to 
analyze the dose distribution over the esophageal wall with and without taking spa-
tio-dosimetric parameters into account. The esophageal wall-based dose parameters 
were used in predictive modeling of AET using the established DVH model to determine 
their added benefit in predictive performance. It was hypothesized that an NTCP model 
incorporating shape-based dosimetric parameters outperforms the NTCP model that is 
based on DVH parameters only. However, the addition of spatio-dosimetric information 
did not improve model performance.
 Some drawbacks of the current study may have lead to the observed result. The 
esophagus is a tubular organ of only a few centimeters in diameter and therefore the 
esophageal dose distribution generally consists of dose to a relatively small and elongated 
volume. Analysis showed that this specific combination of organ geometry and dose 
distribution resulted in conventional DSH and DSM-derived histograms being of similar 
appearance to the original esophageal DVH. Changes in model performance after 
substituting MED from the original model with the 2D dose parameters, i.e. parameters 
from DSH or DSM-derived histograms, are therefore understandably minor. Additionally, a 
large majority (139 out of 149) of patients showed a single CSA of high dose in the dose 
map. Mediastinal lymph nodes were located close to the primary tumor and did not result 
in separated areas of high dose. For a minority of patients (10 out of 149) the surface area 
of high dose was split in two CSAs, but only in 4 patients this led to significantly different 
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DSM-derived histograms when compared to conventional DSH. The DSM-derived histo - 
grams therefore yield no additional information in most patients (145 out of 149).
 To incorporate spatial information of the dose distribution the approach of polar DSM 
generation has been chosen. This methodology is straightforward in its application, has 
an easy interpretation and has previously been shown to be successful, mainly in prostate 
cancer treatment. For instance, rectal DSM-derived parameters have been shown to be 
prognostic for predicting gastrointestinal toxicities 27,41,42 and bladder DSMs are correlated 
with urinary toxicity 43 following prostate cancer radiotherapy. Analysis of rectal wall DSM 
data has shown a high degree of spatial similarity and therefore interpretation and 
post-processing of the DSMs can be more standardized than for esophageal wall DSMs. 
For example, Buettner et al. 41 demonstrated that NTCP model performance increased 
through spatial parameterization of the rectal wall dose distribution. Esophageal wall 
DSMs are much more heterogeneous due to the large variety in tumor volumes and 
location in NSCLC radiotherapy resulting in a diversity of dose distributions, ultimately 
making parameterization and modeling more difficult than for prostate radiotherapy. 
 Another aspect that introduces uncertainties is the rectangular form of the polar 
DSMs. The circumference of the esophagus can change abruptly along the longitudinal 
coordinate, i.e. between adjacent CT slices, due to folding or the presence of air. Converting 
the contours to a polar DSM stretches the circumferences to a normalized length which 
can result in a jagged appearance of the isodoses in the DSM. This may have a detrimental 
effect on the prognostic value of the parameters that are derived from these maps.
 Dose distributions in the esophagus often contain steep dose gradients due to rapid 
dose fall-off outside of tumor volumes when using modern treatment techniques such as 
IMRT and VMAT. This is important, as the esophagus can move up to a few centimeters 
between fractions 30,44. The CT scan that is used for treatment planning is merely a 
‘snapshot’ and the impact of movement on the esophageal dose distributions is not taken 
into account. However, these organ movements can have significant impact on the dose 
distribution that is accumulated in vivo, especially when the esophagus is located near 
high-dose regions with steep dose fall-off. Steep dose gradients are often present in dose 
distributions for patients with advanced stage (non-)small cell lung cancer, frequently 
presenting with multi-level metastatic mediastinal lymph nodes. 2D dose parameters 
derived at the esophageal wall may be more susceptible to organ motion than 
conventional MED which is calculated over the entire volume. The robustness of these 
parameters, i.e. the amount of change in their values for a given movement of the 
esophagus, may be larger than conventional volumetric parameters. To simulate motion 
of the esophagus we applied blurring of the 3D dose matrix with Gaussian probability 
density functions having different standard deviations. After blurring, the 2D dose-surface 
parameters were calculated and subsequently used in predictive modeling. No clear 
difference in model performance was observed between the 2D dose parameters and 
the original MED parameter for the blurred dose distributions. Therefore, it cannot be 
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concluded that the 2D spatio-dosimetric parameters are less robust than the original 
volumetric MED parameter.
 Finally, precise determination of the mucosal dose is not possible due to the usually 
collapsed lumen of the esophagus. The inner wall of the esophagus may be folded, but 
contrast resolution of the planning CT scan is inadequate to observe this. As a first order 
approximation the outer esophageal wall was delineated. However, this may have 
introduced errors during virtually unfolding for DSM generation since the delineated 
contour of the wall was unfolded and not the actual wall contour.
Conclusion
In this work new methods were developed to derive esophageal wall-based dose-surface 
measures that include spatial information of the dose distribution. We tested if these 
shape-based dose measures improved the predictive performance of an established 
multivariable NTCP model for Grade ≥2 AET in patients with advanced stage NSCLC 
undergoing intensity-modulated (chemo-) radiotherapy. We found that incorporation of 
the esophageal wall dose-surface measures with spatial information did not improve the 
predictive performance of the existing model.
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Supplemental material
Table S1 |   Univariate logistic regression analysis to assess the association of Grade ≥2 
AET with the dosimetric variables of the dose-volume, dose-surface and 
dose-length histograms.
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V5Gy 0.033 1.033 (1.006-1.061) 0.017 S5Gy 0.032 1.033 (1.004-1.062) 0.024
V10Gy 0.033 1.034 (1.006-1.063) 0.019 S10Gy 0.030 1.030 (1.002-1.059) 0.037
V15Gy 0.036 1.036 (1.008-1.065) 0.011 S15Gy 0.033 1.033 (1.005-1.062) 0.020
V20Gy 0.041 1.042 (1.014-1.070) 0.003 S20Gy 0.037 1.038 (1.010-1.066) 0.007
V25Gy 0.039 1.040 (1.013-1.067) 0.003 S25Gy 0.035 1.035 (1.010-1.062) 0.007
V30Gy 0.038 1.039 (1.013-1.065) 0.003 S30Gy 0.035 1.036 (1.011-1.061) 0.001
V35Gy 0.038 1.039 (1.014-1.064) 0.002 S35Gy 0.037 1.037 (1.013-1.062) 0.002
V40Gy 0.040 1.040 (1.016-1.065) 0.001 S40Gy 0.037 1.038 (1.014-1.062) 0.001
V45Gy 0.041 1.042 (1.018-1.066) 0.001 S45Gy 0.038 1.039 (1.016-1.063) 0.001
V50Gy 0.043 1.044 (1.019-1.068) <0.001 S50Gy 0.040 1.040 (1.017-1.064) 0.001
V55Gy 0.045 1.046 (1.020-1.072) <0.001 S55Gy 0.042 1.043 (1.018-1.067) 0.001
V60Gy 0.049 1.050 (1.023-1.078) <0.001 S60Gy 0.045 1.046 (1.019-1.073) 0.001
V65Gy 0.049 1.050 (1.014-1.087) 0.006 S65Gy 0.045 1.046 (1.011-1.082) 0.009
V70Gy 0.124 1.139 (0.809-1.585) 0.470 S70Gy 0.033 1.034 (0.768-1.390) 0.827
MED 0.078 1.081 (1.034-1.131) 0.001 MHD 0.071 1.074 (1.028-1.121) 0.001
Dmax 0.024 1.025 (0.959-1.095) 0.473 Dmax 0.026 1.026 (0.960-1.097) 0.449
Abbreviations: AET = acute esophageal toxicity; DVH = dose-volume histogram; DSH = dose-surface histogram; 
VxxGy = relative volume receiving at least xx Gy; SxxGy relative surface area receiving at least xx Gy; MED = mean 
esophageal dose; MHD = mean histogram dose; Dmax = maximum histogram dose; CI = confidence interval. 
Bold p-values are statistically significant; parameters with italic p-values are selected for AUC-4 and AUC-5 model 
generation (MHD is always selected).
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Table S1 |   Continued. Univariate logistic regression analysis to assess the association  
of Grade ≥2 AET with the dosimetric variables of the dose-volume, dose- 
surface and dose-length histograms.
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S5Gy 0.030 1.031 (1.002-1.061) 0.036 0.030 1.030 (1.001-1.060) 0.039
S10Gy 0.023 1.024 (0.996-1.052) 0.092 0.024 1.024 (0.996-1.052) 0.090
S15Gy 0.026 1.026 (0.999-1.054) 0.056 0.026 1.026 (0.999-1.054) 0.055
S20Gy 0.030 1.031 (1.005-1.058) 0.021 0.030 1.031 (1.005-1.058) 0.021
S25Gy 0.029 1.029 (1.005-1.055) 0.020 0.029 1.029 (1.005-1.055) 0.020
S30Gy 0.029 1.029 (1.006-1.053) 0.015 0.029 1.029 (1.006-1.053) 0.015
S35Gy 0.030 1.030 (1.007-1.053) 0.010 0.030 1.030 (1.007-1.053) 0.010
S40Gy 0.031 1.036 (1.010-1.055) 0.005 0.031 1.032 (1.009-1.055) 0.005
S45Gy 0.034 1.035 (1.012-1.058) 0.002 0.034 1.034 (1.012-1.057) 0.003
S50Gy 0.037 1.037 (1.015-1.061) 0.001 0.036 1.037 (1.014-1.060) 0.001
S55Gy 0.041 1.042 (1.018-1.066) 0.001 0.040 1.041 (1.017-1.065) 0.001
S60Gy 0.045 1.046 (1.020-1.073) 0.001 0.045 1.046 (1.019-1.073) 0.001
S65Gy 0.043 1.044 (1.008-1.081) 0.016 0.044 1.045 (1.010-1.082) 0.012
S70Gy 0.044 1.045 (0.749-1.459) 0.794 0.049 1.050 (0.763-1.446) 0.763
MHD 0.064 1.066 (1.022-1.113) 0.003 0.063 1.065 (1.021-1.112) 0.003
Dmax 0.023 1.023 (0.958-1.093) 0.493 0.023 1.023 (0.958-1.093) 0.493
Abbreviations: AET = acute esophageal toxicity; cDSH = contiguous dose-surface histogram; ccDSH = combined 
contiguous dose-surface histogram; SxxGy relative surface area receiving at least xx Gy; MHD = mean histogram 
dose; Dmax = maximum histogram dose; CI = confidence interval. 
Bold p-values are statistically significant; parameters with italic p-values are selected for AUC-4 and AUC-5 model 
generation (MHD is always selected).
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Table S1 |   Continued. Univariate logistic regression analysis to assess the association  
of Grade ≥2 AET with the dosimetric variables of the dose-volume, dose- 
surface and dose-length histograms.
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L5Gy 0.030 1.031 (1.002-1.061) 0.038 N/A N/A N/A
L10Gy 0.025 1.025 (0.998-1.054) 0.072 -0.267 0.766 (0.000-***) 1.000
L15Gy 0.023 1.023 (0.996-1.051) 0.094 -0.218 0.804 (0.000-***) 1.000
L20Gy 0.025 1.026 (0.999-1.053) 0.061 -0.065 0.937 (0.640-1.371) 0.736
L25Gy 0.025 1.025 (1.000-1.051) 0.052 -0.017 0.983 (0.942-1.026) 0.440
L30Gy 0.026 1.026 (1.001-1.052) 0.041 -0.006 0.994 (0.965-1.024) 0.696
L35Gy 0.029 1.029 (1.005-1.054) 0.018 -0.001 0.999 (0.976-1.022) 0.922
L40Gy 0.027 1.027 (1.004-1.051) 0.024 0.006 1.006 (0.986-1.026) 0.549
L45Gy 0.027 1.027 (1.004-1.050) 0.021 0.011 1.011 (0.993-1.028) 0.225
L50Gy 0.029 1.029 (1.006-1.052) 0.012 0.012 1.012 (0.998-1.027) 0.096
L55Gy 0.030 1.030 (1.008-1.053) 0.008 0.015 1.015 (1.002-1.028) 0.026
L60Gy 0.033 1.033 (1.010-1.056) 0.004 0.016 1.017 (1.005-1.028) 0.004
L65Gy 0.038 1.038 (1.012-1.066) 0.005 0.014 1.014 (1.004-1.023) 0.004
L70Gy 0.087 1.091 (0.958-1.243) 0.189 0.014 1.014 (0.992-1.036) 0.217
MHD 0.056 1.058 (1.014-1.104) 0.009 0.038 1.039 (0.996-1.083) 0.074
Dmax 0.023 1.023 (0.958-1.092) 0.498 0.023 1.023 (0.958-1.092) 0.498
Abbreviations: AET = acute esophageal toxicity; lDLH = longitudinal dose-length histogram; cDLH = circumferential 
dose-length histogram; LxxGy relative length receiving at least xx Gy; MHD = mean histogram dose; Dmax = 
maximum histogram dose; CI = confidence interval; N/A = not available. 
Bold p-values are statistically significant; parameters with italic p-values are selected for AUC-4 and AUC-5 model 
generation (MHD is always selected).
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Table S2 |   The area under the curve (AUC) of the receiver operator characteristic for  
the models predicting Grade ≥2 acute esophageal toxicity.
DVH DSH cDSH
MED S40Gy S45Gy S50Gy S55Gy S60Gy MHD S50Gy S55Gy S60Gy MHD
AUC-4 0.84 0.83 0.83 0.83 0.83 0.83 0.84 0.82 0.83 0.83 0.83
p-value - 0.092 0.125 0.237 0.333 0.304 0.281 0.090 0.169 0.286 0.051
AUC-5 0.84 0.84 0.84 0.84 0.84 0.84 0.84 0.84 0.84 0.84 0.85
p-value - 0.576 1.000 0.353 0.292 0.327 0.803 0.656 0.625 0.519 0.623
ccDSH lDLH cDLH
S50Gy S55Gy S60Gy MHD L60Gy MHD L60Gy L65Gy MHD
AUC-4 0.82 0.83 0.83 0.83 0.81 0.82 0.80 0.80 0.79
p-value 0.096 0.176 0.283 0.059 0.030 0.046 0.069 0.083 0.017
AUC-5 0.84 0.84 0.84 0.85 0.85 0.85 0.84 0.84 0.84
p-value 0.480 0.639 0.545 0.529 0.470 0.453 0.725 0.573 0.985
Abbreviations: DVH = dose-volume histogram; DSH = dose-surface histogram; cDSH = contiguous dose-surface 
histogram; ccDSH = combined contiguous dose-surface histogram; lDLH = longitudinal dose-length histogram; 
cDLH = circumferential dose-length histogram; MED = mean esophageal dose; SxxGy relative surface area 
receiving at least xx Gy; MHD = mean histogram dose; LxxGy relative length receiving at least xx Gy; AUC = area 
under the curve. 
Bold p-values indicate statistically significantly different AUC with respect to the AUC of the established DVH 
model.
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Abstract
Background and purpose: The majority of normal-tissue complication probability 
(NTCP) models for acute esophageal toxicity (AET) in advanced stage non-small cell lung 
cancer (AS-NSCLC) patients treated with (chemo-) radiotherapy are based on three- 
dimensional conformal radiotherapy (3D-CRT). Due to distinct dosimetric characteristics 
of intensity- modulated radiation therapy (IMRT), 3D-CRT based models need revision. 
We established a multivariable NTCP model for AET in 149 AS-NSCLC patients undergoing 
IMRT.
Materials and methods: An established model selection procedure was used to develop 
an NTCP model for Grade ≥2 AET (53 patients) including clinical and esophageal dose- 
volume histogram parameters.
Results: The NTCP model predicted an increased risk of Grade ≥2 AET in case of: 
concurrent chemoradiotherapy (CCR) [adjusted odds ratio (OR) 14.08, 95% confidence 
interval (CI) 4.70-42.19; p<0.001], increasing mean esophageal dose [Dmean; OR 1.12 per Gy 
increase, 95% CI 1.06-1.19; p<0.001], female patients (OR 3.33, 95% CI 1.36-8.17; p=0.008), 
and ≥cT3 (OR 2.7, 95% CI 1.12-6.50; p=0.026). The AUC was 0.82 and the model showed 
good calibration.
Conclusions: A multivariable NTCP model including CCR, Dmean, clinical tumor stage and 
gender predicts Grade ≥2 AET after IMRT for AS-NSCLC. Prior to clinical introduction, 
the model needs validation in an independent patient cohort.
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Introduction
The introduction of intensity-modulated radiation therapy (IMRT) and volumetric-modu-
lated arc therapy (VMAT) for advanced stage non-small cell lung cancer (NSCLC) patients 
allows for the delivery of highly conformal dose distributions enabling treatment of larger 
target volumes or the delivery of increased prescription doses 1,2. Nevertheless, patients 
may still suffer from acute esophageal toxicity (AET) during and shortly after radiotherapy 
for advanced stage disease, because large high-dose volumes of centrally located tumors 
or involved mediastinal lymph nodes often border the esophagus 3,4. 
 Furthermore, AET is enhanced with concurrent chemoradiotherapy (CCR) 5. Although 
CCR improves survival, the increased AET has a negative impact on the overall quality of 
life and may lead to hospitalization and treatment interruptions jeopardizing treatment 
outcome. Hence, predicting AET may be helpful in anticipating (chemo-) radiotherapy 
induced esophageal toxicity. 
 Several studies have assessed the prevalence of AET in (non-small cell) lung cancer 
patients in relation to the dose delivered to the esophagus and other tumor and patient 
related characteristics 4,6-17. Heterogeneous outcomes have been reported, particularly for 
the dosimetric variables predicting for AET 4,9,10,18,19. Up till now, there is no consensus on 
the single best dose-volume histogram (DVH) parameter to predict AET with high 
accuracy and precision. Furthermore, most studies are based on patients treated with 
three-dimensional conformal radiotherapy (3D-CRT), while the vast majority of patients is 
being treated with IMRT or VMAT these days. These techniques can deliver more conformal 
dose distributions than 3D-CRT, however, often at the cost of increased target dose 
heterogeneity and larger proportions of surrounding healthy tissues receiving low doses 
2,20. As a consequence, the dosimetric differences between 3D-CRT and IMRT/VMAT may 
possibly influence the risk of AET and thus new predictive models for AET after IMRT/
VMAT are needed.   
 In this study we systematically investigated the relationship between DVH and clinical 
parameters to establish a predictive model for Grade ≥2 AET in advanced stage NSCLC 
patients treated with step-and-shoot IMRT or VMAT.
Materials and Methods 
In this retrospective study, we assessed a cohort of 149 consecutive patients that had 
undergone (chemo-) radiotherapy for histopathologically confirmed advanced stage or 
inoperable NSCLC between March 2008 and June 2013. The study has been carried out in 
accordance with the national applicable rules concerning the review of research ethics 
committees and informed consent. 
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For staging purposes, every patient underwent a diagnostic 18F-Fluorodeoxyglucose 
positron emission tomography (FDG-PET) scan combined with a low-dose computed 
tomography (CT) scan, and magnetic resonance imaging of the brain. CCR was only 
delivered to patients in good clinical condition; all others underwent sequential treatment 
or radiotherapy alone. 
 For radiation treatment planning, an intravenous contrast-enhanced CT scan (Big Bore 
Brilliance CT scanner; Philips Medical Systems, Best, The Netherlands) of the thorax (3 mm 
slice thickness), directly followed by a slow-CT scan of the primary tumor, were acquired 
while the patient was in treatment position. Both CT data sets were transferred to the 
Pinnacle3 (Version 8.0-9.2; Philips Radiation Oncology Systems, Fitchburg, WI) treatment 
planning system (TPS). The primary tumor and suspicious lymph nodes (confirmed by 
histopathology after endobronchial/endoesophageal ultrasonography, enlarged or with 
malignant features on CT scan, and/or FDG-PET positive) were considered the gross tumor 
volume (GTV). Clinical target volumes (CTV) enclosed the GTV of the primary tumor and 
lymph nodes with 10 mm and 5 mm margins, respectively. Planning target volumes (PTVs) 
were created by an isotropic 5 mm expansion of the CTVs. 
 Delineation of the organs at risk (OAR) such as lungs, heart and spinal cord (i.e., inner 
margin entire bony thoracic spinal canal) was automatically performed by the TPS and 
was adjusted manually if necessary. Because of the retrospective nature of this analysis 
and the importance of accurate DVH data concerning the esophagus, the outer rim of the 
esophageal wall (from the lower border of the cricoid cartilage to the gastro-esophageal 
junction) was recontoured by one single physician (RW).
 The prescribed dose to the PTV was 66 Gy in 33 (once-daily) fractions using IMRT 
(step and shoot until June 2011 or VMAT from April 2011 onwards). In 4 (2.7%) patients the 
prescribed dose could not be achieved without violating the normal-tissue dose 
constraints, and hence the number of fractions was reduced to 30 fractions. According to 
the ICRU 50/62 guidelines the -5% and +7% dose heterogeneity criteria for the PTV were 
aimed for 21,22. A standard beam set-up (six co-planar 10 MV photon beams for IMRT and 
one 10 MV photon arc for VMAT) was used avoiding the contralateral uninvolved lung. 
Step-and-shoot IMRT was planned with a minimum of 10 monitor units per segment and 
a maximum of 60 segments. Gantry angular spacing between control points was 4 
degrees for the VMAT arc. Predicted dose deposition was calculated using a 3D 
collapsed-cone convolution superposition algorithm. Routine position verification prior 
to irradiation consisted of an off-line set-up and correction protocol.
 The standard sequential chemotherapy regimen typically consisted of 3 (3-weekly) 
courses of gemcitabine (1250 mg/m2; on day 1 and 8) and cisplatinum (80 mg/m2; on day 1), 
whereas all patients undergoing CCR received 2 (3-weekly) courses of etoposide (100 mg/m2; 
on day 1-3) and cisplatinum (50 mg/m2; on day 1 and 8). Due to local policy, some patients 
from a referring hospital received one additional course of gemcitabine/cisplatinum 3 weeks 
before start of CCR.
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Toxicity scoring
The standard follow-up protocol consisted of weekly assessment of acute toxicity by the 
treating radiation oncologist, even though this may have varied according to the patients’ 
perceived well-being. In general, follow-up continued after the end of treatment until 
acute toxicity resolved. The Radiation Therapy Oncology Group acute radiation morbidity 
scoring criteria have been used by the treating radiation oncologist to evaluate esophageal 
toxicity 23.
Data collection and statistical analysis
All medical records were retrospectively reviewed. Anonymous patient and tumor charac-
teristics together with the (maximum) AET scores (at any time point) were collected in a 
secured and audit trail-equipped database (OpenClinica, version 3.4, Waltham, MA). Full 
DVH data of the esophagus (solid organ including lumen) were retrieved from the TPS to 
extract the parameters: mean and maximum esophageal dose (Dmean and Dmax, 
respectively), and the relative volume receiving ≥5 Gy to ≥70 Gy (V5Gy to V70Gy) in 5 Gy 
increments. To correct for spatial fractionation effects, these parameters were extracted 
from the DVHs after conversion from physical dose to 2 Gy per fraction equi-effective 
(EQD2) dose assuming α/β=10 Gy for acute toxicity.
 Relevant clinical parameters and the abovementioned EQD2-corrected DVH 
parameters were evaluated for Grade ≥2 AET using univariate logistic regression analysis. 
The resulting significant parameters were tested for between-group (Grade ≥2 vs Grade 
≤1 AET) differences using the Mann-Whitney-U or Chi-square test, where appropriate. 
A p-value of <0.05 was considered statistically significant.
Data exploration and predictive modeling
In accordance with the method of El Naqa et al. 24, a Spearman cross-correlation matrix of 
the DVH parameters was first calculated to assess the degree of multicollinearity between 
variables. In case of high inter-variable correlations (correlation coefficient ≥0.8), a surrogate 
variable was selected before actual modeling was performed. Furthermore, the Lyman- 
Kutcher-Burman (LKB) normal-tissue complication probability (NTCP) model was fitted to 
the Grade ≥2 AET data using the EQD2-corrected DVHs to assess the volume effect 25. 
After these data exploration steps, automated multivariable logistic regression model 
selection was performed using the MATLAB-based (version R2013b; The MathWorks, 
Natick, MA) Dose Response Explorer System (DREES; version 1.0 beta) 26. First, the optimal 
model order was estimated by leave-one-out cross validation (2000 samples); i.e., the 
number of model parameters with the highest correlation coefficient for Grade ≥2 AET 
was selected as the optimal number of parameters. The second step comprised the 
estimation of the model parameters by logistic regression analysis with forward selection 
on 2000 bootstrap samples. From these bootstrap samples, the most frequently selected 
model was chosen as the optimal model. Odds ratios (OR) and the accompanying 95% 
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confidence intervals (CI) were calculated for these parameters using SPSS software (version 
20.0; Chicago, IL). 
The multivariable NTCP model for Grade ≥2 AET with k prognostic variables (x) is expressed 
by the multivariable logistic regression formula: 
(1)
where
(2)
and βi are the regression coefficients.
The discriminative power of the model was assessed by calculating the area under the 
curve (AUC) of the receiver operating characteristic. As recommended by Steyerberg et al. 27, 
the AUC was corrected for optimism by a bootstrap sampling procedure. We used an 
in-house software tool based on MATLAB to generate 5000 bootstrap cohorts by randomly 
drawing 149 samples (with replacement) and construct 5000 new predictive models, 
which were subsequently applied on the original patient cohort to acquire new AUCs. The 
mean difference in AUC between the original sample-based model and the bootstrap 
sample-based models was considered the correction for optimism.
 For calibration of the NTCP model, the agreement between the predicted complication 
risk and the observed outcome rates was assessed by generating a calibration plot and by 
performing the Hosmer-Lemeshow test 28.
Results
A total of 149 patients were evaluated (Table 1), of whom 72 (48.4%) patients had ≥cT3 
tumors and 129 (86.5%) patients suffered from advanced nodal disease (i.e., ≥cN2). 
Concurrent and sequential chemoradiation was delivered to 93 (62.4%) and 46 (30.9%) 
patients, respectively. 
 Weekly AET assessment was available for 108 (72.5%) patients, only 5 (3.4%) patients 
were seen less than 4 times during the six-week course of radiotherapy. One hundred and 
twenty-six (84.6%) patients had at least one follow-up contact after finishing radiotherapy, 
whereas for the remaining 23 (15.4%) patients the post-treatment AET scores were not 
available. The majority of these 23 patients (N=14, 61%) had Grade ≤1 AET during 
radiotherapy. 
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Table 1 |   Patient, tumor and treatment characteristics.
Characteristics N=149   Characteristics   N=149
Gender (%) Radiotherapy technique (%)
Male 97 (65) IMRT 99 (66.4)
Female 52 (35) VMAT 50 (33.6)
Age (y) (range) Radiation dose (%)
Median 63 (36-78) 66 Gy 145 (97.3)
Karnofsky Performance (%) 60 Gy 4 (2.7)
≥ 90 95 (64) Chemotherapy (%)
≤ 80 54 (36) Concurrent 93 (62.4)
Tumor cell type (%) Sequential 46 (30.9)
SCC 56 (37.6) None 10 (6.7)
AC 59 (39.6)
NSCLC NOS 22 (14.8)
Other/Missing 6/6 (4/4)
Clinical Stage (%)
IIb 2 (1.3)
IIIa 94 (63.1)
IIIb 53 (35.6)
Tumor stage (%)
0 7 (4.7)
1 24 (16.1)
2 44 (29.6)
3 36 (24.2)
4 36 (24.2)
X 2 (1.3)
Nodal stage (%)
0 12 (8.1)
1 7 (4.7)
2 92 (61.7)
3 37 (24.8)
 X 1 (0.7)     
Abbreviations: SCC = squamous cell carcinoma; AC = adenocarcinoma; NSCLC = non-small cell lung cancer; NOS = 
not otherwise specified; IMRT = intensity-modulated radiation therapy; VMAT = volumetric-modulated arc therapy.
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Grade 0, 1, 2 or 3 AET was scored in 18 (12.1%), 78 (52.4%), 40 (26.8%) and 13 (8.7%) patients, 
respectively. From Table 2, it is clear that the rate of Grade ≥2 AET was significantly higher 
(p<0.001) in patients receiving CCR (N=46) than in patients receiving sequential 
chemoradiation or radiotherapy alone (N=7). 
 Univariate logistic regression analysis revealed a significant increase in Grade ≥2 AET 
in younger patients, in females, in those treated with VMAT, and when concurrent 
chemotherapy was administered (Table 3). Univariate logistic regression analysis of the 
DVH parameters (supplemental material, Table S1) showed a significant increase in Grade 
≥2 AET for all V5Gy to V65Gy parameters, with the most significant increase for V50Gy, V55Gy 
and V60Gy (p<0.001, respectively). Also, the regression coefficient of Dmean was statistically 
significant (p=0.001). For V70Gy and Dmax the regression coefficients were not statistically 
significant.
 Regarding the Spearman self-correlation matrix for the DVH parameters, all parameters 
were significantly correlated, most of them with correlation coefficients ≥0.8 (supplemental 
material, Figure S1A). A strong correlation was also observed between Dmean and V15Gy 
through V60Gy, suggesting a high degree of multicollinearity. 
 Fitting the LKB NTCP model to the DVH data displayed the following parameters: 
n = 1.04 (95% CI 0.48−5.49), m = 0.65 (95% CI 0.27−1.03), and D50 = 32.84 Gy (95% CI 
15.59−50.08 Gy). The volume parameter n appeared to be close to 1, indicating a large 
volume effect and thus implying that Dmean was a good predictor for Grade ≥2 AET. 
Since Dmean in our model was a good surrogate for the other DVH parameters, we decided 
to solely include this dosimetric parameter in the modeling procedure.
Table 2 |   Number of patients (whole group percentage is displayed between brackets) 
according to the maximum scored AET grade divided by the allocated 
treatment.
RTOG AET grading CCR SCR or  
radiotherapy alone
Total
0  absence of symptoms 8 (5.4%) 10 (6.7%) 18 (12.1%)
1  requiring non-narcotic analgesics at most 39 (26.2%) 39 (26.2%) 78 (52.4%)
2   requiring narcotic analgesics or puree/
liquid diet
35 (23.5%) 5 (3.3%) 40 (26.8%)
3   requiring  nasogastric tube feeding or 
intravenous fluids
11 (7.4%) 2 (1.3%) 13 (8.7%)
4   esophageal obstruction, ulceration, 
perforation or fistula
0 0 0
5   death due to toxicity 0 0 0
Abbreviations: RTOG = Radiation Therapy Oncology Group; AET = acute esophageal toxicity; CCR = concurrent 
chemoradiotherapy; SCR = sequential chemoradiotherapy.
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Analyzing Dmean together with the clinical parameters presented in Table 3, the optimal 
model consisted of 4 parameters (supplemental material, Figure S1B). In approximately 
55% of the bootstrap samples, the model including CCR, advanced tumor stage (cT3/4), 
gender and Dmean was considered to be optimal (supplemental material, Figure S1C). The 
regression coefficients and adjusted ORs for this optimal model indicated that patients 
had an increased risk of Grade ≥2 AET with increasing Dmean, when they received CCR, 
were female or had advanced tumor stage (Table 4). Based on these prognostic variables, 
a predicted NTCP estimate for individual patients could be calculated from (1) by 
substituting the variables and corresponding regression coefficients into equation (2).
 The sample-based AUC was 0.84 (95% CI 0.77–0.91); the bootstrap optimism-corrected 
AUC was 0.82, indicating good discriminative ability and robustness of the model. 
The Hosmer-Lemeshow test showed no significant difference (p=0.127), supporting the 
significant agreement between the predicted risk and observed NTCP rates for patients 
suffering from Grade ≥2 AET. The fit (loess smoother) of the actual outcome vs predictions 
in the calibration plot for Grade ≥2 AET (supplemental material, Figure S2) was close to 
the ideal 45° reference line. Nagelkerke’s R2  of this predictive model was 0.407.
Table 3 |   Results from univariate logistic regression analysis of clinical parameters  
for Grade ≥2 AET.
Clinical parameter Coefficient Odds ratio (95% CI) p-value
Age -0.062 0.94 (0.90 - 0.98) 0.002
Gender (female vs male) 0.825 2.28 (1.13 - 4.59) 0.021
Concurrent chemotherapy (yes vs no) 1.924 6.85 (2.81 - 16.69) <0.001
VMAT vs IMRT 0.801 2.23 (1.10 - 4.50) 0.026
Radiation dose 0.086 1.09 (0.74 - 1.60) 0.660
Karnofsky Performance score ≥90 0.550 1.73 (0.84 - 3.57) 0.136
≥5% weight loss (pre-treatment) -0.170 0.84 (0.40 - 1.77) 0.653
≥cT3 0.314 1.37 (0.70 - 2.69) 0.360
≥cN2 0.494 1.64 (0.56 - 4.83) 0.371
Upper and middle lobes vs lower lobes -0.330 0.72 (0.34 - 1.53) 0.390
Abbreviations: AET = Acute Esophageal Toxicity; CI = confidence interval; VMAT = volumetric-modulated arc 
therapy; IMRT = intensity-modulated radiation therapy; cT = clinical tumor stage and cN = clinical nodal stage 
according to the 7th edition of the International Union Against Cancer TNM classification. In case of “x vs y”, the 
latter is the reference category.
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Discussion
Compared to 3D-CRT, the more conformal dose distributions of IMRT/VMAT and its 
influence on AET has not been well documented. This issue has been addressed in a study 
reported by Gomez et al. 29, showing Grade ≥3 AET in 28% of patients treated with IMRT 
(N=139) versus 8% (p<0.05) of patients treated with 3D-CRT (N=405). However, another 
study reported the contrary with equal risks of AET after IMRT or 3D-CRT 30. Due to the 
dosimetric differences between 3D-CRT and IMRT, it is hypothesized that established 
3D-CRT toxicity prediction models are not suitable for predicting toxicity after IMRT. This 
hypothesis is supported by Beetz et al. 31, who showed that their NTCP model for 
xerostomia in head and neck cancer based on 3D-CRT data was less valid for patients 
treated with IMRT. These findings even more imply the need for this study as the increased 
conformality of IMRT paved the way for treatment intensification strategies such as dose 
escalation. These strategies may increase AET and therefore it is important to be able to 
adequately predict AET by means of a predictive model, in particular because model 
based predictions outperform the predictions of physicians 32. Our IMRT-based predictive 
model for AET may guide future dose prescription and treatment planning to keep toxicity 
within acceptable levels. 
 Using a validated systematic approach we constructed a predictive model for Grade 
≥2 AET in advanced stage NSCLC patients treated with IMRT. The model comprises 4 
prognostic variables: delivery of CCR, esophageal Dmean, gender and clinical tumor stage, 
and displayed good predictive performance characteristics. However, from figure S1B, one 
may conclude that a model order of 2 may be equivalent to a model consisting of the 
abovementioned 4 parameters for the correlation with AET is nearly equal. This was 
refuted after performing the likelihood-ratio test for nested models, as the addition of the 
Table 4 |   Predictive parameters from multivariable logistic regression analysis of  
the final model.
Predictor for Grade ≥2 AET Coefficient Adjusted OR (95% CI) p-value
CCR (yes vs no) 2.645 14.08 (4.70 - 42.19) <0.001
Dmean (per Gy increase) 0.117 1.12 (1.06 - 1.19) <0.001
Gender (female vs male) 1.204 3.33 (1.36 - 8.17) 0.008
Tumor stage (cT3/4 vs cT1/2) 0.994 2.70 (1.12 - 6.50) 0.026
Constant -6.418
Abbreviations: AET = Acute Esophageal Toxicity; CI = Confidence Interval; CCR = Concurrent Chemoradiation; Dmean 
= mean esophageal dose. In case of “x vs y”, the latter is the reference category.
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parameters tumor stage and gender contributed significantly (p=0.003) to the predictions 
of the reduced model including only CCR and Dmean (the latter two parameters were 
deemed of greatest relevance based on the bootstrap sampling results, see Figure S1C).
 Although there is a great diversity in predictors for AET as reported in previous 
studies, the esophageal Dmean and the administration of CCR as found in our study are 
in correspondence with earlier studies 7-9,11,33,34. This can be well explained by radio-
sensitization due to CCR and enhanced damage of the esophageal mucosa with increasing 
mean dose to the esophagus. These effects are reflected in our population by high 
adjusted ORs [14.08 and 1.12 (per Gy increase), for CCR and Dmean, respectively] for Grade 
≥2 AET. According to our model, patients with advanced tumor stage (cT3/4) are at higher 
risk of Grade ≥2 AET, which may be due to the fact that the target volumes of these tumors 
do often border on the esophagus due to large tumor dimension or tumor extension into 
the mediastinum. Female patients showed an increased risk for Grade ≥2 AET as well. 
This was also reflected in the clinically validated (3D-CRT based) model for AET of Dehing- 
Oberije et al. 11, however, using a different grading scale and endpoint. 
 Besides CCR and esophageal Dmean, univariate analysis revealed that radiotherapy 
technique (VMAT vs IMRT) and age were also significantly correlated with Grade ≥2 AET 
since more CCR was applied in younger patients and in those treated with VMAT (p<0.001 
and p=0.007 respectively). The explanation for this may be the fact that new insights into 
the added value of CCR above sequential treatment occurred together with the 
introduction of VMAT at our department resulting in relatively more patients receiving 
CCR with a VMAT technique. Only few elderly patients underwent CCR, most probably 
because they were considered unfit or had contraindications for chemotherapy.
 In a meta-analysis by Palma et al. 18, data on 1082 patients who underwent CCR for 
locally advanced NSCLC were evaluated with the goal to design and validate a predictive 
model for AET. Even though the radiation technique (e.g., 3D-CRT vs IMRT) was not 
specified, it can be deducted from the literature references that the majority of patients 
most probably had been treated by 3D-CRT. The authors found the esophageal V60Gy to 
provide the single best predictive value for AET. This DVH parameter was also highly 
significant in our univariate analysis. However, for model building, we decided to replace 
the significant esophageal DVH parameters by one single parameter (Dmean) to circumvent 
the problem of multicollinearity that may lead to unrobust models. This approach seems 
adequate as the esophageal Dmean was found to be most consistently predictive for AET 
in earlier reports 7. Moreover, fitting of the LKB model to our DVH data revealed that this 
Dmean was a good predictor for AET. Furthermore, this is in line with an earlier report 
where the diverse DVH parameters were replaced by the esophageal Dmean resulting in a 
validated AET predictive model 11. Thus, Dmean seems an adequate surrogate DVH 
parameter for non-stereotactic techniques, however, for modeling of AET after stereotactic 
radiotherapy for central lung tumors the maximum dose to the esophagus and doses to 
small volumes correlate best with AET 35.  
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For the modeling procedure we applied the systematic approach as described by 
El Naqa et al. 24 as this has been specifically tested for modeling of radiotherapy toxicity 
outcomes. Also, this approach allows assessment of multicollinearity and selection of the 
optimal model order. These are important issues in finding a model that is likely to fit well 
to other patient populations. Notwithstanding this, our evaluation has some drawbacks. 
Firstly, the retrospective nature of this study may lead to inclusion bias. To minimize this, 
all patients treated in a fixed time period were included. Secondly, the quality of the retro-
spectively retrieved toxicity data may be suboptimal, e.g., the duration of AET may not 
have been reported properly. To overcome these two problems, Niezink et al. 36 have 
developed a standardized program of prospective data acquisition for pulmonary 
radiotherapy, however, internal and external validation is still pending. This approach, 
together with the recently proposed international data exchange strategy, will further 
improve research upon treatment toxicity 37. Thirdly, performance of a predictive model is 
overestimated when determined on the same population that was used to construct the 
model 27. This was the case in our study and therefore we performed an established 
validation procedure (i.e., correction for optimism via bootstrap sampling) to provide a 
more precise estimate of the model’s performance. Nevertheless, the model needs 
validation in an independent patient cohort before it can be used for clinical deci-
sion-making. Fourthly, we only included clinical and dosimetric parameters in this 
retrospective analysis, even though several biomarkers have been reported to be of 
significance as well. The acute phase response (thrombocytosis and anemia) and increased 
serum levels of specific microRNAs were found to be associated with AET 38,39. 
Incorporating these prospectively obtained biomarkers may add to the predictive ability 
of the established model. Fifthly, it is also noted that with the use of DVH data spatial 
dosimetric information is lost. Earlier studies reporting on the influence of spatial dose 
effects (in 3D-CRT) reported ambiguous outcomes on the predictive value of spatial dose 
distribution characteristics 9,16,19,40-42. However, the spatial dose distribution may be more 
important for IMRT than for 3D-CRT as the former technique comes with increased dose 
heterogeneity in the esophagus. The incorporation of spatial dose information in 
predictive modeling of AET is subject of further research.
 In conclusion, a multivariable logistic regression NTCP model to predict Grade ≥2 AET 
rates in patients with advanced stage NSCLC undergoing intensity-modulated (chemo-)
radiotherapy was developed. The most relevant prognostic variables are: concurrent 
chemoradiotherapy, mean dose to the esophagus, clinical tumor stage and gender. 
Although the model has shown good performance, external validation in an independent 
patient cohort is warranted.
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Supplemental material
Table S1 |   Univariate logistic regression analysis for DVH parameters of  
the esophagus and their association with Grade ≥2 AET.
DVH parameters Coefficient Odds ratio (95% CI) p-value
V5Gy 0.033 1.033 (1.006-1.061) 0.017
V10Gy 0.033 1.034 (1.006-1.063) 0.019
V15Gy 0.036 1.036 (1.008-1.065) 0.011
V20Gy 0.041 1.042 (1.014-1.070) 0.003
V25Gy 0.039 1.040 (1.013-1.067) 0.003
V30Gy 0.038 1.039 (1.013-1.065) 0.003
V35Gy 0.038 1.039 (1.014-1.064) 0.002
V40Gy 0.040 1.040 (1.016-1.065) 0.001
V45Gy 0.041 1.042 (1.018-1.066) 0.001
V50Gy 0.043 1.044 (1.019-1.068) <0.001
V55Gy 0.045 1.046 (1.020-1.072) <0.001
V60Gy 0.049 1.050 (1.023-1.078) <0.001
V65Gy 0.049 1.050 (1.014-1.087) 0.006
V70Gy 0.124 1.139 (0.809-1.585) 0.470
Dmean 0.078 1.081 (1.034-1.131) 0.001
Dmax 0.024 1.025 (0.959-1.095) 0.473
Abbreviations: AET = acute esophageal toxicity; CI = confidence interval; V5Gy = relative volume of the 
esophagus receiving ≥5 Gy; Dmean = mean dose; Dmax = maximum dose.
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Figure S1 |   Spearman correlation matrix (1A) for the dosimetric parameters and  
the model selection graphs (1B and 1C).
A: the correlation matrix with the DVH parameters for the esophagus. The correlation coefficients (all 
significant) are denoted for each combination of variables, higher correlations are displayed in fading 
grey. B: figure shows that the optimal model order is 4. C: Bar-graph shows the model that is chosen 
most from the bootstrap samples. 
Abbreviations: VxxGy = relative volume of the esophagus receiving ≥xx Gy; Dmean = mean esophageal 
dose; Dmax = maximum esophageal dose; CCR = concurrent chemoradiotherapy; VMAT = volumetric-
modulated arc therapy; IMRT = intensity-modulated radiation therapy.
V5Gy V10Gy V15Gy V20Gy V25Gy V30Gy V35Gy V40Gy V45Gy V50Gy V55Gy V60Gy V65Gy V70Gy Dmean Dmax
V5Gy 1 0.96 0.86 0.77 0.70 0.64 0.59 0.55 0.51 0.49 0.45 0.39 0.29 0.20 0.71 0.25
V10Gy 0.96 1 0.94 0.86 0.78 0.71 0.65 0.60 0.55 0.52 0.47 0.41 0.30 0.20 0.76 0.25
V15Gy 0.86 0.94 1 0.96 0.89 0.82 0.76 0.70 0.65 0.61 0.56 0.50 0.36 0.21 0.83 0.28
V20Gy 0.77 0.86 0.96 1 0.97 0.92 0.86 0.80 0.75 0.72 0.66 0.59 0.43 0.24 0.89 0.32
V25Gy 0.70 0.78 0.89 0.97 1 0.98 0.94 0.89 0.85 0.81 0.75 0.68 0.50 0.24 0.94 0.35
V30Gy 0.64 0.71 0.82 0.92 0.98 1 0.99 0.95 0.91 0.88 0.83 0.75 0.57 0.27 0.96 0.39
V35Gy 0.59 0.65 0.76 0.86 0.94 0.99 1 0.99 0.96 0.93 0.89 0.82 0.63 0.29 0.97 0.45
V40Gy 0.55 0.60 0.7 0.80 0.89 0.95 0.99 1 0.99 0.97 0.93 0.87 0.69 0.32 0.96 0.50
V45Gy 0.51 0.55 0.65 0.75 0.85 0.91 0.96 0.99 1 0.99 0.97 0.91 0.74 0.36 0.95 0.55
V50Gy 0.49 0.52 0.61 0.72 0.81 0.88 0.93 0.97 0.99 1 0.99 0.94 0.77 0.39 0.93 0.58
V55Gy 0.45 0.47 0.56 0.66 0.75 0.83 0.89 0.93 0.97 0.99 1 0.97 0.82 0.42 0.90 0.62
V60Gy 0.39 0.41 0.50 0.59 0.68 0.75 0.82 0.87 0.91 0.94 0.97 1 0.91 0.49 0.85 0.71
V65Gy 0.29 0.30 0.36 0.43 0.50 0.57 0.63 0.69 0.74 0.77 0.82 0.92 1 0.63 0.69 0.86
V70Gy 0.20 0.20 0.21 0.24 0.24 0.27 0.29 0.32 0.36 0.39 0.42 0.49 0.63 1 0.37 0.82
Dmean 0.71 0.76 0.83 0.89 0.94 0.96 0.97 0.96 0.95 0.93 0.90 0.85 0.69 0.37 1 0.52
Dmax 0.25 0.25 0.28 0.32 0.35 0.39 0.45 0.50 0.55 0.58 0.62 0.71 0.86 0.82 0.52 1
A
B C
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Figure S2 |   Calibration plot of actual outcome vs predictions for the multivariable  
NTCP model for acute esophageal toxicity.
This calibration plot displays the observed frequency vs the predicted probabilities of Grade ≥2 acute 
esophageal toxicity (black solid line). The triangles indicate the average observed frequencies by 
deciles of average predicted probabilities, the open circles indicate the individual outcomes vs their 
predictions. Perfect predictions should be on the dashed 45° reference line. The solid line constitutes 
the loess fit. 
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Abstract
Background and purpose: In this paper, we aim to externally validate a previously 
established multivariable normal-tissue complication probability (NTCP) model for Grade 
≥2 acute esophageal toxicity (AET) after intensity-modulated (chemo-) radiotherapy or 
volumetric- modulated arc therapy for locally advanced non-small cell lung cancer. 
Materials and methods: A total of 603 patients from five cohorts within four different 
Dutch institutes were included. Using the NTCP model, containing the parameters 
concurrent chemoradiation, mean esophageal dose, gender and clinical tumor stage, the 
risk of Grade ≥2 AET was estimated for every individual patient and the performance of 
the model was evaluated for all cohorts (i.e., discrimination and (re)calibration).
Results: Compared to the training cohort, five validation cohorts experienced a higher 
incidence of Grade ≥2 AET (35.6% vs 49.3%-70.2%; borderline significant for one cohort, 
highly significant for four cohorts). For three cohorts, discriminative performance was 
similar (area under the curve (AUC) 0.81-0.89) to that of the training cohort (AUC 0.84). 
In the two remaining cohorts the model showed poor discriminative power (AUC 0.64 and 
0.63). Reasonable calibration performance was observed for two cohorts, and recalibration 
further improved performance in all three cohorts with good discrimination. Recalibration 
for the two poorly discriminating cohorts did not improve model performance.
Conclusions: The NTCP model for the prediction of AET was successfully validated in 
three out of five patient cohorts. The model did not perform well in the other two cohorts, 
which included patients receiving substantially different treatment. Before applying the 
model in clinical practice a thorough check of discrimination and calibration performance 
on a local cohort is recommended. Recalibration of the model is advised to adjust 
predicted probabilities to locally observed frequencies of AET.
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Introduction
Acute esophageal toxicity (AET) is frequently observed in locally advanced non-small cell 
lung cancer (LA-NSCLC) patients undergoing (chemo-) radiotherapy, particularly when 
patients receive concurrent chemotherapy 1,2. Normal-tissue complication probability 
(NTCP) models can help to estimate the risk of moderate or severe AET, which may be of 
benefit for anticipating events of hospitalization or treatment interruptions due to AET 3-7. 
These multivariable NTCP models may also be used by doctors as a tool to support their 
decision on whether or not to treat at the cost of more AET 8-10. Furthermore, in case there 
is an increased risk of AET, patients may be selected that benefit most from other 
radiotherapy techniques such as proton therapy 11,12.
 The vast majority of the reported NTCP models for AET are based on 3-dimensional 
conformal radiotherapy (3D-CRT) techniques. Compared to these 3D-CRT techniques, 
 intensity-modulated radiation therapy (IMRT) and volumetric-modulated arc therapy 
(VMAT) produce more conformal dose distributions at the cost of increased volumes 
receiving lower dose 13-16. Differences in dose distributions may result in a different toxicity 
profile and thus require new NTCP models 17-19. Therefore, the available NTCP models 
based on 3D-CRT may not be appropriate for AET risk prediction in patients treated with 
modern dose delivery techniques. We previously reported on an IMRT- and VMAT-based 
multivariable NTCP model for Grade ≥2 AET 20. This model was internally validated and the 
area under the receiver operating curve (AUC) was 0.84 (0.82 after correction for optimism) 
indicating good discriminative power of the model. Nonetheless, as reproducibility 
(model performance on new samples from the same target population), and transporta-
bility (model performance on samples from different but related populations) of well 
internally validated prediction models can still be poor, external validation is needed to 
assess ‘generalizability’ of the NTCP model to external patient cohorts 21-24.
 In this study, we used five patient cohorts from four different Dutch institutions to 
externally validate the previously reported multivariable NTCP model for Grade ≥2 AET 
after IMRT or VMAT for LA-NSCLC (TRIPOD statement Type 4 external validation  study 24).
Materials and Methods 
Established NTCP model for AET
The model was developed using a training cohort of 149 LA-NSCLC patients who 
underwent (chemo-) radiotherapy using IMRT or VMAT at the Radboud University Medical 
Center (Nijmegen, The Netherlands) between March 2008 and June 2013. Information on 
treatment and patient selection has been previously described in more detail 20. In brief, 
all patients received ≥60 Gy (median 66 Gy) in 2 Gy fractions (once daily), with or without 
(concurrent or sequential) chemotherapy (Table 1). The sequential chemotherapy regimen 
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typically consisted of 3 (3-weekly) courses of gemcitabine/cisplatin, whereas all patients 
undergoing concurrent chemoradiotherapy (CCR) received 2 (3-weekly) courses of 
etoposide/cisplatin.
 AET was scored weekly during treatment by the treating radiation oncologist using 
the Radiation Therapy Oncology Group (RTOG) acute radiation morbidity scoring criteria 
25. Toxicity scoring was continued after treatment until acute toxicity resolved. The AET 
scores were analysed in relation to clinical risk factors and radiation treatment plan derived 
dose volume histogram (DVH) parameters.
 After multivariable logistic regression, with bootstrap sampling for determination of 
model order and parameter selection, the following optimal NTCP model for Grade ≥2 
AET was established:
(1)
with,
S ( x ) = –6.418 + 2.645
  
• CCR + 0.117
  
• MED + 1.204
  
• Gender + 0.994
  * cT, (2)
and CCR = concurrent chemoradiotherapy (1 = yes, 0 = no), MED = mean esophageal dose 
(preferably first converting physical dose to linear-quadratic equivalent dose in 2 Gy 
fractions, α/β = 10 Gy), gender (1 = female, 0 = male) and cT = clinical tumor stage (0 < cT3, 
1 ≥ cT3).
External validation cohorts
Five cohorts from four different Dutch institutions were available for validation of the 
abovementioned NTCP model. The patient, tumor and treatment characteristics of each 
cohort are listed in Table 1 and Supplementary Material Table S1. Except for cohort D and 
E, acute toxicity was scored retrospectively for these cohorts. For all cohorts toxicity was 
scored weekly during radiotherapy and continued after radiotherapy until toxicity 
resolved.
 Cohort A (n=47) was also treated in the Department of Radiation Oncology of the 
Radboud University Medical Center 20. This cohort consisted solely of stage III NSCLC 
patients that were treated with (chemo-) radiotherapy using VMAT between June 2013 
and December 2014. Radiotherapy and chemotherapy regimens and AET scoring were 
similar to those of the training cohort. Cohort B (n=73) consisted of stage III NSCLC patients 
treated at ‘Radiotherapiegroep’ (Arnhem, The Netherlands) between January 2014 and 
March 2016 using mostly VMAT. The radiotherapy regimen and AET scoring were similar to 
the training cohort. Sequential chemotherapy was platinum based, preferentially cisplatin. 
Concurrent chemotherapy consisted of 2 courses of platinum/etoposide sometimes 
preceded by one course of a platinum doublet with either etoposide, or pemetrexed.
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Cohort C consisted of 156 stage I-III NSCLC patients treated at The Netherlands Cancer 
Institute (Amsterdam, The Netherlands) between December 1998 and March 2003 using 
3D-CRT 26. For 27 patients, however, the parameter ‘clinical T-stage’ required in the 
NTCP-model was not available and therefore 129 patients with complete data were 
included in this validation cohort. Varying radiotherapy schedules (total dose 49.5–94.5 
Gy, 2.25–2.75 Gy per fraction) were administered, and sequential and concurrent 
chemotherapy consisted of 2 courses of gemcitabine/cisplatin or daily low-dose cisplatin, 
respectively 26. The incidence of AET in this cohort of patients has been evaluated and 
reported previously; AET was scored using the RTOG scoring criteria 26. Cohort D was also 
retrieved from The Netherlands Cancer Institute comprising of 172 patients treated 
between January 2008 and November 2010, and their AET was scored using the Common 
Toxicity Criteria Adverse Effects (CTCAE) v3.0 27. See Table S2 in the Supplementary Material 
for a comparison between AET scoring using RTOG, CTCAE v3.0 and v4.0. These patients 
all underwent concurrent chemoradiotherapy (daily low-dose cisplatin) using IMRT (66 Gy 
in 24 fractions) 28.
 The patients from cohort E (n=398) were treated at MAASTRO Clinic (Maastricht, The 
Netherlands) between April 2006 and October 2013. Of these, 216 patients had missing 
data, i.e., missing mean esophageal dose (n=201, for technical reasons), AET score (n=4; 
CTCAE v3.0 and v4.0 29), chemotherapy sequence (n=1) and clinical T-stage (n=10), and 
thus 182 patients were included in this validation cohort. Different treatment schedules 
were used. The majority of patients (n=161) received a total dose of 69 Gy in 1.5 Gy fractions 
twice daily up to 45 Gy, followed by 8 to 24 Gy in 2 Gy once daily fractions, depending on 
the dose to the organs at risk (OAR) 30. Eighteen patients were treated within the 
FDG-PET-based international multicenter Phase II dose escalation trial “PET-boost” 31; they 
received 66 Gy in 24 once daily fractions to the gross tumor volume (GTV). In case dose 
escalation was possible (by increasing the fraction dose with equal number of fractions), 
an integrated boost was delivered to the primary tumor as a whole or to the volume of 
the primary tumor encompassed by 50% of the maximum standardized uptake value of 
FDG.
Statistical analysis
Differences between the training cohort from which the NTCP model was developed and 
the validation cohorts were tested for statistical significance using the Mann–Whitney-U 
or Fisher’s exact test, where appropriate (SPSS software, version 22.0; SPSS Inc., Chicago, 
USA). A p-value of <0.05 was considered statistically significant.
Model performance
The risk of Grade ≥2 AET was calculated for each individual patient from the validation 
cohorts by inserting patient specific parameters into the original NTCP model (Formula 1 
and 2) 20. Overall performance was evaluated by examining discrimination and calibration. 
521543-L-sub01-bw-Wijsman
Processed on: 20-7-2018 PDF page: 154
154
CHAPTER 9
The discriminative power of the model for the validation cohorts was assessed by 
calculating the area under the curve (AUC) of the receiver operating characteristic (ROC). 
Furthermore, the discrimination slopes were calculated by the absolute difference 
between the mean predicted risk of the groups with and without Grade ≥2 AET.
 Model calibration performance was assessed by generating calibration plots 
displaying grouped observed frequencies versus predicted outcome 32. A loess smoother 
was plotted, which approximates the y=x identity line in case of good calibration 33. 
The 95% confidence intervals of the binomially distributed grouped frequencies were 
calculated according to the Wilson interval 34. Double histograms of predicted probabilities 
for patients with and without Grade ≥2 AET were also generated for inclusion in the 
calibration plots.
 To assess possible miscalibration in the cohorts, the method of logistic recalibration 
was applied 35,36. The linear predictors for each patient, i.e., the calculated results after 
inserting patient specific parameters into Formula 2, were used as a single covariate in a 
new logistic regression model according to:
(3)
with updated linear predictor
(4)
The resulting calibration intercept a, or ‘calibration-in-the-large’, compares the mean of 
the predicted risks with the mean of the observed risk and gives an indication whether 
predictions are systematically under- (a>0) or overestimated (a<0) 21,32. The calibration 
slope b indicates the level of overfitting (b<1), i.e., the predictions are too extreme, or 
underfitting (b>1), the predictions are too mild. Recalibration does neither affect sensitivity 
nor specificity and thus ROC and AUC both remain the same.
 The overall performance of the recalibrated models in each cohort was additionally 
assessed by calculation of the scaled Brier score, a quadratic scoring rule corrected for 
dependence on the incidence of the outcome 21. Additionally, Nagelkerke’s R2 was 
calculated, which is a logarithmic scoring rule to express the amount of variance in the 
dependent variables explained by the model 36,37.
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Results
Comparison of cohorts
A comparison of training and validation cohort characteristics for the NTCP model 
predictors and AET is listed in Table 1. The incidence of Grade ≥2 AET in cohorts A, D and 
E was (nearly) twice the incidence of Grade ≥2 AET in the training cohort (70.2%, 59.3% 
and 68.1% vs 35.6%, respectively; p<0.001). The patients in cohort C experienced lower 
rates of Grade ≥2 AET compared to the training cohort (21.7% vs 35.6%, respectively; 
p=0.01). Other patient, tumor and treatment characteristics of the cohorts are listed as 
Supplementary Material in Table S1.
Model performance
A summary of model performance in the validation cohorts, i.e., overall performance, 
discrimination and (re)calibration, is listed in Table 2. Unsurprisingly, the best performance, 
as indicated by the highest value of the scaled Brier and Nagelkerke R2, was seen in the 
training cohort. The overall performance was high for cohorts A, B and C, but was poor for 
cohorts D and E. Negative values were seen for cohorts D and E, demonstrating that the 
model is not a good fit for the observed data in these cohorts.
 The ROC curves for all cohorts are displayed in Figure 1. High discriminative performance 
of similar quality to the training cohort was obtained for cohorts A, B and C, as indicated 
by high AUCs (0.89, 0.81 and 0.84, respectively). Poor discrimination of the model was 
found in cohort D and E (AUC 0.64 and 0.63, respectively). This poor discrimination 
performance is also demonstrated by the calculated discrimination slopes (Table 2).
 Model calibration performance, without recalibration, can be visually assessed from 
the calibration plots shown in Figure S1 of the Supplementary Material. Reasonable 
performance without recalibration was found by the model for cohorts A and B, 
demonstrated by the loess smoother which was relatively close to the identity line. The 
model generally underestimated the risk of Grade ≥2 AET. Increasingly poor calibration 
was observed for cohorts C, D and E.
 Calibration plots generated after recalibration are shown in Figure 2, and the values 
for the calibration-in-the-large and calibration slope are listed in Table 2. As expected, 
recalibration did not change the calibration plot of the training cohort. For cohorts A and 
B, good calibration was achieved after recalibration. Similarly, for cohort C recalibration 
moderately improved the agreement between predicted risk and observed risk. For 
cohorts D and E, calibration did not improve after recalibration, indicated by the limited 
range of predicted probabilities (see Figure 2). 
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Figure 1 |   Receiver operator characteristic curves for the NTCP model on  
all patient cohorts.
ROC curves of the previously published NTCP model 20 applied on all patient cohorts showing good 
discriminating performance for 3 out of 5 validation cohorts as indicated by the AUC values (>0.80).
Abbreviations: ROC = receiver operating characteristic; NTCP = normal-tissue complication probability; 
AUC = area under the curve.
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Discussion
Modelling to predict AET induced by (chemo-) radiotherapy may be helpful in selecting 
patients that benefit from intensified treatment or other treatment techniques such as 
proton therapy 11. Recently, we established a multivariable NTCP model for AET in 
LA-NSCLC patients undergoing IMRT or VMAT and after thorough internal validation the 
model proved to be robust 20. However, it is of paramount importance to perform external 
validation in order to ensure that the model is transportable to other patient cohorts 21,23. 
This means that the model produces accurate predictions in a sample that was drawn 
from a different but plausibly related population. Several components of ‘transportability’ 
can be distinguished, such as historical (e.g., a different time period), geographical (e.g., 
treated in a different hospital) and methodological (e.g., differences in toxicity scoring) 
transportability 38. To account for all these components of transportability, we externally 
validated our previously established NTCP model for Grade ≥2 AET on cohorts of (LA-)
NSCLC patients that were treated by (chemo-) radiotherapy in different hospitals (cohort 
B-E), receiving different radiation fractionation schedules (cohort C-E) and in a historically 
different period of time with less conformal dose delivery techniques (cohort C). Ideally, 
an NTCP model performs well on every patient cohort external to the cohort the model 
was developed on. However, this so-called ‘strong calibration’ is only considered possible 
in utopia 32. Therefore, applying an established NTCP model on different patient cohorts 
often needs some form of adjustments to account for local circumstances 39,40.
 The increased incidence of Grade ≥2 AET in cohort A, D and E compared to the 
training cohort may be partially explained by the statistically significantly larger proportion 
of patients receiving CCR in these cohorts: 100% and 85.7% of patients received CCR in 
cohort D and E vs 62.4% of patients in the training cohort. Likewise, the lower incidence of 
Grade ≥2 AET in cohort C may be explained by the notion that only 19.4% of these patients 
received CCR.
Figure 2 |   Recalibrated calibration plots of the NTCP model on all cohorts.
Calibration plots of the NTCP model applied on all patient cohorts and after recalibration per cohort. 
Recalibrated predicted probabilities are calculated by inserting the cohort-specific calibration-in-
the-large and calibration slope values in Formulas 3 and 4. The triangles indicate grouped predicted 
probabilities of Grade ≥2 AET vs grouped observed frequencies. Vertical Lines represent 95% 
confidence intervals. A loess smoother was fitted and displayed by the black line. Perfect predictions 
should be close to the dashed 45° reference line. Double histograms of patients with and without 
Grade ≥2 AET, binned according to their predicted probabilities, are displayed at the bottom.
Abbreviations: NTCP = normal-tissue complication probability; AET = acute esophageal toxicity; 
AUC = area under the curve.
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Recalibration is a controlled form of model updating; i.e., the coefficients of the model 
are adjusted to correct for differences in for instance event rates. Initial calibration of the 
model on cohort A and B was moderate (see Figure S1 in the Supplementary Material). 
Underestimation of Grade ≥2 AET was seen, which is possibly due to a lower incidence of 
Grade ≥2 AET in the training cohort (35.6%) compared to cohort A (70.2%) and cohort B 
(49.3%). The class imbalance in the training cohort can affect the estimate of the model 
intercept and skews the predicted probabilities. After recalibration of the NTCP model for 
cohort A and B, calibration improved; the predicted outcomes matched the observed 
outcomes well (see Figure 2). Discrimination of the model was good for the patients in 
cohort A and B, the AUC was 0.89 and 0.81 respectively. 
 Formerly, we hypothesized that differences in dose delivery techniques influenced 
NTCP modelling since the models based on 3D-CRT did not perform well in head and 
neck cancer patients who underwent IMRT 18,20,41,42. Although cohort C differs substantially 
from the training cohort regarding treatment technique (3D-CRT vs IMRT/VMAT), radiation 
dose (49.5-94.5 Gy vs 66 Gy), the application of concurrent chemotherapy, and the time 
period (1998-2003 vs 2008-2010), the current model performed surprisingly well for this 
population (AUC 0.84 with a moderately good recalibration curve). Cohorts D and E 
showed poor discrimination (AUC 0.64 and 0.63, respectively) and (re)calibration (see 
Figure 1 and Supplementary Material Figure S1). For these cohorts the probability of Grade 
≥2 AET is not explained by the current NTCP model predictors and regression coefficients. 
Re-estimating the regression coefficients or adding additional predictors that are known 
for their association with AET (for example, overall treatment time (OTT) and chemotherapy 
regimen; see below) are approaches to further improve model predictions. Besides this, 
there may be several other reasons for the poor model performance in these cohorts. 
 Firstly, the NTCP model was developed using the RTOG grading scale for AET. 
However, toxicity for the patients in cohort D and E was scored using the CTCAE grading 
scales for AET. Differences between scoring systems were reported to be of importance in 
modelling of toxicity, for instance for modelling the risk of radiation-induced pneumonitis 
43. It is likely that such differences in grading scales affect AET modelling as well. This was 
illustrated for the patients of cohort B for whom both the RTOG and CTCAE v4.0 grading 
of AET were available. Applying the NTCP model using the CTCAE-based AET scores 
resulted in a high discrimination with AUC of 0.80 (compared to 0.81 for the RTOG based 
scores), however, model calibration was poor since it considerably underestimated the risk 
of CTCAE Grade ≥2 AET (data not shown). The latter can be explained by the finding that 
in 35.6% of the patients AET was scored as Grade 1 using the RTOG scale and as Grade 2 
using the CTCAE scale (soft diet vs regular diet, see Table S2 in the Supplementary Material). 
Secondly, the patients from cohort D received concurrent chemoradiotherapy in a 
fundamentally different protocol compared to the patients in the training cohort as they 
received daily low-dose cisplatin and moderately hypofractionated radiotherapy schedules. 
This may induce a different radiosensitization effect of the esophageal mucosa, resulting 
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in differences in AET. Thirdly, the OTT is shorter for cohort D and E than for the training 
cohort. The OTT of the patients in the training cohort was 6.5 weeks, whereas the OTT in 
cohort D and E was approximately 5 weeks. Besides, the majority of patients (88.5%) from 
cohort E were treated twice-daily. Both factors are known to result in a strong increase of 
AET 3,6; including OTT in the NTCP model for patients receiving treatment with a shorter 
OTT is likely to improve model performance for these cohorts as reported by 
Dehing-Oberije et al. 3.
 Despite our aim to thoroughly validate the established NTCP model for Grade ≥2 AET 
by assessing the transportability of the model using multiple different patient cohorts, 
some potential limitations should be noted. Firstly, the data of most cohorts were retrieved 
retrospectively (except cohort D and E). Retrospective collection is well known to possibly 
introduce unwanted biases and this may have affected the reliability of AET scoring 
(although in this study the retrospectively scored cohorts appear to outperform the 
prospectively scored cohorts). Furthermore, for some patients of the validation cohorts 
the necessary NTCP model predictor values could not be retrieved resulting in exclusion 
of these patients from the validation cohort. Straightforward mean/mode imputation to 
increase dataset size of this missing data in the validation cohorts did not improve model 
performance (data not shown). The number of patients of the separate cohorts may be 
considered low for model validation, however, the total number of patients (n=603) 
included in the validation cohorts is substantial. For future work, by making data smarter 
and more easily accessible, e.g., by adhering to the FAIR data principles (data has to be 
Findable, Accessible, Interoperable, and Reusable 44), training and validation of models 
can be performed on much larger cohorts of patients that were not treated in any specific 
study protocol 45.
 In conclusion, the established NTCP model for the prediction of Grade ≥2 AET in 
patients treated for locally advanced NSCLC was successfully validated in 3 out of 5 patient 
cohorts. Model performance was poor for 2 out 5 cohorts of patients, and did not improve 
after recalibration. Before implementing the NTCP model in clinical practice, it is advised 
to check model discrimination and calibration performance and optionally perform a 
local recalibration of the model to improve the correspondence between predicted 
probabilities and observed frequencies of AET. In case of large differences in treatment 
with respect to the training cohort, additional predictors may become relevant and 
complete remodelling may be necessary.
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Figure S1 |   Calibration plots of the NTCP model applied on all cohorts.
Calibration plots of the NTCP model applied on all patient cohorts without recalibration (calibration-
in-the-large and calibration slope are given but not applied). The triangles indicate grouped 
predicted probabilities of Grade ≥2 AET vs grouped observed frequencies. Vertical Lines represent 
95% confidence intervals. A loess smoother is fitted and displayed by the black line. Perfect 
predictions should be close to the dashed 45° reference line. Double histograms of patients with 
and without Grade ≥2 AET, binned according to their predicted probabilities, are displayed at the 
bottom.
Abbreviations: NTCP = normal-tissue complication probability; AUC = area under the curve; 
AET = acute esophageal toxicity.
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General discussion and future perspectives
The past two decades, the leap of technology provided new options for treatment 
optimization for advanced stage NSCLC patients. The introduction of positron emission 
tomography (PET) enabled characterization of the micro-environment of the tumor. 
This, combined with the technological advances in radiotherapy delivery (i.e., more 
conformal radiation dose delivery), facilitated more individualized treatment of advanced 
stage NSCLC patients. This thesis discusses PET guidance in radiotherapy and the effect 
of new radiotherapy delivery techniques on toxicity (prediction). 
Functional imaging based radiotherapy
As reviewed in chapter 2, treatment resistant tumor subvolumes can be visualized with 
PET 1. Radiotherapy dose escalation directed to these specific subvolumes may improve 
local control, however, breathing motion artefacts causes blurring of the image which 
hampers PET guided target volume delineation. To reduce blurring of the image, several 
respiratory gated PET techniques have been developed 2,3. Gated PET-based tumor 
delineation for radiotherapy in NSCLC patients has been studied 4,5, however, the actual 
impact on radiation dose to the organs at risk was not subject of study. In Chapter 3 we 
described the use of amplitude-based optimally respiratory gated PET imaging compared 
with conventional non-gated PET imaging in radiotherapy planning with respect to the 
radiation dose delivered to healthy tissues. Although the target volumes based on the 
gated PET scans were smaller as compared to the non-gated PET scans, this did not result 
in a clinically relevant dose reduction for the organs at risk 6. Apparently, the reduction in 
target volume is insufficient to achieve a clinical relevant decrease in dose to the healthy 
tissues. Nonetheless, gated PET reduces inaccuracies regarding tumor volume quantification 
(less blurring of the image) and radiotracer uptake (higher standardized uptake values). 
Therefore, the image acquired with gated PET imaging may still be of use in defining 
subvolumes within the target volume that harbour more treatment resistant tumor cells as 
the true tumor volume and tracer uptake can be more accurately assed with gated PET 7,8.
 High local tumor control is achieved with the use of stereotactic body radiation 
therapy (SBRT) for limited stage NSCLC 9. SBRT is characterized by high dose-to-target 
conformality that enables safe prescription of high fraction doses. In turn, these high 
fraction doses result in the high biologically effective doses (BED ≥100 Gy) that are needed 
to achieve tumor control 10. Local tumor control in advanced stage NSCLC patients needs 
improvement, however, dose escalation strategies that only moderately increases 
radiation dose for the whole target volume have shown disappointing results 11. Therefore, 
Chapter 4 describes an approach to apply PET for the delineation of the more treatment 
resistant subvolumes of the tumor towards which an SBRT boost can be directed that 
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limits the increase in radiation dose for the OARs. For the majority of patients included in 
the planning study described in Chapter 4, it was feasible to escalate the dose substantially 
for the subvolumes harbouring high tracer uptake without exceeding the dose constraints 
for the organs at risk; the median dose covering 95% of the boost planning target volume 
was 18.4 Gy (range 5.9 - 32.3), in total this allowed a median BED of 101.7 Gy (range 79.1 - 
139.1), compared to a BED of 79.2 Gy obtained with the standard radiotherapy schedule 
(66 Gy in 2 Gy fractions). The delivery of higher radiotherapy doses solely to treatment 
resistant subvolumes may overcome the issues recently reported on radiotherapy dose 
escalation in advanced stage NSCLC patients 12. For example, the RTOG 0617 trial showed 
that dose escalation up to 74 Gy for the entire target volume resulted in a lower overall 
survival compared with the standard radiotherapy dose of 60 Gy in the control arm 11. 
This may be the result of an increase in overall treatment time in the high dose arm, 
the creation of smaller target volumes in order to meet the dose constraints and/or 
increased incidental radiation dose to the heart. Besides this, a few other factors may have 
compromised outcome. Firstly, the dose was escalated for the entire tumor, not for the 
more radioresistant subvolumes only. These relatively large target volumes hamper 
sufficient dose escalation due to radiation dose to the organs at risk. Secondly, compliance 
with normal dose constraints was not mandatory in this trial, which may have exposed 
the healthy tissues (the heart in particular) of these patients to radiotherapy doses that 
exceeded the usually applied dose constraints. Thirdly, older radiotherapy techniques 
were allowed that may have unnecessarily increased radiation exposure to the healthy 
tissues. Concerning the latter, it was indeed concluded from a secondary analysis of the 
RTOG 0617 study that the patients treated with intensity-modulated radiation therapy 
(IMRT) experienced less Grade ≥3 radiation pneumonitis and received lower heart doses 
compared to the group of patients that were treated with 3-dimensional conformal 
radiotherapy (3D-CRT) 13.
 The approach described in chapter 4 of this thesis overcomes the abovementioned 
issues by using PET for depicting the more treatment resistant subvolumes of the tumor 
considered for boosting. By directing the boost dose only to the subvolumes that will not be 
eradicated by the standard radiotherapy dose, the boost volume is reduced allowing for 
substantial dose escalation that is needed for a true increase in tumor control. Furthermore, 
the boost dose was delivered using highly conformal stereotactic body radiotherapy 
techniques and strict dose constraints were applied for the organs at risk. Efforts should 
be made to conduct clinical trials to evaluate this approach with respect to outcome and 
safety 14. Currently there is a multicenter study in preparation that will assess outcome and 
toxicity of a stereotactic boost directed to subvolumes of the tumor that persist in 
metabolic activity as depicted on the PET scan acquired in the second week of (concurrent) 
chemoradiation.  
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Radiotherapy induced toxicity: IMRT and VMAT
In recent years, conformal radiotherapy techniques such as IMRT and volumetric-modulated 
arc therapy (VMAT) have been widely introduced in clinical practice. Compared to 3D-CRT, 
both IMRT and VMAT have the ability to modulate the beam intensity during radiotherapy 
delivery, leading to superior dose to target conformality (Figure 1) 15-17. The IMRT technique 
delivers its dose by a ‘step-and-shoot’ movement of the gantry, whereas the VMAT technique 
delivers its dose continuously during gantry rotation. Compared to IMRT, the continuous 
delivery of radiotherapy with VMAT offers two advantages: the dose distributions are more 
conformal and treatment times are shorter. Due to the more conformal dose deposition of 
IMRT and VMAT, the volume of healthy tissues outside the target volume receiving high 
doses is lower. However, the low-dose deposition in the surrounding tissues (the so called 
‘low-dose bath’) may be increased (which is more pronounced for VMAT) 18-20. Differences in 
dose-volume histogram (DVH) parameters and reported toxicity between patients treated 
with IMRT and VMAT for advanced stage NSCLC are described in chapter 5 of this thesis 21. 
Overall survival did not differ between the IMRT and VMAT treated patients. The group of 
patients treated with a VMAT technique showed a statistically significant increase in Grade 
≥2 acute esophageal toxicity (AET). The relative volume of the esophagus receiving at least 
50 Gy, an DVH parameter that has been reported to be predictive for AET 22, was significantly 
higher in the group of patients that underwent VMAT. Not only the increase of incidental 
dose to the esophagus may explain the higher incidence of Grade ≥2 AET. The patients 
that underwent radiotherapy using a VMAT technique more often received concurrent 
chemotherapy in stead of sequential treatment. Therefore, the radiosensitizing effect of 
chemotherapy may in part explain this increase in AET. Regarding radiation induced 
pneumonitis, the incidence nearly doubled in the patients treated with VMAT. It is known 
that the low-dose bath for the lungs is of clinical relevance as the relative volume of the lung 
receiving ≥5 Gy has been reported to be predictive for radiation pneumonitis 20. Surprisingly, 
in our study the low-dose bath was less pronounced after VMAT for the relative volume of 
the lung receiving ≥5 Gy was significantly lower compared to the IMRT group. The increase 
of both AET and pneumonitis after VMAT may be due to the differences in dose distributions 
between IMRT and VMAT, however, patient selection may also have played a role. Notwith-
standing that age and performance scores did not significantly differ between the patients 
receiving IMRT or VMAT, differences in patient characteristics may still exist. While doctors 
have gained more experience with concurrent chemoradiation for the treatment of 
advanced stage NSCLC patients, the fear of inducing severe toxicity may have been reduced. 
As a consequence, patients previously supposed to be ineligible for concurrent treatment 
may now be considered suitable for concurrent chemoradiation using VMAT. This nicely 
illustrates the need for continuous evaluation of clinical practice because newly introduced 
treatment modalities or modifications of established treatments may result in similar 
outcomes at the cost of increased toxicity. 
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Figure 1 |   Dose distributions obtained with a 3-dimensional conformal radiotherapy 
technique (upper panel), an intensity-modulated radiotherapy technique 
(middle panel) and a volumetric-modulated arc technique (lower panel).  
By courtesy of Peter van Kollenburg.
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Incidental radiation dose to the heart: predictive  
for radiation pneumonitis?
Animal studies have shown that irradiation of both the heart and lungs may have a 
synergistic effect on developing radiation pneumonitis 23,24. Despite this, the clinical 
studies reported on incidental heart dose and its association with radiation pneumonitis 
in NSCLC patients show contradicting results 25,26. In these studies, the heart has been 
considered as a whole solid organ. This may be too simplistic as the physiology of the 
cardio-pulmonary system is complex. For example, radiation dose to the left ventricle may 
result in different physiological changes as does radiation dose to the right atrium 23. 
The high conformality of the IMRT and VMAT techniques will often not distribute incidental 
radiation dose to the whole heart, instead it will probably only affect some of its specific 
functional subunits (i.e., atria and ventricles). Thus, if only whole heart exposure is taken 
into account, thereby neglecting exposure of the functional subunits of the heart, valuable 
predictive information may be lost. For this reason, we evaluated (Chapter 6) whether the 
DVH parameters of the lung together with those of the ventricles and atria of the heart 
were of value in predicting severe radiation pneumonitis. Contrary to the heart DVH 
parameters that were never included in the optimal prediction model, the mean lung 
dose appeared to be the best DVH parameter for the prediction of severe radiation 
pneumonitis. Besides the drawbacks that should be noted regarding retrospective 
studies, another issue in this study is the low number of events. With only 26 events in this 
study, the power to detect a relevant contribution of heart dose in radiation pneumonitis 
may be too low. To overcome this issue, databases that constitute of large numbers of 
patients are mandatory to draw final conclusions.
Prediction of acute esophageal toxicity
The past decades, the ‘one size fits all’ approach in oncology has been replaced for more 
individualized care. In radiation oncology, the introduction of PET enabled the selection 
of patients that harbour treatment resistant tumors that may benefit from dose escalation 
as handled in Chapter 4. The introduction of IMRT and VMAT radiotherapy techniques 
facilitated this dose escalation, however, treatment related toxicity is still an issue since 
treatment of side effects is either only symptomatic or not possible at all. Well performing 
multivariable NTCP models are important as they may guide doctors to decide whether or 
not treatment intensification such as radiotherapy dose escalation is feasible for a specific 
patient. Furthermore, in case there is an increased risk of moderate to severe toxicity, NTCP 
models can select patients that benefit most from other (more conformal) radiotherapy 
techniques such as proton therapy 27,28. In this light, the use of NTCP models also 
contributes to customizing cancer treatment.
521543-L-sub01-bw-Wijsman
Processed on: 20-7-2018 PDF page: 180
180
CHAPTER 10
Concerning the esophagus, several different clinical and DVH parameters are frequently 
used to estimate the risk of toxicity and guide in radiotherapy planning 29,30. Most studies 
on AET prediction are based on patients treated with 3D-CRT 31-36, while the majority of 
patients with advanced stage NSCLC is being treated with IMRT or VMAT these days. As 
aforementioned, IMRT and VMAT have their own characteristic dose deposition. It is 
therefore questionable if the predictive DVH parameters derived from patients treated 
with 3D-CRT are valid in patients treated with IMRT or VMAT. This is supported by a study 
in head and neck cancer patients which showed that the normal tissue complication 
probability (NTCP) model for xerostomia based on 3D-CRT data was less valid for patients 
treated with IMRT 37. Another issue with the use of DVH data for NTCP modelling is that 
spatial dosimetric information is lost. Incorporating spatial dose information in predictive 
modelling of AET may result in more accurate NTCP models. For these reasons, we 
developed a multivariable NTCP model for AET in advanced stage NSCLC patients treated 
with IMRT or VMAT with and without the incorporation of spatial dose information in the 
NTCP model.
 Despite the fact that the true predictive model does not exist (‘all models are 
wrong, …….’) 38,39, predictive models can still be useful for individualizing treatment. 
Issues such as overfitting of the data, multicollinearity and reproducibility have to be taken 
into account to develop a robust (and thus useful) NTCP model (‘...... but some are useful’) 
38,40. Sophisticated parameter selection techniques are available to generate robust NTCP 
models 41. In chapter 8 such an approach was investigated which resulted in an NTCP 
model for AET that showed good discrimination between patients with Grade ≤1 AET and 
Grade ≥2 AET (area under the curve (AUC) of 0.82 after correction for optimism) 42. 
Although this internally cross-validated NTCP model performed well, performance of the 
model in other patient populations can still be poor and thus this needs to be assessed 
(i.e., external validation of the model) 43. For this purpose, we used several different cohorts 
of patients from four different radiation oncology departments. The majority of patients 
had advanced stage NSCLC and were treated with (chemo-) radiation (Chapter 9). For three 
out of the five validation cohorts of patients treated at another department than the 
department of the training cohort, the NTCP model for AET discriminated well (AUCs 0.81, 
0.84 and 0.89). The calibration of the NTCP model on these three cohorts was moderate, 
which was expected, because perfect calibration of an established model on an external 
cohort of patients is considered impossible 44. Therefore, applying an established NTCP 
model on a different patient cohort often warrants some form of updating to adjust the 
model to local circumstances (i.e., recalibration) 45,46. After recalibration, the agreement 
between predicted outcome and observed outcome improved substantially for the 
aforementioned three cohorts. For the two other validation cohorts the NTCP model 
showed, besides poor discrimination, also poor calibration that did not improve after 
recalibration. This is most probably due to heterogeneity of the cohorts; the patients in 
these cohorts received substantially different treatments compared to the patients from 
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the cohort the NTCP model was developed on. For instance, radiotherapy dose and 
fractionation differed substantially. This resulted in a shorter overall treatment time, a 
factor that has been associated with increased AET, but since all patients in the training 
cohort were treated with similar overall treatment times this was not a parameter included 
in the resulting model 29,31. Cohort heterogeneity is one of the main causes for replication 
failure of prediction models across cohorts 43, which nicely illustrates that the true model 
does not exist and that recalibration of a predictive model is often necessary to generate 
valid predictions in cohorts other than the cohort the model was developed on.
 Assessment of the esophageal spatial dose distribution was described in Chapter 7 of 
this thesis. We created esophageal wall dose-surface maps (DSMs) to evaluate the benefit 
of adding spatial dose information to an existing NTCP model for AET 47. This approach of 
creating DSMs for toxicity prediction has been shown useful in prostate cancer patients 
for the NTCP model performance improved by adding spatial dose information 48. 
However, the addition of spatio-dosimetric information to the established NTCP model for 
AET did not improve the prediction. Apparently, the spatial information provided by the 
esophageal DSMs is of no added value over the regular DVH parameter that lacks spatial 
dose information. This may be due to the fact that, contrary to rectal wall DSMs, the 
esophageal DSMs show much more heterogeneity because of the small and elongated 
anatomy of the esophagus that borders tumors of greatly varying volumes and locations. 
The specific combination of this esophageal geometry and the dose distributions resulted 
in DSM derived dose histograms that are similar to the DVH (that contains no spatial 
information) from the original NTCP model. Hence, for this population the spatial 
information provided by the DSMs did not add to the predictive performance of the NTCP 
model for AET. 
Future perspectives
Several approaches have been studied to improve the outcome in advanced stage NSCLC 
patients. The balance between gain in outcome and an increase in toxicity in this group of 
patients is fragile. For instance, intensified treatments in the form of concurrent 
chemoradiation (compared to sequential treatment) and radiotherapy dose escalation are 
known to increase toxicity 49. The key questions are: 1) which patient will benefit from 
treatment intensification? And 2) if treatment intensification is indicated, to what extend is 
the intensified treatment bearable for the patient? The information provided by PET is 
valuable as it characterizes the functional status of the tumor and its microenvironment. If 
features associated with worse outcome are visualized, for example increased metabolism 
and/or hypoxia, modern radiotherapy techniques enable the direction of increased 
radiation doses to these areas to attempt to improve local control. Using this approach, 
unnecessary increase in toxicity is prevented for patients that are not likely to benefit from 
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treatment intensification (because tumor characteristics associated with worse outcome 
are lacking). The answer to the second question may be found in NTCP modelling. A 
variety of 3D-CRT based NTCP models for AET and lung toxicity are available, however, it 
is questionable if these models perform well on patients treated with more conformal 
radiotherapy techniques such as IMRT and VMAT. Moreover, concurrent chemoradiation 
has become standard practice and is not only reserved anymore for patients in excellent 
clinical condition. Due to these treatment adaptations, newly developed NTCP models are 
warranted that incorporate these possible predictors in the model. 
 The scoring of toxicity is often a weak link in modelling of toxicity as interpretation 
can be difficult and shows high inter-observer variability 50,51. Despite the fact that the 
data for the novel developed multivariable NTCP model for AET reported in this thesis 
have been retrieved retrospectively, the model was robust and performed well after 
external validation on cohorts of patients receiving similar treatment. The model probably 
performed well due to the fact that sophisticated statistical procedures were applied to 
minimize for example overfitting of the data. For future NTCP modelling, it is of paramount 
importance that the data are of high quality and that the statistical procedures executed 
are sound 52. A comprehensive programme for the prospective collection of patient, 
treatment and outcome data supporting the collection of high quality data, has already 
been developed 53. Departments can implement such a program to collect treatment 
data that allows the clinician to evaluate treatment outcome variables such as survival and 
toxicity. Furthermore, it enables the exchange of good quality research data between 
institutions. Such a data pooling approach would greatly improve research concerning 
NTCP modelling because the ample number of patients in these combined cohorts 
overcome the often faced statistical problems such as low number of events and the 
absence of a validation cohort 54,55. Despite the challenges (ethical, technical, administrative 
and legal) when it comes to exchanging data for NTCP modelling, the distributed learning 
approach showed to be feasible for the development of a predictive model for post- 
radiotherapy dyspnea without the data leaving the five participating hospitals 56. At this 
moment, an advanced computer network is being developed that supports this data 
exchange between hospitals 57. In the near future, these technical advances in data 
capturing and data sharing will be readily available and will probably take NTCP modelling 
to a higher level. 
 Collaboration between departments of radiation oncology, nuclear medicine and 
biostatistics is key in improving the individualization of radiotherapy for NSCLC patients. 
The sharing of data and knowledge is of paramount importance; physicians, modellers 
and researchers have to work in close collaboration to generate robust NTCP models that 
can adequately guide in radiotherapy dose escalation research and clinical practice. 
Further improvement will be found in the characterisation of the biology of the tumor 
and its microenvironment. Besides visualizing the microenvironment of the tumor using 
PET, the tumor biology and its intricate web of pathways needs further understanding. 
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Once the abovementioned conditions are met, we are one step closer to true treatment 
individualization for NSCLC patients.  
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Summary
Patients diagnosed with advanced stage non-small cell lung cancer (NSCLC) face a 
cumbersome prognosis. Aggressive treatment is warranted, however, treatment induced 
toxicity often hampers further treatment intensification. Modern imaging techniques 
such as positron emission tomography (PET) may help in the improvement of treatment 
outcome as the biology of the tumor and its microenvironment can be visualized. In case 
tumor (sub)volumes harbour characteristics that are associated with increased treatment 
resistance (e.g., hypoxia and/or increased metabolism), modern highly conformal radio- 
therapy techniques like intensity-modulated radiation therapy (IMRT) and volumetric- 
modulated arc therapy (VMAT) enables radiotherapy dose escalation directed to these 
specific parts of the tumor with only a limited increase in toxicity. These modern 
radiotherapy techniques have different dose distribution characteristics compared to the 
older radiotherapy techniques (i.e., 3-dimensional conformal radiotherapy, 3D-CRT). 
Therefore, the available 3D-CRT based normal-tissue complication probability (NTCP) 
models need revision before these NTCP models may be useful in toxicity prediction in 
patients treated with either IMRT or VMAT. In this thesis the results of studies evaluating 
toxicity (prediction) for advanced staged NSCLC patients and the use of PET for radio- 
therapy planning are described.  
PET for radiotherapy purposes
Molecular imaging using PET for the individualisation of treatment is discussed in Chapter 2. 
The emphasis is on tumor metabolism and tumor hypoxia, because these two biological 
characteristics of the tumor are related to treatment outcome. For example, increased 
metabolic rate reflects increased proliferation and glycolysis indicating increased 
treatment resistance. PET provides this information and thus may be useful in the individ-
ualization of treatment. For instance, in case PET reveals a high level of metabolism within 
a tumor, the radiotherapy dose for this subvolume of the tumor can be escalated to 
improve tumor control. 
One drawback of PET-based tumor delineation for radiotherapy purposes is that breathing 
motion artefacts result in blurred images. Nowadays, this blurring can be reduced by 
using respiratory gated PET. The radiotherapy planning study described in Chapter 3 
evaluated tumor delineation in 21 patients with NSCLC using both optimally respiratory 
gated and non-gated fluorodeoxyglucose-PET (FDG-PET). The radiotherapy target 
volumes were determined for both the gated and the non-gated PET scans. Afterwards, 
radiotherapy plans were created to evaluate the radiation doses to the organs at risk (OAR). 
The median volumes of the gated target volumes were statistically significantly smaller 
compared to the corresponding non-gated target volumes. Nonetheless, this reduction 
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in target volume for the gated scans did not result in a clinically relevant reduction of dose 
to the OAR. 
 A PET-based dose escalation approach was evaluated in the planning study described 
in Chapter 4. In this study, stereotactic body radiation therapy (SBRT) was applied (using 
an VMAT technique) for FDG-PET guided dose escalation to improve local control in ten 
advanced stage NSCLC patients that received 60 Gy chemoradiation. These patients 
underwent a pre-treatment FDG-PET scan and an early response monitoring (ERM) 
FDG-PET scan during treatment. The subvolumes within the tumor harboring the highest 
FDG uptake were determined on both PET scans. Afterwards, radiotherapy plans were 
generated with escalated radiotherapy doses directed to these subvolumes within the 
tumor till the OAR constraints were met. In five patients the volume of the planning target 
volume (PTV) based on the ERM PET was 9-40% smaller compared to the volume of the 
PTV based on the pre-treatment PET. This decline in PTV volume resulted in a decrease of 
overlap of the PTV with the OAR, however, overlap with the OAR remained in four out of 
five patients. The median boost volume receiving a physical dose of ≥18 Gy was 87.5% 
(range 50.6-100). The results of this planning study demonstrate that, while meeting the 
strict dose constraints for the OAR, a clinically significant stereotactic boost can be 
delivered after 60 Gy chemoradiation, resulting in a summed equivalent uniform dose in 
2 Gy fractions (EQD2) of ≥84 Gy directed to subvolumes of the tumor that harbor increased 
metabolic activity. 
Radiotherapy for advanced stage NSCLC: IMRT vs VMAT
Compared to 3D-CRT, IMRT and VMAT both have more conformal dose distributions at the 
cost of increased low-dose deposition in the surrounding tissues (the ‘low-dose bath’). 
The VMAT technique is the most conformal technique due to the continuous radiotherapy 
delivery while the gantry is rotating. For IMRT, for example 5 or 7 beams angles are chosen 
for radiotherapy delivery. These differences in technique result in dissimilar dose 
distributions. Consequently, radiation induced toxicity may differ between the IMRT and 
VMAT techniques. Chapter 5 describes treatment induced toxicity of IMRT and VMAT 
in 188 advanced stage NSCLC patients receiving 66 Gy (chemo-) radiotherapy. Acute and 
late esophageal plus pulmonary toxicity were scored. Patient, tumor and treatment 
 characteristics together with the dose-volume histogram (DVH) parameters for the 
esophagus and lungs were evaluated for their association with toxicity. 
 Some imbalances between the IMRT and VMAT cohorts were observed: fewer 
patients in the IMRT cohort received concurrent chemoradiation (CCR) compared to the 
patients in the VMAT cohort. Furthermore, the relative volume of the lung receiving ≥5 Gy 
was significantly lower and the relative volume of the esophagus receiving ≥50 Gy was 
significantly higher with VMAT. After a median follow-up of 18.4 months, the median 
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overall survival and progression free survival were 20.2 months and 11.5 months, 
respectively, without a significant difference between the IMRT and VMAT cohorts. 
Compared to IMRT, increased Grade 2 and Grade 3 AET were observed after VMAT. 
Differences in acute pulmonary toxicity between IMRT and VMAT could not be observed. 
Likewise, Grade ≥3 late pulmonary toxicity (i.e., radiation pneumonitis, RP) and Grade ≥3 
late esophageal toxicity did not significantly differ. On multivariate logistic regression 
analysis, Grade ≥2 AET statistically significantly increased in females, in those treated with 
VMAT, when patients received concurrent chemoradiation (CCR) and with increased mean 
esophageal dose. The toxicity profile of VMAT differs from that of IMRT regarding AET and 
RP. For AET this is partially explained by the number of patients receiving CCR, however, 
VMAT itself also contributed to the increase of AET, since VMAT remained significantly 
associated with AET on multivariable analysis. The incidence of RP nearly doubled in the 
VMAT cohort; this finding is interesting in the light of the complex pathophysiology of RP. 
Is there a role for the combined exposure of the lungs and the heart in the development 
of RP? This was evaluated as described in Chapter 6 (next section).
Does incidental heart dose matter for the prediction  
of radiation pneumonitis?
Chapter 6 describes whether or not the inclusion of incidental radiation dose the atria 
and ventricles of the heart improves the prediction of Grade ≥3 RP in advanced stage 
NSCLC patients that have been treated with IMRT or VMAT. Patient, tumor and treatment 
characteristics, together with the DVH parameters of both the lungs and the heart 
(assessing the atria and ventricles separately and combined), were included in the 
bootstrap modeling procedure. Twenty-six patients (13.8%) out of the 188 patients 
included in this analysis developed Grade ≥3 RP after a median follow-up of 18.4 months. 
The median mean lung dose (MLD) was significantly higher for the patients experiencing 
Grade ≥3 RP compared to those who did not (15.3 Gy vs 13.7 Gy , respectively). In general, 
the lung parameters were stronger correlated with Grade ≥3 RP than did any of the heart 
DVH parameters. From all the DVH parameters (of the lungs and the atria and ventricles of 
the heart) included, the MLD displayed the highest Spearman correlation coefficient for 
Grade ≥3 RP. The modeling procedure showed that the MLD was always included in the 
predictive model for Grade ≥3 RP, whereas the heart DVH parameters were seldomly 
included in the model. In other words, incidental dose to the cardiac atria and ventricles 
did not improve the prediction of Grade ≥3 RP in this cohort of patients. It should be 
noted, however, that the low number of events may have been insufficient to reveal a true 
effect of heart exposure on the development of Grade ≥3 RP.
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IMRT/VMAT and the need for new NTCP models
Radiotherapy with IMRT or VMAT enables ‘sculpting’ of the radiation dose around the 
target volume. Therefore, information upon the esophageal spatial dose distribution 
may be of importance in AET prediction. We evaluated this as described in Chapter 7 of 
this thesis. Dosemaps reflecting the esophageal spatial dose distribution were generated 
for 149 advanced stage NSCLC patients treated with IMRT or VMAT. It was investigated 
whether the incorporation of spatial dose data of the esophagus improves the predictive 
power of our previously established NTCP model for AET. The new models incorporating 
esophageal spatial dose data did not show improved predictive performance over the 
established multivariable NTCP model for AET that lacks spatial dose information. From 
these findings, it was concluded that it is sufficient to incorporate dose data not containing 
spatial dose information in the multivariable NTCP model for Grade ≥2 AET as described 
in Chapter 8. This multivariable NTCP model was developed using dedicated software for 
modeling of radiotherapy data using sophisticated bootstrapping techniques. The final 
multivariable NTCP model predicted an increased risk of Grade ≥2 AET in case of: 
concurrent chemoradiotherapy, increasing mean esophageal dose, female patients, and 
≥cT3 tumors. This model has been internally validated and the area under the receiver 
operator curve was 0.82 (after correction for optimism), indicating good discriminative 
ability of the model. Nonetheless, external validation is needed to assess how well the 
model performs on external cohorts of patients. Chapter 9 describes the external validation 
of the NTCP model that predicts Grade ≥2 AET. Five cohorts from four different radiation 
oncology departments were available for the external validation procedure. The cohorts 
differed substantially regarding the incidence of AET and whether or not patients received 
CCR. The model showed good discriminative ability for three out of the five patient 
cohorts. After recalibration, the model also calibrated well on these three cohorts. Both 
the discriminative ability of the model and model calibration were poor for the remaining 
two cohorts. These findings illustrate the importance of external validation of a prediction 
model before clinical use; despite a model is well internally validated, the predictions in an 
independent cohort of patients may not be accurate.
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Nederlandse samenvatting
Patiënten met loco-regionaal gevorderd stadium niet-kleincellig bronchuscarcinoom 
hebben doorgaans een sombere prognose. Intensieve behandeling van de tumor is nodig om 
de ziekte onder controle te krijgen, echter de toxiciteit geïnduceerd door deze behandeling 
beperkt vaak verdere intensivering van de behandeling. Moderne beeldvormende technieken 
zoals positron emissie tomografie (PET) zouden kunnen bijdragen aan de verbetering van 
de uitkomsten van het gevorderd stadium niet-kleincellig bronchuscarcinoom; met behulp 
van deze techniek kan namelijk de biologie van de tumor en het bijbehorende micromilieu 
in kaart gebracht worden. Indien een tumor ongunstige biologische kenmerken heeft 
(bijvoorbeeld hypoxie en/of toegenomen tumormetabolisme), dan kan met behulp van 
moderne bestralingstechnieken zoals intensiteit-gemoduleerde radiotherapie (IMRT) en 
‘volumetric-modulated arc therapy’ (afgekort VMAT; een vorm van IMRT waarbij de lineaire 
versneller tijdens het veranderen van de bundelhoeken de straling afgeeft) extra 
bestralings dosis gegeven worden op het deel van de tumor waar de resistente cellen zich 
bevinden.
 In vergelijking met de oudere 3-dimensionele conformele radiotherapietechnieken 
(3D-CRT) hebben IMRT en VMAT hun eigen karakteristieke dosisverdeling in de patiënt. 
De beschikbare modellen voor het voorspellen van toxiciteit zijn veelal gebaseerd op 
3D-CRT technieken. Deze modellen zullen dus herzien moeten worden alvorens ze 
gebruikt kunnen worden voor het voorspellen van bijwerkingen bij patiënten die 
behandeld worden met IMRT of VMAT. 
 Dit proefschrift behandelt de toepassing van PET voor radiotherapie doeleinden. 
Tevens worden de bijwerkingen na IMRT of VMAT voor het gevorderd stadium bronchus-
carcinoom in kaart gebracht en wordt er dieper ingegaan op het voorspellen van deze 
bijwerkingen.
Het gebruik van PET in de radiotherapie
Het gebruik van PET ten behoeve van de individualisatie van oncologische behandelingen 
wordt besproken in hoofdstuk 2. In dit hoofdstuk ligt de nadruk op het in beeld brengen 
van biologische kenmerken van de tumor die gerelateerd zijn aan (slechtere) uitkomsten 
van oncologische behandelingen. Toegenomen metabole activiteit weerspiegelt 
bijvoorbeeld toegenomen proliferatie (en glycolyse) die kan wijzen op toegenomen-
behandelresistentie. Indien deze tumorspecifieke informatie beschikbaar is kan het 
behandelplan van de patiënt hierop aangepast worden. Een voorbeeld: indien de PET 
scan een hoge mate van metabole activiteit laat zien in delen van de tumor, dan kan de 
radiotherapie dosis voor dit deel van de tumor verhoogd worden met als doel de tumor 
controle te verbeteren. 
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Een nadeel van het gebruik van PET in de radiotherapie voor longtumoren is dat er bij het 
vervaardigen van PET beelden artefacten ontstaan door het ademen van de patiënt. Door 
de ademhaling beweegt de tumor, wat er voor zorgt dat de tumor dikwijls niet scherp 
afgrensbaar is op de vervaardigde scan. De uiteindelijke afbeelding van de tumor is 
daardoor enigszins uitgesmeerd, wat een onscherpe afbeelding van de tumor oplevert. 
Thans zijn er moderne PET technieken beschikbaar (bekend als ‘gated’ PET; gPET) die het 
mogelijk maken om PET afbeeldingen te reconstrueren die minder (tumor) beweging 
vertonen. De toepassing van een gPET techniek voor het plannen van radiotherapie 
wordt beschreven in Hoofdstuk 3. Dit hoofdstuk beschrijft een studie waarbij voor 
21 patiënten een radiotherapieplan werd berekend: eenmaal voor het doelvolume 
gebaseerd op de reguliere (niet ‘gated’) PET techniek en eenmaal voor het doelvolume 
gebaseerd op een gPET techniek. Vervolgens werden de verschillen in grootte van de 
doelvolumina berekend en werd er ook geanalyseerd of de radiotherapieplannen 
gebaseerd op de gPET resulteerde in een lagere dosis voor de gezonde omringende 
weefsels. Ondanks dat de mediane tumor volumes op basis van de gPET kleiner bleken, 
was er geen klinisch relevant verschil in de dosis voor de gezonde weefsels rondom de 
tumor. 
 In Hoofdstuk 4 wordt een radiotherapie planningsstudie beschreven die evalueert of 
het mogelijk is om op basis van PET een hogere radiotherapie dosis (radiotherapie ‘boost’) 
te geven voor die volumes van de tumor die ongunstige metabole kenmerken tonen. 
Voor deze planningsstudie werden de PET scans gebruikt zoals vervaardigd in een groep 
patiënten met longkanker die reeds chemoradiotherapie hadden ondergaan in een andere 
klinische studie. Deze PET scans waren vervaardigd voor start van de chemoradiotherapie 
en nogmaals in de tweede week van de behandeling. De subvolumes van de tumor met 
de hoogste metabole activiteit werden geïdentificeerd op beide tijdstippen. Vervolgens 
werden radiotherapieplannen vervaardigd met een radiotherapie boostdosis (middels 
een stereotactische bestralingstechniek in 3 fracties) gericht op deze biologisch ongunstige 
volumina van de tumor. De hoogte van de boostdosis werd bepaald door de maximale 
tolerantiedosis van de omliggende gezonde weefsels. Voor vijf patiënten was het 
doelvolume in de tweede week van de chemoradiotherapie 9-40% kleiner in vergelijking 
met het doelvolume bepaald voor de start van chemoradiotherapie. Deze reductie van 
het doelvolume resulteerde in een afgenomen overlap van de doelvolumes met de 
gezonde omringende weefsels; voor vier van deze patiënten bleef er echter sprake van 
overlap. Het mediane boostvolume dat een fysische dosis van 18 Gy of hoger ontving 
was 87.5% (bereik 50.6-100). Uit deze radiotherapie planningsstudie kan geconcludeerd 
worden dat het mogelijk is om een klinisch significante stereotactische boost te geven als 
aanvulling op 60 Gy radiotherapie, zonder dat de tolerantiedosis van de gezonde weefsels 
overschreden wordt. In totaal kan derhalve een dosis van tenminste 84 Gy (equivalent 
uniforme dosis in 2 Gy fracties) gegeven worden voor de subvolumes van de tumor met 
persisterende metabole activiteit.
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Radiotherapie voor het gevorderd stadium NSCLC:  
IMRT vs VMAT
In vergelijking met 3D-CRT, hebben IMRT en VMAT beiden een dosisverdeling waarbij de 
voorgeschreven dosis het doelvolume nauwer omsluit (zogenoemde ‘conformele’ dosis- 
verdeling). Hier vloeit uit voort dat de lagere radiotherapiedosis meer wordt verspreid 
over de omliggende gezonde weefsels. De VMAT techniek is de meest conformele 
radiotherapietechniek doordat de lineaire versneller de straling afgeeft terwijl deze om 
de patiënt beweegt. Bij IMRT wordt er gekozen voor bijvoorbeeld 5 of 7 statische bundel- 
hoeken van waaruit de patiënt bestraald wordt. Deze verschillen in bestralingstechnieken 
resulteren in verschillen in dosisverdelingen in de patiënt. Hierdoor kan het zijn dat de 
radiotherapie geïnduceerde toxiciteit tussen de IMRT en VMAT technieken verschillend is. 
Hoofdstuk 5 beschrijft de radiotherapie gerelateerde toxiciteit van zowel IMRT als VMAT in 
een groep van 188 gevorderd stadium NSCLC patiënten die 66 Gy (chemo-)radiotherapie 
hebben ondergaan. De acute en late bijwerkingen van zowel de slokdarm alsook de 
longen werden geanalyseerd. Patiënt-, tumor- en behandelkarakteristieken tezamen met 
de dosis-volume parameters van de slokdarm en longen werden geëvalueerd voor hun 
verband met toxiciteit.
 De groepen patiënten behandeld middels IMRT of VMAT verschilden in sommige 
opzichten van elkaar: minder patiënten in de IMRT groep ontvingen concomitante chemo - 
radiotherapie (CCR) in vergelijking met de groep patiënten die VMAT had ondergaan. 
Tevens was het volume van de long dat ≥5 Gy ontving significant lager in de VMAT groep, 
terwijl het volume van de slokdarm dat ≥50 Gy ontving in deze groep juist significant 
hoger was in vergelijking met de IMRT groep. Na een mediane follow-up van 18.4 
maanden was de algehele overleving en de progressie vrije overleving respectievelijk 20.2 
en 11.5 maanden (beide niet significant verschillend tussen de IMRT en VMAT groepen). 
Vergeleken met IMRT werd er meer Graad 2 en Graad 3 acute slokdarm toxiciteit gezien in 
de groep patiënten die behandeld waren met VMAT. Zowel de acute en late longtoxiciteit 
alsook de late slokdarm toxiciteit verschilden niet significant tussen beide groepen. Op 
basis van multivariaat logistische regressie analyse bleek dat Graad ≥2 acute slokdarm 
toxiciteit statistisch significant verhoogd was bij vrouwen, bij patiënten behandeld met 
VMAT, in het geval patiënten CCR ondergingen en bij een hogere gemiddelde slokdarm 
dosis. Het toxiciteitsprofiel na VMAT verschilt dus van dat na IMRT als het gaat om acute 
slokdarm toxiciteit en radiatiepneumonitis. Voor acute slokdarm toxiciteit kan dit deels 
verklaard worden doordat er meer patiënten CCR hadden ondergaan in de VMAT groep, 
echter VMAT zelf lijkt ook bij te dragen aan meer acute slokdarm toxiciteit aangezien VMAT 
significant geassocieerd bleef met acute slokdarm toxiciteit bij multivariaat analyse. 
De incidentie van radiatiepneumonitis bleek bijna verdubbeld in de groep patiënten 
behandeld met VMAT (echter statistisch niet significant verschillend). Dit is een interessante 
bevinding met het oog op de complexe pathofysiologie van het ontstaan van radiatie-
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pneumonitis. Speelt zowel de stralingsbelasting van het hart alsook de longdosis een rol 
bij het ontwikkelen van radiatiepneumonitis? In Hoofdstuk 6 wordt deze vraag nader 
bekeken (volgende sectie). 
Is er een rol voor de stralingsbelasting van het hart bij 
het voorspellen van radiatiepneumonitis? 
In Hoofdstuk 6 wordt beschreven of de voorspelling van het ontstaan van Graad ≥3 
 radiatiepneumonitis (RP) verbeterd kan worden indien de stralingsbelasting van de atria 
en ventrikels van het hart  worden meegenomen in het predictiemodel. Voor 188 NSCLC 
patiënten met gevorderd stadium van de ziekte werden de patiënt-, tumor- en behandel-
karakteristieken alsook de dosis-volume parameters van het hart en de longen geanalyseerd. 
Met behulp van bootstrap technieken werd een model vervaardigd voor het voorspellen 
van RP. 26 patiënten (13.8%) in dit cohort ontwikkelde RP na een mediane follow-up van 
18.4 maanden. De mediane gemiddelde longdosis was significant hoger voor de groep 
patiënten gediagnosticeerd met RP vergeleken met de patiënten die deze bijwerking niet 
ontwikkelden (15.3 Gy vs 13.7 Gy). Het bleek dat de dosis-volume parameters van de long 
sterker correleerden met RP dan alle dosis-volume parameters van het hart; de gemiddelde 
longdosis was de parameter die de sterkste correlatie toonde met RP. Bij het ontwikkelen 
van het voorspellende model voor RP bleek dan ook dat de gemiddelde longdosis altijd 
onderdeel was van het model. De dosis-volume parameters van het hart waren, op een 
enkele keer na, nooit onderdeel van het model. Met andere woorden: toevoegen van de 
bestralings dosis voor het hart (en de atria en ventrikels) aan het model verbeterde de 
voorspelling van RP niet in dit cohort. Definitieve conclusies kunnen op basis van deze 
gegevens echter nog niet worden getrokken; het aantal patiënten dat een RP ontwikkelde 
is in dit cohort mogelijk onvoldoende  om een daadwerkelijk effect van dosis op het hart 
en de relatie met RP aan te tonen. 
IMRT/VMAT en de behoefte aan nieuwe NTCP modellen
Radiotherapie met IMRT of VMAT maakt het mogelijk om de bestralingsdosis nauwkeurig 
aan het doelvolume af te geven met zo min mogelijk stralingsbelasting (hoge dosis) voor 
de omliggende gezonde weefsels. Informatie met betrekking tot de ruimtelijke verdeling 
van de bestralingsdosis (de zogenoemde spatiële dosisdistributie) over de slokdarm 
kan mogelijk helpen bij het voorspellen van het al dan niet ontstaan van slikklachten 
gerelateerd aan de behandeling. Het toevoegen van deze spatiële dosisinformatie aan de 
modellen die voorspellen voor slikklachten wordt beschreven in Hoofdstuk 7. Voor 149 
patiënten met gevorderd stadium NSCLC werd de spatiële dosisdistributie gevisualiseerd 
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middels ‘dose-maps’ (dit is een grafische weergave van de spatiële verdeling van de dosis). 
Vervolgens werd er geanalyseerd of het toevoegen van deze spatiële informatie het 
voorspellend vermogen van ons eerder ontworpen predictiemodel voor slikklachten 
verbeterde. Dit bleek echter niet het geval. Blijkbaar is een model zoals gepresenteerd in 
Hoofdstuk 8 met alleen een dosisparameter zonder spatiële dosisinformatie afdoende 
voor het voorspellen van slikklachten voor deze groep patiënten. Het multivariabele 
model zoals beschreven in Hoofdstuk 8 werd ontwikkeld met behulp van speciaal voor dit 
doel ontwikkelde software die model selectie met bootstrapping technieken mogelijk 
maakt. Het ontwikkelde model voorspelt een hoger risico op Graad ≥2 acute slokdarm 
toxiciteit indien er sprake is van: concomitante behandeling met chemotherapie, bij een 
toenemende gemiddelde slokdarmdosis, bij vrouwen, en/of als er sprake is van een cT3 of 
cT4 tumor. Dit model is intern gevalideerd; de oppervlakte onder de curve die het 
discriminerend vermogen van het model aangeeft bedroeg (na correctie voor optimisme) 
0.82 (een waarde van 1.0 geeft aan dat het model perfect discrimineert, een waarde van 
0.5 geeft aan dat de voorspelling net zo nauwkeurig is als het opgooien van een munt). 
Ondanks het goede discriminerende vermogen van het model is externe validatie nodig 
om te beoordelen hoe het model presteert in cohorten patiënten anders dan het 
cohort waar het model op gebaseerd is. Hoofdstuk 9 van dit proefschrift beschrijft deze 
externe validatie van het bovengenoemde model. Hiervoor waren vijf cohorten van 
vier verschillende radiotherapieafdelingen beschikbaar. Deze cohorten verschilden 
substantieel in incidentie van Graad ≥2 acute slokdarm toxiciteit. Verder waren er onder 
andere verschillen in het gebruik van concomitante chemoradiatie. Het model discrimineerde 
goed in drie van de vijf cohorten. Na recalibratie van het model was ook de calibratie van 
het model op deze cohorten redelijk tot goed. Zowel het discriminerend vermogen 
alsook de calibratie voor de overige twee cohorten waren ondermaats. Deze bevindingen 
illustreren het belang van externe validatie voordat een predictie model in de kliniek 
toegepast kan worden; ook al presteert een model goed bij de interne validatie, het 
voorspellend vermogen kan in een onafhankelijk cohort patiënten slechter zijn. 
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Allereerst de patiënten. Zij leveren in een kwetsbare periode van het leven extra inspanning 
om wetenschappelijk onderzoek mogelijk te maken.
Prof. Bussink, beste Jan. Bedankt voor het vertrouwen en de vrijheid die jij mij hebt gegeven 
om de opleiding te combineren met onderzoek. Ik bewonder je nimmer aflatende 
enthousiasme (“nietje er door, klaar!”) en je kritische maar toch pragmatische aanpak.
Prof. Troost, beste Esther. Jij bent degene die mij geënthousiasmeerd heeft voor het 
onderzoek. Dank voor het aan mij toevertrouwen van de PET-gestuurde dosisescalatie 
studie. Van dat prachtig uitgestippelde plan moesten we helaas enigszins afwijken door 
de stagnerende inclusie. Desondanks bleef je positief en erg betrokken, wat voor mij 
een goede stimulans is geweest om andere paden te verkennen waarvan de resultaten in 
dit boekje te vinden zijn.
Prof. De Geus-Oei, beste Lioe-Fee. Dank voor je goede ideeën om de toepassing van PET 
scans voor de radiotherapie verder te onderzoeken. Een frisse blik vanuit een ander 
vakgebied komt het onderzoek ten goede. Evenzo geldt dit voor Dr. Van der Heijden, 
beste Erik. Dank voor je bijdragen aan dit proefschrift. 
Dr. Hoffmann, beste Aswin. Jij bent het voorbeeld waarom de radiotherapie niet zonder 
klinisch fysici kan. Je weet complexe technische problemen om te zetten naar begrijpelijke 
taal voor de dokter. Dit, in combinatie met een kritische blik, heeft zeker bijgedragen aan 
dit proefschrift. Dank daarvoor. 
De manuscriptcommissie: prof. Verhagen, prof. Van Ginneken en prof. Langendijk. 
Dank dat u bereid bent geweest om deel uit te maken van de manuscriptcommissie. 
Prof. Langendijk, beste Hans, dank dat je mij de kans hebt gegeven om verder te gaan 
met het vraagstuk rondom het modelleren van radiotherapie geïnduceerde toxiciteit.     
Frank Dankers, partner in crime. Hoe een, naar mijn idee, relatief eenvoudige vraag over 
het maken van dosemaps kan leiden tot een mooie en vruchtbare samenwerking. Hoe de 
klinische fysica en de ‘medische kant’ van de radiotherapie soms een andere taal spreken, 
maar elkaar (uiteindelijk….) wel lijken te verstaan. Zonder jou zou dit proefschrift letterlijk de 
helft dunner zijn. Dank voor de fijne samenwerking en wat fijn dat je mijn paranimf wilt zijn. 
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Tineke van Zon – Meijer. ‘Over and over again’. Vandaag de dag is de waardering voor 
planningsstudies omgekeerd evenredig aan de tijd die het kost om een goede plannings-
studie uit te voeren. Dank voor de toch wel gezellige uren achter het planningsstation.
De planningslaboranten: in het bijzonder Peter van Kollenburg, Leontien Abbenhuis en 
Liza Bouwmans. Dank voor jullie geduld en uitleg als ik weer eens aan het plannen was 
geslagen maar de dosis toch niet zo in de patiënt belandde zoals ik bedoeld had. Zonder 
jullie inzet en enthousiasme was een deel van dit proefschrift nooit afgekomen. Gill McColl, 
dank voor de onmisbare ondersteuning in het ‘data managen’! 
Bart van der Werf, een onmisbare hulplijn als het op ICT aankomt. Bedankt voor het 
gedogen van mijn ‘illegale’ PC. Ton de Haan en Paul Span, de andere onmisbare hulplijnen 
voor al uw statistische vragen. Dank!
Willem Grootjans. De technische ontwikkelingen in de gezondheidszorg vragen om 
personen zoals jij: een bruggenbouwer tussen techniek en zorg. Dank voor de prettige en 
leerzame samenwerking.
De A(N)IOS, de staf, eigenlijk alle medewerkers van de afdeling radiotherapie. Dank voor 
het verzorgen van zo veel werkvreugde! Een goede band met directe collega’s vergroot 
de werkvreugde significant. 
Ingrid Kleiss. Als je allebei aan een proefschrift werkt schept dat een band: in het (dienst-)
weekend tijdens het schrijven in het Radboud waren de onderbrekingen voor koffie/
taart/lunch zeer welkom. Ik denk daar met veel plezier aan terug. 
De ‘Zwolle groep’: Anke, Jordy, Ilse, Marije, Frank, Neri, Erwin, Aiden, Ivo en Vincent. Tsja, wie 
had dat in de brugklas gedacht! We kunnen elkaar tijden niet spreken, maar als we elkaar 
weer zien is het als vanouds. Het is fijn zulke vrienden te hebben voor de nodige 
ontspanning. 
Het is echt waar: in de eerste werkgroep van de studie geneeskunde maak je vrienden 
voor het leven. Evelien, Kim en Jacolien. Dank voor het delen/aanhoren van promotie-
perikelen, maar vooral ook voor de ontspannen uitjes/etentjes/borrels. Zou het lukken de 
frequentie daarvan te verhogen?
Neri Busbroek. Een vriendschap die terug gaat tot de kleuterschool. Je interesse in mijn 
onderzoek werkte zeer motiverend! Dank voor het luisterende oor, maar bovenal ook 
dank voor de momenten van ontspanning. Dit is een vriendschap die mij zeer dierbaar is. 
En hoe leuk is het dan dat je mijn paranimf wilt zijn?!
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De familie: mijn broer, schoonzussen en schoonouders. Het is eindelijk af! Dank voor de 
oprechte interesse in het onderzoek.
Lieve pap en mam. Dank voor de mogelijkheden en steun die jullie mij hebben gegeven. 
Mam, ik bewonder je positieve instelling ondanks het feit dat de laatste jaren niet de 
makkelijkste waren zonder pap. Hij is vast trots op ons! 
Maarten, mijn allerliefste. Het is moeilijk in woorden te vatten hoe fijn het thuiskomen is 
nu jij in mijn leven bent. Met jou is het genieten, elke dag een beetje meer. 
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RESEARCH DATA MANAGEMENT
Research data management
According to the doctorate regulations of the Radboud University, every thesis requires 
a page describing the management of research data. Below follow some comments on 
the retrieval, handling and storage of data. 
The research described in this thesis has been carried out in accordance with the national 
applicable rules concerning the review of research ethics committees and informed 
consent. All data retrieved have been collected and processed fully anonymized. To 
pursue proper data collection, OpenClinica (version 3.4, Waltham, MA) was used to store 
the clinical data needed for this thesis. OpenClinica is an audit trail-equipped data storage 
system that ensures save, accurate and anonymous data retrieval. 
The FAIR-principles in research data management
A guideline to provide machine-readable data to allow for easy sharing of high quality 
data has recently been proposed 1. This guideline for both data providers and data 
consumers is thought to enable the easy discovery, access and re-use of already available 
valuable research data. Once the majority of research is adapted to these guidelines, 
research concerning ‘big-data’ will be taken to the next level. The data retrieved and 
stored for this thesis, however, are not yet adapted to the proposed guidelines. This is due 
to the fact that all data have been collected before the abovementioned guidelines were 
published. Notwithstanding this, the (fully anonymized) databases have already been 
transferred to other research groups to help them in their research. 
Reference
1 Wilkinson MD, Dumontier M, Aalbersberg IJ, et al. The FAIR Guiding Principles for scientific data management 
and stewardship. Sci Data 2016;3:160018.
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